NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES

Abstract

The present invention relates to novel heteroaryl-triazole compounds of general formula (I), wherein the structural elements R1, R2, R3, R4 and R5 have the meanings assigned to them in the detailed description, formulations and compositions comprising such compounds, and their use in the control of animal pests, including arthropods and insects, in plant protection, and their use for the control of ectoparasites in animals. (See Formula).

Description

NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES The present invention relates to novel heteroaryl-triazole compounds, to formulations and compositions comprising said compounds and to their use in the control of animal pests including arthropods and insects for the protection of plants and to their use for the control of ectoparasites. in animals. Certain heteroaryl-triazole compounds for use in the control of ectoparasites in animals are disclosed in WO 2017 / 192385 and for use in the control of animal pests including arthropods and insects in the field of plant protection in WO 2019 / 170626 and WO 2019 / 215198. Likewise, patent applications WO 2019 / 197468, WO 2019 / 201835, WO 2019 / 202077 and WO 2019 / 206799 disclose certain heteroaryl-triazole compounds for use in the control of ectoparasites in animals and for the control of animal pests including arthropods and insects in the field of plant protection. WO 2020 / 002563, WO 2020 / 053364, WO 2020 / 053365, WO 2020 / 079198, WO 2020 / 094363 describe azole amide compounds all of which can be used as insecticides. Modern plant protection products and ectoparasiticides for veterinary use must meet many demands, for example with regard to efficacy, persistence, spectrum and resistance [breaking] properties. Questions come into play about toxicity, the possibility of combination with other active compounds or auxiliary formulations, as well as the question of the expense required for the synthesis of an active compound. On the other hand, there may be resistance. For all these reasons, the search for novel compositions for crop protection or ectoparasiticides for veterinary use cannot be considered complete and there is a constant need for novel compounds that have improved properties, at least with regard to individual aspects, in comparison with known compounds. One of the objects of the present invention was to provide compounds that broaden the spectrum of pesticides in several aspects. Therefore, the present invention discloses compounds having the general formula (I) EITHER where (Settings 1-1): R1 is hydrogen; R2 is phenyl or pyridine, where the phenyl or pyridine is optionally substituted with one to two substituents, as long as the substituent or substituents are not found on any of the carbons adjacent to the carbon attached to the C=O group, selecting each one considered in independently of the group consisting of fluorine, chlorine, bromine, CN, -NO2, -SF5, methyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, methoxy, difluoromethoxy, trifluoromethoxy, difluoromethylthio, trifluoromethylthio, difluoroethylthio, and trifluroethylthio; R3 is Ci-Caalkyl; R4 is pyridine, pyrimidine or pyrazine, where pyridine, pyrimidine or pyrazine is substituted with CN. R5 is ethyl, iso-propyl, tert-butyl, difluoromethyl, cyclopropyl, methoxy, ethoxy, iso-propoxy, or halogen. The compounds of the formula (I) also encompass any existing diastereomers or enantiomers and E / Z isomers, and also salts and N-oxides of compounds of the formula (I), and the use thereof for the control of animal pests. . The definitions of the preferred radicals for the formulas specified above and below are provided below. Preferred (Configuration 2-1) are compounds of formula (I) in which R1 is hydrogen; R23-chloro-5-(thfluoromethyl)phenyl, 3-chloro-5-(difluoromethyl)phenyl, 3-chloro-5(pentafluoroethyl)phenyl, 3-chloro-5-(trifluoromethoxy)phenyl, 3-chloro -5-(thfluoromethylth¡o)phenyl, 3chloro-5-(difluoromethylth¡o)phenyl, 3-chloro-5-(difluoromethoxy)phenyl, 3-bromo-5(trifluoromethoxy)phenyl, 3- bromo-5-chlorophenyl, 3,5-dichlorophenyl, 3,5-dibromophenyl, 3,5bis(trifluoromethyl)phenyl, 3-cyano-5-(trifluoromethyl)phenyl, 3,5-bis(difluoromethoxy) phenyl, 5-bromopyridin-3-yl, 3-bromo-5-(trifluoromethyl)phenyl, 3-fluoro-5-cyanophenyl, 3-bromo-5-cyanophenyl, 6-bromopyridin-2-yl, 5-(trifluoromethyl)pyridin -3-yl, 6-(trifluoromethyl)pyridin-2-yl, 2-chloro-6-(trifluoromethyl)pyridin-4-yl or 4-bromo-6-(trifluoromethyl)pyridin-2-yl; R3 is methyl; R4is 5-cyanopyridin-2-yl, R5 is ethyl, iso-propyl, tert-butyl, difluoromethyl, cyclopropyl, methoxy, ethoxy, iso-propoxy, chloro or bromine. Also preferred (Configuration 2-2) are compounds of formula (I) in which R1 is hydrogen; R23-chloro-5-(trifluoromethyl)phenyl, 3-chloro-5-(difluoromethyl)phenyl, 3-chloro-5(pentafluoroethyl)phenyl, 3-chloro-5-(trifluoromethoxy)phenyl, 3-chloro -5-(trifluoromethylthio)phenyl, 3chloro-5-(difluoromethylthio)phenyl, 3-chloro-5-(difluoromethoxy)phenyl, 3-bromo-5(trifluoromethoxy)phenyl, 3-bromo-5- chlorophenyl, 3,5-dichlorophenyl, 3,5-dibromophenyl, 3,5-bis(trifluoromethyl)phenyl, 3-cyano-5-(trifluoromethyl)phenyl, 3,5-bis(difluoromethoxy) phenyl, 5-bromopyridin-3-yl, 3-bromo-5-(trifluoromethyl)phenyl, 3-fluoro-5-cyanophenyl, 3-bromo-5cyanophenyl, 3-(difluoromethyl)-5-(trifluoromethoxy¡)phen io, 3-(difluoromethoxy)-5(difluoromethyl)phenyl, 6-bromopyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6(trifluoromethyl)pyridin- 2-ílo, 2-chloro-6-(trifluoromethyl)pyridín-4-ílo or 4-bromo-6(trifluoromethyl)pyridín-2-ílo; R3 is methyl; R4is 5-cyanopyridin-2-yl, R5 is ethyl, iso-propyl, tert-butyl, difluoromethyl, cyclopropyl, methoxy, ethoxy, iso-propoxy, chloro or bromine. In a more preferred embodiment, the invention relates to compounds of formula (I') in which R3 is Ci-Csalkyl, methyl being especially preferred, and where the structural elements R1, R2, R4 and R5 have the meanings defined in Configuration (1-1) or in Configuration (2-1) or in Configuration (2-2). In a more preferred embodiment, the invention relates to compounds of the formula (I") in which R3 is Ci-Csalkyl, methyl being especially preferred, and where the structural elements R1, R2, R4 and R5 have the meanings defined in Configuration (1-1) or in Configuration (2-1) or in Configuration (2-2). According to another aspect, the present invention encompasses intermediate compounds that are useful for the preparation of the compounds of general formula (I), indicated above. In particular, the invention covers intermediate compounds of general formula (e): where the structural elements R3, R4 and R5 have the meanings defined in Configuration (1-1) or in Configuration (2-1) or in Configuration (2-2), including free amine of INT-1: hydrochloride 6-[5-[(1S)-1-aminoethyl]-3-ethyl-1,2,4-thazol-1-¡l]pyridine-3carbonitrile; INT-2: 6-[5-[(1S)-1-aminoethyl]-3-isopropyl-1,2,4-triazol-1-yl]pyridine-3-carbon trilo; INT-3 free amine: 6-[5-[(1S)-1-aminoethyl]-3-cyclopropyl-1,2,4-triazol-1yl]pyridine-3-carbonitrile hydrochloride; INT-4: 6-[5-(1-aminoethyl)-3-(difluoromethyl)-1,2,4-triazol-1-yl]pyridine-3-carbonitrile; INT-5: 6-[5-[(1S)-1-aminoethyl]-3-methoxy¡-1,2,4-triazol-1 -yl]pyridine-3-carbonitrile; INT-6: 6-[5-[(1S)-1-aminoethyl]-3-ethoxy¡-1,2,4-triazol-1 -yl]pyridine-3-carbonátrile; ΙΝΤ-7: 6-[5-[(1 S)-1 -aminoethyl]-3-isopropoxy-1,2,4-triazol-1 -yl]pyridine-3-carbonitrile; INT-8: 6-[5-[(1 S)-1 -aminoethyl]-3-tert-butyl-1,2,4-triazol-1 -yl]pyridine-3-carbonitrile; INT-11: 6-[5-(1-aminoethyl)-3-chloro-1,2,4-triazol-1-yl]pyridine-3-carbonitrile; and INT-12: 6-[5-(1 -aminoethyl)-3-bromo-1,2,4-triazol-1 -yl]pyridine-3-carbonitrile; and the hydrochlorides of free amines. The invention also encompasses the intermediates 3-chloro-5[(difluoromethyl)sulfan¡l]benzo¡ic acid (INT-9), 3-chloro-5-(difluoromethyl)benzo¡ic acid (INT-10), 3-chloro-5-(difluoromethyl)benzo¡ic acid (INT-10), -chloro-5-(pentafluoroethyl)benzoic acid (INT-13), 3-(trifluoromethoxy¡)-5(difluoromethyl)benzoic acid (INT-14), and 3-(difluoromethoxy¡)-5-(d¡ fluoromethyl)benzoic (INT15) and its salts. It is also possible that the compounds of formula (I), depending on the nature of the substituents, are in the form of stereoisomers, that is, in the form of geometric and / or optical isomers or mixtures of isomers of varied compositions, the The present invention discloses both pure stereoisomers and any desired mixtures of said isomers, although only compounds of formula (I) are discussed herein. However, preference is given according to the invention to the use of the optically active stereoisomeric forms of the compounds of the formula (I) and their salts. The invention therefore relates to both pure enantiomers and diastereomers and mixtures thereof for controlling animal pests, including arthropods and particularly insects. If appropriate, the compounds of formula (I) may be present in various polymorphic forms or as a mixture of several polymorphic forms. Both pure polymorphs and mixtures of polymorphs are disclosed by the invention and can be used according to the invention. Definitions A person skilled in the art is aware that, if not made explicit, the expressions a or an as used in the present application, depending on the situation, may mean one (1), one (1) or more or at least one (1). For all structures described herein, such as ring systems and groups, adjacent atoms cannot be -O-O- or -O-S-. In this application, structures that have a variable number of possible carbon atoms (C atoms) are referred to as Lower Limit of Carbon Atoms-Upper Limit of Carbon Atoms structures (CLL-CUL structures), so as to be able to stipulate them. in a more specific way. Example: an alkyl group can consist of 3 to 10 carbon atoms and in that case corresponds to C3-C1 Oalkyl. You can refer to ring structures composed of carbon atoms and heteroatoms as LL to UL member structures. An example of a 6-membered ring structure is toluene (a 6-membered ring structure substituted with a methyl group). If a collective term for a substituent, e.g. CLL-CULalkyl, e.g. CLL-CULcycloalkyl-CLL-CULalkyl, appears at the end of the compound substituent, the substituent at the beginning of the compound substituent, e.g. polysubstituted in an identical or different way and independent of the last substituent, for example CLL-CULalkyl. All collective terms used in this application for chemical groups, cyclic systems and cyclic groups may be stipulated more specifically by the addition of the term CLL-CUL or LL to UL members. In the definitions of the symbols assigned in the previous formulas, the collective terms that are generally representative of the following substituents were used: Halogen refers to the elements of the seventh main group, preferably fluorine, chlorine, bromine and iodine, more preferably fluorine, chlorine and bromine, and even more preferably fluorine and chlorine. Examples of heteroatom are N, O, S, P, B, Si. Preferably, the term heteroatom refers to N, S and O. According to the invention, alkyl - in isolated form or as part of a chemical group represents straight or branched chain hydrocarbons preferably having 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl , sobutyl, sbutyl, t-butyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethylpropyl, 1,3-dimethylbutyl, 1,4-dimethylbutyl, 2,3-dimethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2trimethylpropyl, 1-ethylbutyl and 2-ethylbutyl. Preference is also given to alkyls having 1 to 4 carbon atoms such as, among others, methyl, ethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl or t-butyl. The alkyls of the invention may be substituted with one or more identical or different radicals. frCRnnn / zznz / B / YiAi According to the invention, "alkenyl" - in isolation or as part of a chemical group - represents straight or branched chain hydrocarbons preferably having 2 to 6 carbon atoms and at least one double bond, for example vinyl, 2-propenyl , 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3 -methyl-2-butenyl, 1 -methyl-3-butenyl, 2methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl , 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2pentenyl, 3-methyl-2-pentenyl, 4-methyl-2 -pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl , 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl2-butenyl , 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2 -ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl it. Preference is also given to alkenyls having 2 to 4 carbon atoms such as, among others, 2-propenyl, 2-butenyl or 1-methyl-2-propenyl. The alkenyls of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkynyl" - in isolated form or as part of a chemical group - represents straight or branched chain hydrocarbons preferably having 2 to 6 carbon atoms and at least one triple bond, for example 2-propynyl, 2 -butynyl, 3-butynyl, 1 -methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1 -methyl-3-butynyl, 2-methyl-3-butynyl, 1 -methyl-2-butynyl, 1,1 -dimethyl-2-propynyl, 1 -ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentenyl, 1-methyl-3 -pentinyl, 1-methyl-4-pentinyl, 2-methyl-3pentinyl, 2-methyl-4-pentinyl, 3-methyl-4-pentinyl, 4-methyl-2-pentinyl , 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1 -ethyl-1-methyl-2propynyl and 2,5-hexadiynyl. Preference is also given to alkynyls having 2 to 4 carbon atoms such as, among others, ethynyl, 2-propynyl or 2-butynyl-2-propenyl. The alkynyls of the invention may be substituted with one or more identical or different radicals. According to the invention, "cycloalkyl" - in isolated form or as part of a chemical group - represents mono-, bi- or tricyclic hydrocarbons preferably having 3 to 10 carbons, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl or adamantyl. Preference is also given to cycloalkyls having 3, 4, 5, 6 or 7 carbon atoms such as, among others, cyclopropyl or cyclobutyl. The cycloalkyls of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkylcycloalkyl" represents a mono-, bi- or tricyclic alkylcycloalkyl preferably having 4 to 10 or 4 to 7 carbon atoms, for example methylcyclopropyl, ethylcyclopropyl, isopropylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. Preference is also given to alkylcycloalkyls possessing 4, 5 or 7 carbon atoms such as, among others, ethylcyclopropyl or 4-methylcyclohexyl. The alkylcycloalkyls of the invention may be substituted with one or more identical or different radicals. According to the invention, "cycloalkylalkyl" represents a mono-, bi- or tricyclic cycloalkylalkyl preferably having 4 to 10 or 4 to 7 carbon atoms, for example cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl and cyclopentylethyl. Preference is also given to cycloalkylalkyls having 4, 5 or 7 carbon atoms such as, among others, cyclopropylmethyl or cyclobutylmethyl. The cycloalkylalkyls of the invention may be substituted with one or more identical or different radicals. According to the invention, "hydroxyalkyl" represents a straight- or branched-chain alcohol that preferably has 1 to 6 carbon atoms, for example methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, s-butanol and t-butanol. Preference is also given to hydroxyalkyl groups possessing 1 to 4 carbon atoms. The hydroxyalkyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, alkoxy represents straight- or branched-chain O-alkyl, preferably having 1 to 6 carbon atoms, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butox and t-butox! Preference is also given to alkoxy groups possessing 1 to 4 carbon atoms. The alkoxy groups of the invention may be substituted with one or more identical or different radicals. According to the invention, alkylthio, or "alkylsulfanyl" represents a straight or branched chain S-alkyl preferably having from 1 to 6 carbon atoms, for example methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, s -butylthio and t-butylthio. Preference is also given to alkylthio groups possessing 1 to 4 carbon atoms. The alkylthio groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkylsulfinyl" represents a straight- or branched-chain alkylsulfinyl preferably having 1 to 6 carbon atoms, for example methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, isobutylsulfinyl, s-butylsulfinyl and t-butylsulfinyl . Preference is also given to alkylsulfinyl groups possessing 1 to 4 carbon atoms. The alkylsulfinyl groups of the invention may be substituted by one or more identical or different radicals and encompass both enantiomers. According to the invention, "alkylsulfonyl" represents a straight- or branched-chain alkylsulfonyl preferably having 1 to 6 carbon atoms, for example methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, s-butylsulfonyl and t-butylsuIfonyl. Preference is also given to alkylsulfonyl groups possessing 1 to 4 carbon atoms. The alkylsulfonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, cycloalkylthio or "cycloalkylsulfanyl" represents -S-cycloalkyl which preferably has 3 to 6 carbon atoms, for example cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio. Preference is also given to cycloalkylthio groups possessing 3 to 5 carbon atoms. The cycloalkylthio groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "cycloalkylsulfinyl" represents an -S(O)-cycloalkyl preferably having 3 to 6 carbon atoms, for example cyclopropylsulfinyl, cyclobutylsulfinyl, cyclopentylsulfinyl, cyclohexylsulfinyl. Preference is also given to cycloalkylosulfinyl groups possessing 3 to 5 carbon atoms. The cycloalkylsulfinyl groups of the invention may be substituted by one or more identical or different radicals and encompass both enantiomers. According to the invention, "cycloalkylsulfonyl" represents a -SO2-cycloalkyl preferably having 3 to 6 carbon atoms, for example cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl. Preference is also given to cycloalkylsulfonyl groups possessing 3 to 5 carbon atoms. The cycloalkylsulfonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, phenylthio, or “phenylsulfanyl” represents an -S-phenyl, for example phenylthio. The phenylthio groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "phenylsulfinyl" represents a -S(O)-phenyl, for example phenylsulfinyl. The phenylsulfinyl groups of the invention may be substituted by one or more identical or different radicals and encompass both enantiomers. According to the invention, “phenylsulfonyl” represents a -SO2-phenyl, for example phenylsulfonyl. The phenylsulfonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkylcarbonyl" represents a straight or branched chain C(=O) alkyl preferably having 2 to 7 carbon atoms such as methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, s-butylcarbonyl and t-butylcarbonyl. Preference is also given to alkylcarbonyls having 1 to 4 carbon atoms. The alkylcarbonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkoxycarbonyl" - in isolation or as a constituent of a chemical group - represents a straight or branched chain alkoxycarbonyl preferably having 1 to 6 carbon atoms or having 1 to 4 carbon atoms in the alkoxy radical, for example methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, s-butoxycarbonyl and t-butoxycarbonyl. The alkoxycarbonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "alkylaminocarbonyl" represents a straight or branched chain alkylaminocarbonyl preferably having 1 to 6 carbon atoms or 1 to 4 carbon atoms in the alkyl radical, for example methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, s-butylaminocarbonyl and t-butylaminocarbonyl. The alkylaminocarbonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "Ν,Ν-dialkylaminocarbonyl" represents a straight or branched chain N,Ndialkylaminocarbonyl preferably having 1 to 6 carbon atoms or 1 to 4 carbon atoms in the alkyl radical, for example N,Ndimethylaminocarbonyl, Ν,Ν-diethylaminocarbonyl, N,N-di(n-propylamino)carbonyl, N,Ndi(isopropylamino)carbonyl and N,N-di-(s-butylamino)carbon it. The Ν,Νdialkylaminocarbonyl groups of the invention may be substituted with one or more identical or different radicals. According to the invention, "aryl" represents a mono-, bi- or polycyclic aromatic system preferably having 6 to 14, especially 6 to 10, carbon atoms in the ring, for example phenyl, naphthyl, anthryl, phenanthrenyl, preferably phenyl. On the other hand, aryl also represents polycyclic systems such as tetrahydronaphthyl, indenyl, indanyl, fluorenyl, biphenyl, where the bonding site is located in the aromatic system. The aryl groups of the invention may be substituted with one or more identical or different radicals. Examples of substituted aryls are arylalkyls, which may also be substituted with one or more identical or different radicals in the C1-C4alkyl and / or C6C14ahlo radical. Examples of such arylalkyls include benzyl and phenyl-1-ethyl. According to the invention, heterocycle, heterocyclic ring or heterocyclic ring system represents a system of heterocyclic rings that has at least one ring in which at least one carbon atom is replaced by a heteroatom, preferably by a heteroatom to be selected from the set. which consists of N, O, S, P, B, Si, Se, and which is saturated, unsaturated or heteroaromatic, and may be substituted or unsubstituted, the binding site being on a ring atom. Unless defined differently, the heterocyclic ring preferably contains 3 to 9 ring atoms, especially 3 to 6 ring atoms, and one or more, preferably 1 to 4, especially 1.2 or 3 , heteroatoms in the heterocyclic ring, preferably to be selected from the set consisting of N, O, and S, although in no case can there be two directly adjacent oxygen atoms. Heterocyclic rings usually contain no more than 4 nitrogen atoms and / or no more than 2 oxygen atoms and / or no more than 2 sulfur atoms. When the heterocyclyl radical or heterocyclic ring is optionally substituted, it may be fused to other carbocyclic or heterocyclic rings. In the case of optionally substituted heterocyclyl, the invention also encompasses polycyclic systems, for example 8-azabicyclo[3.2.1]octanyl or 1-azabicyclo[2.2.1]heptyl. In the case of optionally substituted heterocyclyl, the invention also encompasses spirocyclic systems, for example 1-oxa-5-azaspiro[2.3]hexyl. Heterocyclyl groups of the invention are, for example, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dihydropyranyl, tetrahydropyranyl, dioxanyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, dioxolanyl, dioxolyl, pyrazolidinyl, tetrahydrofuranyl, dihydrofuranyl, ox ethanyl, oxiranyl , azetidinyl, aziridinyl, oxazetidinyl, oxaziridinyl, oxazepanyl, oxazinanyl, azepanyl, oxopyrrolidinyl, dioxopyrrolidinyl, oxomorpholinyl, oxopiperazinyl and oxepanil. Heteroaryls, that is, heteroaromatic systems, are of great importance. According to the invention, the term heteroaryl represents heteroaromatic compounds, that is to say completely unsaturated aromatic heterocyclic compounds that fall under the above definition of heterocycles. Preference is given to 5- to 7-membered rings having 1 to 3, preferably 1 or 2, heteroatoms identical or different from the group described above. The heteroaryls of the invention are, for example, furyl, thienyl, pyrazolyl, imidazolyl, 1,2,3- and 1,2,4-triazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-, 1,3, 4-, 1,2,4-and 1,2,5-oxadiazolyl, azepinyl, pyrrolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-, 1,2,4- and 1,2,3- triazinyl, 1,2,4-, 1,3,2-, 1,3,6- and 1,2,6-oxazinyl, oxepinyl, thiepinyl, 1,2,4-triazolonyl and 1,2,4-diazepinyl . The heteroaryl groups of the invention may also be substituted with one or more identical or different radicals. The term "in each case optionally) substituted" means that a group / substituent such as an alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cycloalkyl, aryl, phenyl, benzyl, heterocyclyl and heteroaryl radical is substituted, for example, a substituted radical derived from an unsubstituted base structure, where the substituents, for example, one (1) substituent or a plurality of substituents, preferably 1, 2, 3, 4, 5, 6 or 7, are selected from the set consisting of the substituents amino, hydroxyl, halogen, nitro, cyano, isocyano, mercapto, isothiocyanato, C1-C4carboxyl, carbonamide, SF5, aminosulfonyl, C1-C4alkyl, C1-C4haloalkyl[,] C3-C4cycloalkyl, C2-C4alkenyl, C5 -C6cycloalkenyl, C2-C4alkynyl, N-mono-C1-C4alkylamino, N,N-d¡C1-C4alkylamino, N-C1-C4alkanoylamino, C1-C4alkoxy¡, C1-C4haloalkoxy¡, C2C4alkenyloxy, C2-C4alkynyloxy, C3-C4cycloalkoxy, C5 -C6cycloalkenyloxycarbonyl, C1C4alkoxycarbonyl, C2-C4alkenyloxycarbonyl, C2-C4alkynyloxycarbonyl, C6-,C10-,C14aryloxycarbonyl, C1-C4alkanoyl, C2-C4alkenylcarbonyl, C2-C4alkynylcarbonyl, C6-,C10,C14-ahlcarbonyl , C1-C4alkylthio, C1-C4haloalkylthio, C3-C4cycloalkylthio, C2C4alkenylthio, C5-C6cycloalkenylthio, C2-C4alkynylthio, C1-C4alkylsulfinyl, including both enantiomers of the C1-C4alkylsulfinyl group, C1-C4haloalkylsulfinyl, including both enantiomers of the group C1-C4haloalkylaminosulfinyl, C1-C4alkylaminosulfonyl, C1C4haloalkylsulfonyl, N-mono-C1-C4alkylaminosulfonyl, N,N-di-C1 C4alkylaminosulfonyl, C1-C4alkylphosphinyl, C1-C4alkylphosphonyl, including both enantiomers of C1-C4alkylphosphinyl it and C1-C4alkylphosphonyl, N-C1-C4alkylaminocarbonyl, N,N-di-C1 -C4alkylaminocarbonyl, N-C1 -C4alkanoylaminocarbonyl, N-C1 -C4alkanoyl-NC1-C4alkylaminocarbonyl, C6-,C10-, C14-aryl, 06-,010-,C14-aryloxy, benzyl, benzyloxy, benzylthio, 06-,010-,014-arylthio, 06-,010-,014-arylamino, benzylamino, heterocyclyl and trialkylosilyl, linked by a double bond, such as C1-C4alkylidene (eg methylidene or ethylidene), an oxo group, an imino group and a substituted imino group. When two or more radicals form one or more rings, these can be carbocyclic, heterocyclic, saturated, partially saturated, unsaturated, for example including aromatic rings with a higher degree of substitution. The substituents mentioned at frCRnnn / zznz / E / YiAi as an example (first level of substituents), if they contain hydrocarbonaceous components, may optionally possess a higher degree of substitution therein (second level of substituents), for example with one or more of the substituents to be selected, considering each one independently, from halogen, hydroxyl, amino, nitro, cyano, isocyano, azido, acylamino, an oxo group and an amino group. The term (optionally) substituted group preferably encompasses only one or two levels of substituents. The halogen-substituted or halogenated (e.g. alkyl or alkoxy) chemical groups of the invention are mono- or polysubstituted with halogen up to the maximum possible number of substituents. Such groups are also referred to as halo (e.g. haloalkyl) groups. In the case of polysubstitution with halogen, the halogen atoms may be the same or different, and may all be bonded to one carbon atom or be bonded to a plurality of carbon atoms. Halogen is especially fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine and more preferably fluorine. More particularly, halogen-substituted groups are monohalocycloalkyl such as 1-fluorocyclopropyl, 2-fluorocyclopropyl or 1-fluorocyclobutyl, monohaloalkyl such as 2-chloroethyl, 2-fluoroethyl, 1-chloroethyl, 1-fluoroethyl, chloromethyl, or fluoromethyl; perhaloalkyl such as trichloromethyl or trifluoromethyl or CF2CF3, polyhaloalkyl such as difluoromethyl, 2fluoro-2-chloroethyl, dichloromethyl, 1,1,2,2-tetrafluoroethyl or 2,2,2-trifluoroethyl. Other examples of haloalkyls are trichloromethyl, chlorodifluoromethyl, dichlorofluoromethyl, chloromethyl, bromomethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 2-chloro-2,2 -difluoroethyl, pentafluoroethyl, 3,3,3-thfluoropropyl and pentafluoro-tbutyl. Preference is given to haloalkyls having 1 to 4 carbon atoms and 1 to 9, preferably 1 to 5, identical or different halogen atoms to be selected from fluorine, chlorine and bromine. Particular preference is given to haloalkyls possessing 1 or 2 carbon atoms and 1 to 5 identical or different halogen atoms to be selected from fluorine and chlorine, such as, among others, difluoromethyl, trifluoromethyl or 2,2- difluoroethyl. Other examples of halogen-substituted compounds are haloalkoxy such as OCF3, OCHF2, OCH2F, OCF2CF3, OCH2CF3, OCH2CHF2 and OCH2CH2CI, haloalkylosulfanyls such as difluoromethylthio, trifluoromethylthio, trichloromethylthio, chlorodifluoromethylthio, 1-fluoroethylthio, 2-fluoroethylthio, 2,2- difluoroethylthio, 1,1,2,2-tetrafluoroethylthio, 2,2,2-trifluoroethylthio or 2-chloro-1,1,2-trifluoroethylthio, haloalkylsulfinyls such as difluoromethylsulfinyl, trifluoromethylsulfinyl, trichloromethylsulfinyl, chlorodifluoromethylsulfinyl, 1fluoroethylsulfinyl, 2-fluoro ethyl sulfin lo, 2,2-difluoroethylsulfinyl, 1,1,2,2-tetrafluoroethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 2-chloro-1,1,2-trifluoroethylsulfinyl, the haloalkylsulfinyls such as difluoromethylsulfinyl, trifluoromethylsulfinyl, trichloromethylsulfinyl, chlorodifluoromethylsulfinlium, 1-f luoroethylsulfinyl, 2-fluoroethylsulfinyl, 2,2-difluoro ethylsulfinlium, 1 ,1,2,2-tetrafluoroethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 2-chloro-1,1,2-trifluoroethylsulfinyl, haloalkylsulfonyl groups such as difluoromethylsulfonyl, trifluoromethylsulfonyl, trichloromethiIsulfonyl, chlorodifluoromethylsulfonyl, 1-fluoroethylsulfonyl, 2 -fluoroethylsuIfon lo, 2,2-difluoroethylsulfonyl, 1,1,2,2-tetrafluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, and 2-chloro1,1,2-trifluoroethylsulfonyl. In the case of radicals possessing carbon atoms, preference is given to those possessing 1 to 4 carbon atoms, especially 1 or 2 carbon atoms. In general preference is given to substituents selected from the set consisting of halogen, for example fluorine and chloro, (C1-C4)alkyl, preferably methyl or ethyl, (C1-C4)haloalkyl, preferably trifluoromethyl, (C1-C4 )alkoxy, preferably methoxy or ethoxy, (C1-C4)haloalkoxy, nitro and cyano. Particular preference is given herein to the methyl, methoxy, fluoro and chloro substituents. Substituted amino such as mono- or disubstituted amino means a radical to be selected from the set of substituted amino radicals that are N-substituted, for example, with one or two identical or different radicals to be selected from the set consisting of alkyl, hydroxy , amino, alkoxy, acyl and aryl; preferably N-mono- and N,Ndialkylamino, (for example methylamino, ethylamino, Ν,Ν-dimethylamino, Ν,Ν-diethylamino, N,Ndi-n-propylamino, Ν,Ν-diisopropylamino or Ν,Ν-dibutylamino), N-mono- or N,Ndialkoxyalkylamino groups (e.g. N-methoxymethylamino, N-methoxyethylamino, N,Ndi(methoxymethyl)amino or N,N-di(methoxyethyl)amino), N-mono- and Ν, Ν-diarylamino, such as optionally substituted anilines, acylamino, Ν,Ν-diacylamino, N-alkyl-N-arylamino, N-alkyl-N-acylamino and also saturated N-heterocycles; Preference is given herein to alkyl radicals having 1 to 4 carbon atoms; Herein, aryl is preferably phenyl or substituted phenyl; for acyl, the definition given below applies, preferably (C1-C4)-alkanoyl. The same applies for hydroxylamino or substituted hydrazino. Substituted amino also includes quaternary ammonium compounds (salts) that have four organic substituents on the nitrogen atom. Optionally substituted phenyl is preferably unsubstituted or mono- or polysubstituted phenyl, preferably up to trisubstituted, [with] radicals identical or different from the set consisting of halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4) )alkoxy-(C1 C4)alkoxy¡, (C1-C4)alkoxy-(C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)haloalkoxy¡, (C1C4)alkylthio, (C1-C4)haloalkylthio, (C1 -C4) )alkylosulfinyl[,] (C1-C4)haloalkylosulfinyl, (C1C4)alkylosulfonyl[,] (C1-C4)haloalkylosulfonyl, cyano, isocyano and nitro, for example o-, m and p-tolyl, dimethylpheinyls, 2-, 3- and 4-chlorophenyl, 2-, 3-, and 4-fluorophenyl, 2-, 3-, and 4-trifluoromethyl, and 4-trichloromethylphenyl, 2,4-, 3,5-, 2,5-, and 2,3-dichlorophenyl, or , m- and p-methoxyphenyl, 4heptafluorophenyl. Optionally substituted cycloalkyl is preferably unsubstituted or mono- or polysubstituted cycloalkyl, preferably up to trisubstituted, [with] radicals identical or different from the set consisting of halogen, cyano, (C1-C4)alkyl, (C1-C4)alkoxy ¡, (C1-C4)alkoxy¡(C1-C4)alkoxy, (C1-C4)alkoxy-(C1-C4)alkyl, (C1-C4)haloalkyl and (C1-C4)haloalkoxy¡, especially with one or two (C1-C4)alkyl radicals. The compounds of the invention can be found in preferred embodiments. The individual embodiments described herein can be combined with each other. Not included are combinations that are not in accordance with the laws of nature which a person skilled in the art would therefore rule out on the basis of expert knowledge thereof. Ring structures that have three or more adjacent oxygen atoms, for example, are excluded. Isomers Depending on the nature of the substituents, the compounds possessing formula (I) can be found in the form of geometric and / or optically active isomers or the corresponding mixtures of isomers in different compositions. Such stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Accordingly, the invention encompasses both pure stereoisomers and any mixture of such isomers. Methods and uses The invention also relates to methods for the control of animal pests, in which the compounds having formula (I) are allowed to act on animal pests and / or their habitat. The control of animal pests is preferably carried out in agriculture and forestry, and in the protection of materials. Preferably excluded from the present invention are methods of surgical or therapeutic treatment of the human or animal body and diagnostic methods carried out on the human or animal body. The invention also relates to the use of the compounds having formula (I) as pesticides, in particles as crop protection agents. In the context of the present application, the term pesticide in each case always also includes the term crop protection agent. The compounds having formula (I), having good plant tolerance, favorable homeothermic toxicity and good environmental compatibility, are suitable for the protection of plants and plant organs against biotic and abiotic stressors, to increase the crop yields, to improve the quality of harvested material and to control animal pests, especially insects, arachnids, helminths, particularly nematodes, and mollusks, which are found in agriculture, horticulture, animal husbandry , in aquatic crops, in forests, in gardens and leisure facilities, in the protection of stored products and materials, and in the hygiene sector. Within the context of the present patent application, the term “hygiene” is understood to mean any and all measures, procedures and practices that aim to prevent disease, in particular infectious disease, and that serve to protect health. of humans and animals and / or protect the environment, and / or maintain cleanliness. According to the invention, this especially includes cleaning, disinfection and sterilization measures of, for example, textiles or hard surfaces, especially surfaces made of glass, wood, concrete, porcelain, ceramics, plastic or also metal(s), and to ensure that they are kept free of hygienic pests and / or their excretions. Surgical or therapeutic treatment procedures applicable to the human body or animal bodies and diagnostic procedures carried out on the human body or animal bodies are preferably excluded from the scope of the invention in this sense. The term “hygiene sector” therefore covers all areas, technical fields and industrial applications in which such measures, procedures and practices are important, in relation, for example, to hygiene in kitchens, bakeries, airports, bathrooms, swimming pools. , shops, hotels, hospitals, stables, animal farms, etc. The term “hygienic pest” is therefore understood to mean one or more animal pests whose presence in the hygiene sector is problematic, in particular for health reasons. Therefore, a primary objective is to avoid or minimize the presence of hygiene pests, and / or exposure to them, in the hygiene sector. This can be achieved in particular by applying a pesticide that can be used both to prevent infestation and to address an infestation that is already present. Preparations that prevent or reduce exposure to pests can also be used. Hygiene pests include, for example, the organisms mentioned below. The term “hygiene protection” therefore encompasses all actions to maintain and / or improve said hygiene measures, procedures and practices. Compounds having formula (I) can preferably be used as pesticides. They are active against normally sensitive and resistant species and against all or some stages of development. The pests referenced above include: pests of the phylum Arthropoda, in particular of the class Arachnida, e.g. Acarus spp., e.g. Acarus siró, Acero kuko, Acero sheldoní, Aculops spp., Aculus spp., e.g. Aculus fockeui, Aculus schlechtendali, Amblyomma spp., Amphitetranychus viennensis, Argas spp., Boophilus spp., Brevipalpus spp., e.g. Brevipalpus phoenicis, Bryobia graminum, Bryobia praetiosa, Centruroides spp., Chorioptes spp., Dermanyssus gallinae, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Dermacentor spp., Eotetranychus spp. ., for example Eotetranychus hicoriae, Epitrimerus pyri, Eutetranychus spp., for example Eutetranychus banksi, Eriophyes spp., for example Eriophyes pyri, Glycyphagus domesticus, Halotydeus destructor, Hemitarsonemus spp., for example Hemitarsonemus latus (=Poliphagotarsonemus latus), Hyalomma spp., Ixodes spp., Latrodectus spp., Loxosceles spp., Neutrombicula autumnalis, Nuphersa spp., Oligonychus spp., e.g. Oligonychus coffeae, Oligonychus coniferarum, Oligonychus ilicis, Oligonychus indicus, Oligonychus mangiferus, Oligonychus pratensis, Oligonychus punicae, Oligonychus yothersi, Ornithodorus spp., Ornithonyssus spp., Panonychus spp., for example Panonychus citri (=Metatetranychus citri), Panonychus ulmi (=Metatetranychus ulmi), Phyllocoptruta oleivora, Platytetranychus multidigituli, Polyphagotarsonemus latus, Psoroptes spp., Rhipicephalus spp., Rhizoglyphus spp., Sarcoptes spp., Scorpio maurus, Steneotarsonemus spp., Steneotarsonemus spinki, Tarsonemus spp., for example Tarsonemus confusus, Tarsonemus pallidus, Tetranychus spp., for example Tetranychus canadensis, Tetranychus cinnabarinus, Tetranychus turkestani, Tetranychus urticae, Trombicula alfredd ugesi, Vaejovis spp. , Vasates lycopersici; from the class Chilopoda, for example Geophilus spp., Scutigera spp.; of the order or class Collembola, for example Onychiurus armatus; Sminthurus viridis; from the class Diplopoda, for example Blaniulus guttulatus; frCRnnn / zznz / B / YiAi of the class Insecta, for example of the order Blattodea, for example Blatta orientalis, Blattella asahinai, Blattella germanica, Leucophaea maderae, Loboptera decipiens, Neostylopyga rhombifolia, Panchlora spp., Parcoblatta spp., Periplaneta spp., for example Periplanetaamericana, Periplaneta australasiae, Pycnoscelus surinamensis, Supella longipalpa; of the order Coleoptera, e.g. Acalymma vittatum, Acanthoscelides obtectus, Adoretus spp., Aetina túmida, Agelastica alni, Agrilus spp., e.g. Agrilus planipennis, Agrilus coxalis, Agrilus bilineatus, Agrilus anxius, Agrietes spp., e.g. Agriotes linneatus, Agrietes mancus, Agriotes obscurus, Alphitobius diaperinus, Amphimallon solstitíalís, Anobium punctatum, Anomala dubia, Anoplophora spp., e.g. Anoplophora glabripennis, Anthonomus spp., e.g. Atomaria spp., e.g. Ceutorrhynchus rapae, Chaetocnema spp., For example Chaetocnema confinis, chaetocnema denticulata, chaetocnema ectypa, Cleonus mendicus, conoderus spp., Cosmopolites spp., For example cosmopolites deordidus, costelytra zealandica, ctenicera spp., Curculio spp. , Curculio caryatrypes,Curculio obtusus, Curculio sayi, Cryptolestes ferrugineus, Cryptolestes pusillus, Cryptorhynchus lapathi, Cryptorhynchus mangiferae, Cylindrocopturus spp., Cylindrocopturus adspersus, Cylindrocopturus furnissi, Dendroctonus spp., e.g. Dendroctonus ponderosae, Dermestes spp., Dia brotica spp., for example Diabrotica balteata, Diabrotica barberi, Diabrotica undecimpunctata howardi, Diabrotica undecimpunctata undecimpunctata, Diabrotica virgifera virgifera, Diabrotica virgifera zeae, Dichocrocis spp., Dicladispa armigera, Diloboderus spp., Epicaerusspp., Epilachna spp., e.g. Epilachna borealis, Epilachna varivestis, Epitrix spp ., for example Epitrix cucumeris, Epitrix fuscula, Epitrix hirtipennis, Epitrix subcrinita, Epitrix tuberis, Faustinus spp., Gibbium psylloides, Gnathocerus cornutus, Hellula undalis, Heteronychus arator, Heteronyx spp., Hoplia argentea, Hylamorpha elegans, Hylotrupes bajulus, Hypera postica , Hypomeces squamosus, Hypothenemus spp., e.g. Hypothenemus hampei, Hypothenemus obscurus, Hypothenemus pubescens, Lachnosterna consanguinea, Lasioderma serricorne, Latheticus oryzae, Lathridius spp., Lema spp., Leptinotarsa ​​decemlineata, Leucoptera spp., e.g. coffeella, Limonius ectypus , Lissorhoptrus oryzophilus, Listronotus (= Hyperodes) spp., Lixus spp., Luperodes spp., Luperomorpha xanthodera, Lyctus spp., Megacyllene spp., for example Megacyllene robiniae, Megascelis spp., Melanotus spp., e.g. Melanotus longulus oregonensis, Meligetes aeneus, Melolontha spp., e.g. Melolontha melolontha, Migdolus spp., Monochamus spp., Naupactus xanthographus, Necrobia spp., Neogalerucella spp., Niptus hololeucus , Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorhynchus spp., e.g. oryzae, Oxicetonia jucunda, Phaedon cochleariae, Phyllophaga spp., Phyllophaga helleri, Phyllotreta spp., e.g. Phyllotreta armoraciae, Phyllotreta pusilla, Phyllotreta ramosa, Phyllotreta striolata, Popillia japonica, Premnotrypes spp., Prostephanus truncatus, Psylliodes spp., e.g. Psylliodes affinis, Psylliodes chrysocephala, Psyl liodes punctulata, Ptinus spp., Rhizobius ventralis, Rhizopertha dominica, Rhynchophorus spp., Rhynchophorus ferrugineus, Rhynchophorus palmarum, Scolytus spp., e.g. Scolytus multistriatus, Sinoxilon perforaos, Sitophilus spp., e.g. Sphenophorus spp., Stegobium paniceum, Sternechus spp., e.g. Sternechus paludatus, Symphyletes spp., Tanymecus spp., e.g. Tanymecus dilaticollis, Tanymecus indicus, Tanymecus palliatus, Tenebrio molitor, Tenebrioides mau retanícus, Tribolium spp., e.g. Tribolium audax, Tribolium castaneum, Tribolium confusum, Trogoderma spp., Tychius spp., Xylotrechus spp., Zabrus spp., for example Zabrus tenebrioides; from the order Dermaptera, for example Anisolabis maritime, Forficula auricularia, Labidura riparia; of the order Diptera, e.g. Aedes spp., e.g. Aedes aegypti, Aedes albopictus, Aedes sticticus, Aedes vexans, Agromyza spp., e.g. gambiae, Asphondylia spp., Bactrocera spp., e.g. Bactrocera cucurbítae, Bactrocera dorsalis, Bactrocera oleae, Bibio hortulanus, Calliphora erythrocephala, Calliphora vicina, Ceratitis capitata, Chironomus spp., Chrysomya spp., Chrysops spp., Chrysozona pluvíalís, Cochliomya spp. ., Contarinia spp., e.g. Contarinia johnsoni, Contarinia nasturtii, Contarinia pyrivora, Contarinia schulzi, Contarinia sorghicola, Contarinia tritic, Cordylobia anthropophaga, Cricotopus sylvestris, Culex spp., e.g. Culex pipiens, Culex quinquefasciatus, Culicoides spp. , Culiseta spp., Cuterebra spp., Dacus oleae, Dasineura spp., e.g. Dasineura brassicae, Delia spp., e.g. Delia antiqua, Delia coarctata, Delia florilega, Delia platura, Delia radicum, Dermatobia hominis, Drosophila spp., e.g. example Drosphila melanogaster, Drosophila suzukii, Echinocnemus spp., Euleia heraclei, Fannia spp., Gasterophilus spp., Glossina spp., Haematopota spp., Hydrellia spp., Hydrellia griseola, Hylemya spp., Hippobosca spp., Hypoderma spp., Liriomyza spp., e.g. Liriomyza brassicae, Liriomyza huidobrensis, Liriomyza sativae, Lucilia spp., e.g. Lucilia cuprina, Lutzomyia spp., Mansonia spp., Musca spp., e.g. Musca domestica, Musca domestica vicina, Oestrus spp., Oscinella frit , Paratanytarsus spp., Paralauterborniella subcincta, Pegomya or Pegomyia spp., for example Pegomya betae, Pegomya hyoscyami, Pegomya rubivora, Phlebotomus spp., Phorbia spp., Phormia spp., Piophila casei, Platyparea poeciloptera, Prodiplosis spp., Psila rosae, Rhagoletis spp., For example Rhagoletis cingulata, Rhagoletis, Rhagoletis Fausta, Rhagoletis Indifferens, Rhagoletis Mendax, Rhagoletis Pomonella, Sarcophaga spp., Simulium spp., For example Simulium southern, Stomoxis spp., Tabanus spp. , Typula spp., for example Típula paludosa, Típula simplex, Toxotrypana curvicauda; of the order Hemiptera, e.g. Acizzia acaciaebaileyanae, Acizzia dodonaeae, Acizzia uncatoides, Acrida turrita, Acyrthosipon spp., e.g. Acyrthosiphon pisum, Acrogonia spp., Aeneolamia spp., Agonoscena spp., Aleurocanthus spp., Aleyrodes proletella, Aleurolobus barodensis, Aleurothrix us floccosus, Allocaridara malayensis, Amrasca spp., for example Amrasca bigutulla, Amrasca devastaos, Anuraphis cardui, Aonidiella spp., for example Aonidiella aurantii, Aonidiella citrina, Aonidiella inomata, Aphanostigma piri, Aphis spp., for example Aphis citricola, Aphis craccivora, Aphis fabae, Aphis forbesi, Aphis glycines, Aphis gossypii, Aphis hederae, Aphis illinoisensis, Aphis middletoni, Aphis nasturtii, Aphis nerii, Aphis pomi, Aphis spiraecola, Aphis viburniphila, Arboridia apicalis, Arytainilla spp., Aspidiella spp., Aspidiotus s pp. , e.g. Aspidiotus nerii, Atanus spp., Aulacorthum solani, Bemisia tabaci, Blastopsylla occidentalis, Boreioglycaspis melaleucae, Brachycaudus helichrysi, Brachycolus spp., Brevicoryne brassicae, Cacopsylla spp., e.g. Cacopsylla pyricola, Calligypona margínala, Capulinia spp., Carneo cephala fulgida , Ceratovacuna wooly, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlorita onukii, Chondracris rosea, Chromaphis juglandicola, Chrysomphalus aonidum, Chrysomphalus ficus, Cicadulina mbila, Coccomytílus hall!, Coccus spp., for example Coccus hes peridum, Coccus longulus, Coccus pseudomagnoliarum, Coccus viridis, Cryptomyzus ribis, Cryptoneossa spp., Ctenarytaina spp., Dalbulus spp., Dialeurodes chittendeni, Dialeurodes citri, Diaphorina citri, Diaspis spp., Diuraphis spp., Doralis spp., Drosicha spp., Dysaphis spp., for example Dysaphis apiifolia, Dysaphis plantaginea, Dysaphis tulipae, Dysmicoccus spp., Empoasca spp., for example Empoasca abrupta, Empoasca fabae, Empoasca maligna, Empoasca solana, Empoasca stevensi, Eriosomaspp., for example Eriosoma americanum, Eriosoma lanigerum, Eriosoma pyricola, Erythroneura spp., Eucalyptolyma spp., Euphyllura spp., Euscelis bilobatus, Ferrisia spp., Fiorinia spp., Furcaspis oceanica, Geococcus coffeae, Glycaspis spp., Heteropsylla cubana, Heteropsylla spinulosa, Homalodisca coagúlala, Hyalopterus arundinis, Hyalopterus pruni, Icerya spp ., for example Icerya purchasi, Idiocerus spp., Idioscopus spp., Laodelphax striatellus, Lecanium spp., for example Lecanium comí (=Parthenolecanium corni), Lepidosaphes spp., for example Lepidosaphes ulmi, Lipaphis erysimi, Lopholeucaspis japonica, Lycorma delicatula, Macrosiphum spp., e.g. Macrosiphum euphorbiae, Macrosiphum lilii, Macrosiphum rosae, Macrosteles facifrons, Mahanarva spp., Melanafis sacchari, Metcalfiella spp., Metcalfa pruinosa, Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus spp., e.g. Myzus ascalonicus, Myzus cerasi, Myzus ligustri, Myzus ornatus, Myzus persicae,. Myzus nicotianae, Nasonovia ribisnigri, Neomaskellia spp., Nephotettix spp., e.g. Nephotettix cincticeps,, Nephotettix nigropictus, Nettigoniclla spectra, Nilaparvata lugens, Oncometopia spp., Orthezia praelonga, Oxia chinensis, Pachypsylla spp., Parabemisia myricae, Paratrioza spp., e.g. Paratrioza cockerelli, Parlatoria spp., Pemphigus spp., e.g. Pemphigus bursarius, Pemphigus populivenae, Peregrinus maidis, Perkinsiella spp., Phenacoccus spp., e.g. devastatrix, Phylloxeranotabilis, Pinnaspis aspidistrae, Planococcus spp., e.g. Planococcus citri, Prosopidopsylla flava, Protopulvinaria pyriformis, Pseudaulacaspis pentagona, Pseudococcus spp., e.g. Pseudococcus calceolarias, Pseudococcus comstocki, Pseudococcus longispinus, Pse udococcus maritimus, Pseudococcus viburni, Psyllopsis spp. , Psylla spp., e.g. Rhopalosiphum spp., e.g. Rhopalosiphum maidis, Rhopalosiphum oxiacanthae, Rhopalosiphum padi, Rhopalosiphum rufiabdominale, Saissetia spp., e.g. Saissetia coffeae, Saissetia miranda, Saissetia neglecta, Saissetia oleae, Scaphoideus titanus, Schizaphis graminum, Selenaspidus articulatus, Sipha flava, Si Tobion Avenae , Sogata spp., Sogatella fumifera, Sogatodes spp., Stictocephala festina, Siphoninus phillyreae, Tenalaphara malayensis.Tetragonocephela spp., Tinocallis caryaefoliae, Tomaspis spp.,. Toxoptera spp., e.g. Toxoptera aurantii, Toxoptera citricidus, Trialeurodes vaporariorum, Trioza spp., e.g. Trloza diospyri, Typhlocyba spp., Unaspis spp., Viteus vitifolii, Zygina spp.; of the suborder Heteroptera, e.g. , Cimex pilosellus, Collaria spp., Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp., Euschistus spp., e.g. Euschistus heros, Euschistus servus, Euschistus tristigmus, Euschistus variolarius, Eurydema spp., Eurygaster spp. ., Halyomorpha halys, Heliopeltis spp., Horcias nobilellus, Leptocorisa spp., Leptocorisa varicornis, Leptoglossus occidentalis, Leptoglossus phyllopus, Lygocoris spp., e.g. Lygocoris pabulinus, Lygus spp., e.g. Lygus elisus, Lygus hesperus, Lygus lineolaris, Macropes excavatus, Megacopta cribraria, Miridae, Monalonion atratum, Nezara spp., e.g. Nezara viridula, Nysius spp., Oebalus spp., Pentomidae, Piesma quadrata, Piezodorus spp., e.g. Piezodorus guildinii, Psallus spp., Pseudacysta persea, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophora spp., Stephanitis nashi, Tibraca spp., Triatoma spp.; of the order Hymenoptera, e.g. testudínea, Lasius spp., Linepíthema (Iridiomyrmex) humile, Monomorium pharaonis, Paratrechína spp., Paravespula spp., Plagiolepis spp., Sirex spp., e.g. Sirex noctilio, Solenopsis invicta, Tapinoma spp., Technomyrmex albipes, Urocerus spp., Vespa spp., for example Vespa crabro, Wasmannia auropunctata, Xeris spp.; from the order Isopoda, for example Armadillidium vulgare, Oniscus asellus, Porcellio scaber; of the order Isoptera, for example Coptotermes spp., for example Coptotermes formosanus, Cornitermes cumulaos, Cryptotermes spp., Incisitermesspp., Kalotermes spp., Microtermes obesi, Nasutítermes spp., Odontotermes spp., Porotermes spp., Reticulitermes spp., for example Reticulitermes flavipes, Reticulitermes hesperus; of the order Lepidoptera, e.g. Achroia grisella, Acronicta major, Adoxophyes spp., e.g. Adoxophyes orana, Aedia leucomelas, Agrotis spp., e.g. Agrotis segetum, Agrotis ipsilon, Alabama spp., e.g. Alabama argillacea, Amyelois transitella, Anarsia spp. ., Anticarsia spp., e.g. Anticarsia gemmatalis, Argyroploce spp., Autographa spp., Barathra brassicae, Blastodacna atra, Borbo cinnara, Bucculatrix thurberiella, Bupalus piniarius, Busseola spp., Cacoecia spp., Caloptilia theivora, Capua reticulana, Carpocapsa pomonella , Carposine niponnsis, cheimatobia Brumata, Chilo spp., For example Chilo Plejadellus, Chil Ortrachelus spp. , Copitarsia spp., Cydia spp., e.g. Cydia nigricana, Cydia pomonella, Dalaca noctuides, Diaphania spp., Diparopsis spp., Diatraea saccharalis, Dioryctria spp., e.g. Dioryctria zimmermani, Barias spp., Ecdytolopha aurantium, Elasmopalpus lignosellus, Eldana saccharina, Ephestia spp., e.g. Euproctis chrysorrhoea, Euxoa spp., Feltia spp., Gallería mellonella, Gracillaria spp., Grapholitha spp., e.g. Grapholita molesta, Grapholita prunívora, Hedyleptaspp., Helicoverpa spp., e.g. example Heliothís virescens, Hepialus spp., e.g. Hepialus humuli, Hofmannophila pseudospretella, Homoeosoma spp., Homona spp., Hyponomeuta padella, Kakivoria flavofasciata, Lampides spp., Laphygma spp., Laspeyresia molesta, Leucinodes orbonalis, Leucoptera spp., e.g. Leucoptera coffeella, Lithocolletis spp., e.g. Lithocolletis blancardella, Lithophane antennata, Lobesia spp., e.g. Lobesia botrana, Loxagrotis albicosta, Lymantria spp., e.g. Lymantria dispar, Lyonetia spp., e.g. Lyonetia clerkella, Malacosoma neustria, Maruca testulalis , Mamestra brassicae, Melanitis leda, Mocis spp., Monopis obviella, Mythimna separata, Nemapogon cloacellus, Nymphula spp., Oiketicus spp., Omphisa spp., Operophtera spp., Oria spp., Orthaga spp., Ostrinia spp., for example Ostrinia nubilalis, Panolis flammea, Parnara spp., Pectinophora spp., e.g. Pectinophora gossypiella, Perileucoptera spp., Phthorimaea spp., e.g. Phthorimaea operculella, Phyllocnistis citrella, Phyllonorycter spp., e.g. Phyllonorycter blancardella, Phyllonorycter crataegella, Pier is spp. , for example Pieris rapae, Platynota stultana, Plodia interpunctella, Plusia spp., Plutella xylostella (=Plutella maculipennis), Podesia spp., for example Podesia syringae, Prays spp., Prodenia spp., Protoparce spp., Pseudaletia spp., for example e.g. Pseudaletia unipuncta, Pseudoplusia includens, Pyrausta nubilalis, Rachiplusia nu, Schoenobius spp., e.g. Schoenobius bipunctifer, Scirpophaga spp., e.g. Scirpophaga innotata, Scotia segetum, Sesamia spp., e.g. Sesamia inferens, Sparganothis spp., Spodoptera spp. , for example Spodoptera eradiana, Spodoptera exigua, Spodoptera frugiperda, Spodoptera praefica, Stathmopoda spp., Stenoma spp., Stomopteryx t7C«nnn / 77n7 / B / YiAi subsecivella, Synanthedon spp., Tecla solanivora, Thaumetopoea spp., Thermesia gemmatalis, Tinea cloacella, Tinea pellionella, Tineola bisselliella, Tortrix spp., Trichophaga tapetzella, Trichoplusia spp., e.g. Trichoplusia ni, Tryporyza incertulas, Tuta ABSOLUTA, Virachola spp.; of the order Orthoptera or Saltatoria, e.g. gregarious; from the order Phthiraptera, for example Damalinia spp., Haematopinus spp., Linognathus spp., Pediculus spp., Phylloxera vastatrix, Phthirus pubis, Trichodectes spp.; from the order Psocoptera, for example Lepinotus spp., Liposcelis spp.; from the order Siphonaptera, for example, Ceratophyllus spp., Ctenocephalides spp., for example Ctenocephalides canis, Ctenocephalides felis, Pulex irritans, Tunga penetrans, Xenopsylla cheopis; of the order Tisanoptera, e.g. Anafothrips obscurus, Baliothrips biformis, Chaetanatothrips leeuweni, Drepanothrips reuteri, Enneothrips flavens, Frankliniella spp., e.g. Frankliniella fusca, Frankliniella occidentalis, Frankliniella schultzei, Frankliniella tritici, Frankliniella vaccinii, Frankliniella williamsi, Haplothrips spp., Heliothrips spp., Hercinothrips femoralis, Kakothrips spp., Rhipiphorothrips cruentatus, Scirtothrips spp., Taeniothrips cardamomi, Thrips spp., for example Thrips palmi, Thrips tabaci; from the order Zygentoma (= Tisanura), for example Ctenolepisma spp., Lepisma saccharina, Lepismodes inquilinus, Thermobia domestica; from the class Symphyla, for example Scutigerella spp., for example Scutigerella immaculata; pests of the phylum Mollusca, for example of the class Bivalvia, for example Dreissena spp., and also of the class Gastropoda, for example Arion spp., for example Arion ater rufus, Biomphalaria spp., Bulinus spp., Deroceras spp., for example example Deroceras laeve, Galba spp., Lymnaea spp., Oncomelania spp., Pomacea spp., Succinea spp.; plant pests of the phylum Nematoda, i.e. phytoparasitic nematodes, in particular Aglenchus spp., e.g. Aglenchus agricultural, Anguina spp., e.g. Anguina tritici, Aphelenchoides spp., e.g. Aphelenchoides arachidis, Aphelenchoides fragariae, Belonolaimus spp., e.g. Belonolaimus gracilis, Belonolaimus longicaudatus, Belonolaimus nortoni, Bursaphelenchus spp., e.g. Bursaphelenchus cocophilus, Bursaphelenchus eremus, Bursaphelenchus xylophilus, Cacopaurus spp., e.g. Cacopaurus pestis, Criconemella spp., e.g. Criconemella curvata, Criconemella onoensis, Criconem she ornata, Criconemella rusium , Criconemella xenoplax (= Mesocriconema xenoplax), Criconemoides spp., e.g. Criconemoides ferniae, Criconemoides onoense, Criconemoides ornatum, Ditylenchus spp., e.g. Ditylenchus dipsaci, Dolichodorus spp., Globodera spp., e.g. Globodera pallida, Globodera rostochiensis, Helicotylenchus spp., e.g. Helicotylenchus dihystera, Hemicriconemoides spp., Hemicicliophora spp., Heterodera spp., e.g. Heterodera gallinae, Heterodera glycines, Heterodera schachtii, Hirschmaniella spp., Hoplolaimus spp., Longidorus spp., e.g. African Longidorus, Meloidogyne spp. ., for example Meloidogyne chitwoodi, Meloidogyne fallax, Meloidogyne hapla, Meloidogyne incógnita, Meloinema spp., Nacobbus spp., Neotylenchus spp., ., Paralongidorus spp., Paraphelenchus spp., Paratrichodorus spp., for example Paratrichodorus minor, Paratylenchus spp. , Pratylenchus spp., e.g. Pratylenchus penetrans, Pseudohalenchus spp., Psilenchus spp., Punctodera spp., Quinisulcius spp., Radopholus spp., e.g. Radopholus citrophilus, Radopholus similis, Rotylenchulus spp., Rotylenchus spp., Scutellonema spp. , Subanguina spp., Trichodorus spp., e.g. Trichodorus obtusus, Trichodorus primitivus, Tylenchorhynchus spp., e.g. Tylenchorhynchus annulatus, Tylenchulus spp., e.g. Tylenchulus semipenetrans, Xiphinema spp., e.g. Compounds having formula (I) can optionally, at certain concentrations or application rates, also be used as herbicides, antidotes, growth regulators or agents to improve plant properties, such as microbicides or gametocides, for example as fungicides, antifungal, bactericidal, viricidal (including anti-viroid agents) or as agents against mycoplasma-like organisms (MLO) and rickettsia-like organisms (RLO). If appropriate, they can also be used as intermediates or precursors for the synthesis of other active compounds. Formulations / Usage Forms The present invention further relates to formulations, in particular formulations for controlling unwanted animal pests. The formulation can be posed to the pest animal and / or its habitat. The formulation of the invention can be provided to the end user as a ready-to-use form, that is, the formulations can be applied directly to the plants or seeds by a suitable device, such as a spray or dusting device. Alternatively, the formulations may be provided to the end user in the form of concentrates which must be diluted, with water, before use. Unless otherwise indicated, the term formulation therefore means said concentrate, while the term use form means the end user as a ready-to-use solution, i.e. usually said diluted formulation. The formulation of the invention may be prepared in conventional ways, for example by mixing the compound of the invention with one or more suitable auxiliaries, as described herein. The formulation comprises at least one compound of the invention and at least one agriculturally suitable auxiliary, for example, carrier(s) and / or surfactant(s). A carrier is a solid or liquid, natural or synthetic, organic or inorganic substance that is generally inert. The carrier generally enhances the application of the compounds, for example, to plants, plant parts or seeds. Examples of suitable carriers include, but are not limited to, ammonium salts, in particular ammonium sulphates, ammonium phosphates and ammonium nitrates, natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite and diatomaceous earth, silica gel and synthetic rock flours, such as finely divided silica, alumina and silicates. Examples of carriers typically useful for the preparation of granules include, but are not limited to, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, synthetic granules of inorganic and organic flours and granules of organic material such as paper, sawdust, coconut shells, corn cobs and tobacco stalks. Examples of suitable liquid carriers include, but are not limited to, water, organic solvents and combinations thereof. Examples of suitable solvents include polar and non-polar organic chemical liquids, for example from the classes of aromatic and non-aromatic hydrocarbons (such as cyclohexane, paraffins, alkylbenzenes, xylene, toluene, tetrahydronaphthalene, alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes or methylene chloride), alcohols and polyols (which may optionally also be substituted, etherified and / or esterified, such as ethanol, propanol, butanol, benzyl alcohol, cyclohexanol or glycol), ketones (such as acetone, methyl ethyl ketone, methyl isobutyl ketone, acetophenone, or cyclohexanone), esters (including fats and oils) and (poly)ethers, unsubstituted and substituted amines, amides (such as dimethylformamide or fatty acid amides) and their esters, lactams (such as Nalkylpyrrolidones, in particular N -methylpyrrolidone) and lactones, sulfones and sulfoxides (such as dimethyl sulfoxide), oils of plant or animal origin, nitriles (alkyl nitriles such as acetonitrile, propionotrile, butyronitrile, or aromatic nitriles, such as benzonitrile), carbonic acid esters ( cyclic carbonic acid esters, such as ethylene carbonate, propylene carbonate, butylene carbonate, or dialkyl carbonic acid esters, such as dimethyl carbonate, diethyl carbonate, dipropyl carbonate, dibutyl carbonate, dioctyl carbonate). The vehicle may also be a liquefied gaseous extender, that is, liquid that is gaseous at standard temperature and under standard pressure, for example, aerosol propellants such as halohydrocarbons, butane, propane, nitrogen and carbon dioxide. Preferred solid carriers are selected from clays, talc and silica. Preferred liquid carriers are selected from water, fatty acid amides and their esters, aromatic and non-aromatic hydrocarbons, lactams, lactones, carbonic acid esters, ketones, (poly) esters. The amount of carrier typically ranges from 1 to 99.99%, possibly from 5 to 99.9%, greater than 10 to 99.5%, and greater than 20 to 99% by weight of the formulation. Liquid carriers are typically present in a range of 20 to 90%, for example 30 to 80% by weight of the formulation. Solid carriers are typically present in a range of 0 to 50%, especially 5 to 45%, for example 10 to 30% by weight of the formulation. If the formulation comprises two or more carriers, the ranges described refer to the total number of carriers. The surfactant may be an ionic (cationic or anionic), amphoteric or nonionic surfactant, such as ionic or nonionic emulsifier, foam former(s), dispersant(s), wetting agent(s), penetration enhancer (s) and any mixture thereof. Examples of suitable surfactants include, but are not limited to, polyacrylic acid salts, ethoxylated (alpha-substituted) dick acrylate derivatives, lignosulfonic acid salts (such as sodium lignosulfonate), phenolsulfonic acid or naphthalenesulfonic acid salts, polycondensates. of ethylene oxide and / or propylene oxide with or without alcohols, fatty acids or fatty amines (for example, polyoxyethylene fatty acid esters such as castor oil ethoxylate, polyoxyethylene fatty alcohol ethers, for example alkyl ethers of polyglycol), substituted phenols (alkylphenols or arylphenols), salts of sulfosuccinic esters, taurine derivatives (alkylated alkyls), phosphoric esters of polyethoxylated alcohols or phenols, polyol fatty esters (such as fatty acid esters of glycerol, sorbitol or sucrose) , sulfates (such as alkyl sulfates and alkyl ether sulfates), sulfonates (e.g., alkyl sulfonates, arylsulfonates and alkylbenzene sulfonates), sulfonated naphthalene / formaldehyde polymers, phosphate esters, protein hydrolysates, waste lignosulfite liquorsulfates and methylcellulose . Any reference to salts in this paragraph refers to the respective alkali, alkaline earth and ammonium salts. Preferred surfactants are selected from ethoxylated (alpha-substituted) cockerel acrylate derivatives, polycondensates of ethylene oxide and / or propylene oxide with alcohols, polyoxyethylene fatty acid esters, alkylbenzene sulfonates, sulfonated naphthalene / formaldehyde polymers, esters of polyoxyethylene fatty acid such as castor oil ethoxylate, sodium lignosulfonate and arylphenol ethoxylate. The amount of surfactants typically varies from 5 to 40%, for example from 10 to 20%, by weight of the formulation. Other examples of suitable auxiliaries include water repellents, driers, binders (adhesive, adhesive, fixing agent, such as carboxymethyl cellulose, natural and synthetic polymers in the form of powders, granules or sheets, such as gum arabic, polyvinyl alcohol and polyvinyl acetate , natural phospholipids such as cephalins and lecithins and synthetic phospholipids, polyvinylpyrrolidone and tylose), thickeners and secondary thickeners (such as cellulose esters, acrylic acid derivatives, xanthan gum, modified clays, for example products available under the name Bentone, finely silica divided), stabilizers (for example, cold stabilizers, preservatives (for example dichlorophene, benzyl alcohol hemiformal, 1,2-benzisothiazolin-3-one, 2-methyl-4isothiazolin-3-one), antioxidants, light stabilizers, in particular UV stabilizers, or other agents that improve chemical and / or physical stability), dyes or pigments (such as inorganic pigments, for example, iron oxide, titanium oxide and Prussian blue; organic dyes, e.g. alizarin, metal azo dyes and phthalocyanine), antifoams (e.g. silicone defoamers and magnesium stearate), antifreezes, sealants, gibberellins and process auxiliaries, mineral and vegetable oils, perfumes, waxes, nutrients (including trace nutrients, such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc), protective colloids, thixotropic substances, penetrants, sequestering agents and complexing agents. The choice of auxiliaries depends on the intended mode of application of the compound of the invention and / or on the physical properties of the compound(s). Furthermore, auxiliaries can be chosen to impart particular properties (technical, physical and / or biological properties) to the formulations or use forms prepared from them. The choice of auxiliaries can allow formulations to be customized to specific needs. The formulation comprises an insecticidal / acaricidal / nematicidal effective amount of the compound(s) of the invention. The term effective amount denotes an amount, which is sufficient to control harmful insects / mites / nematodes on cultivated plants or in protection materials and which does not result in substantial damage to the treated plants. Such amount can vary over a wide range and depends on several factors, such as the species of insect / mite / nematode to be controlled, the plant or cultivated material treated, the climatic conditions and the specific compound of the invention used. Usually, the formulation according to the invention contains from 0.01 to 99% by weight, probably from 0.05 to 98% by weight, more preferably from 0.1 to 95% by weight, even more directly from 0.5 to 90% by weight, more probably from 1 to 80% by weight of the compound of the invention. It is possible that a formulation comprises two or more compounds of the invention. In such case, the ranges described refer to the total amount of compounds of the present invention. The formulation of the invention can be any type of custom formulation, solutions such as (for example, aqueous solutions), emulsions, water-oil base suspensions, powders (for example, wettable powders, soluble powders), powders, pastes , granules (for example, soluble granules, diffusion granules), suspoemulsion concentrates, natural or synthetic products impregnated with the compound of the invention, fertilizers and also microencapsulations in polymeric substances. The compound of the invention may be present in a suspended, emulsified or dissolved form. Examples of particular suitable formulation types are solutions, water-soluble concentrates (e.g. SL, LS), dispersible concentrates (DC), suspensions and suspension concentrates (e.g. SC, OD, OF, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME, SE), capsules (e.g. CS, ZC), pastes, tablets, wettable powders or powders (e.g. WP, SP, WS, DP, DS), pressed (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG, GG, MG), insecticidal articles (e.g. LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e.g. GW, GF). These and other types of formulations are defined by the Food and Agriculture Organization of the United Nations (FAO). An overview is given in the Catalog of Pesticide Formulation Types and International Coding System, Technical Monograph Ns2, 6aed. May 2008, Croplife International. Preferably, the formulation of the invention is in the form of one of the following types: EC, SC, FS, SE, OD, WG, WP, CS, EC, SC, OD, WG, CS are more preferred. Other details about examples of formulation types and their preparation are provided below. If two or more compounds of the invention are present, the indicated amount of compound of the invention refers to the total amount of compounds of the present invention. This applies mutatis mutandis for any other component of the formulation, if two or more representatives of said component, e.g. wetting agent, binder, are present. i) Water-soluble concentrates (SL, LS) 10-60% by weight of at least one compound of the invention and 5-15% by weight surfactant (for example polycondensates of ethylene oxide and / or propylene oxide with alcohols) are dissolved in such an amount of water and / or water-soluble solvent (for example alcohols such as propylene glycol or carbonates such as propylene carbonate) to give a total amount of 100% by weight. Before application the concentrate is diluted with water. i) Dispersible concentrates (DC) 5-25% by weight of at least one compound of the invention and 1-10% by weight surfactant and / or binder (for example polyvinylpyrrolidone) are dissolved in such an amount of organic solvent (for example cyclohexanone) to give a total amount 100% by weight. Dilution with water results in a dispersion. iii) Emulsifiable concentrates (EC) 15-70% by weight of at least one compound of the invention and 5-10% by weight surfactant (for example a mixture of calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in such an amount of water-insoluble organic solvent (eg aromatic hydrocarbon or fatty acid amide) and if necessary water-soluble solvent to give a total amount of 100% by weight. Dilution with water gives rise to an emulsion. iv) Emulsions (EW, EO, ES) 5-40% by weight of at least one compound of the invention and 1-10% by weight surfactant (for example a mixture of calcium dodecylbenzenesulfonate and castor oil ethoxylate, or polycondensates of ethylene oxide and / or propylene oxide with or without alcohols) are dissolved in 20-40% by weight water-insoluble organic solvent (for example aromatic hydrocarbon). This mixture is added to such an amount of water by an emulsifying machine to give a total amount of 100% by weight. The resulting formulation is a homogeneous emulsion. Before application the emulsion can be further diluted with water. v) Suspensions and suspension concentrates v-1) Water-based (SC, FS) frCRnnn / zznz / E / YiAi In suitable grinding equipment, for example a stirred ball mill, 20-60% by weight of at least one compound of the invention are ground with the addition of 2-10% by weight surfactant (for example sodium lignosulfonate and sodium ether). fatty acid and polyoxyethylene), 0.1-2% by weight thickener (for example xanthan gum) and water to give a fine suspension of the active substance. Water is added in such an amount to give a total amount of 100% by weight. Dilution with water gives rise to a stable suspension of the active substance. For formulations of the FS type, up to 40% by weight of a binder (for example polyvinylalcohol) is added. v-2) Oil based (OD, OF) In suitable grinding equipment, for example a stirred ball mill, 20-60% by weight of at least one compound of the invention is grinded with the addition of 2-10% by weight surfactant (for example sodium ether lignosulfonate of fatty acid and polyoxyethylene, 0.1-2% by weight of thickener (for example modified clay, in particular Bentone, or silica) and an organic carrier to give a fine oily suspension of the active substance. The organic carrier is added in an amount such to give a total amount of 100% by weight. Dilution with water results in a stable dispersion of the active substance. vi) water dispersible granules and water soluble granules (WG, SG) 1-90% by weight, preferably 20-80%, more preferably 50-80% by weight of at least one compound of the invention is finely ground with the addition of a surfactant (for example sodium lignosulfonate and sodium alkylnaphthylsulfonates) and potentially a carrier material and converted into water-dispersible or water-soluble granules by typical technical applications such as extrusion, spray drying, fluid bed granulation. The surfactant and carrier material is used in such an amount to give a total amount of 100% by weight. Dilution with water gives rise to a dispersion or stable solution of the active substance. vii) Water-dispersible powders and water-soluble powders (WP, SP, WS) 50-80% by weight of at least one compound of the invention are ground in a rotor and stator mill with the addition of 1-20% in weight surfactant (for example sodium lignosulfonate, sodium alkylnaphthylsulfonates) and such an amount of solid carrier, for example silica gel, to give a total amount of 100% by weight. Dilution with water gives rise to a dispersion or stable solution of the active substance. viii) Gel (GW, GF) In a stirred ball mill, 5-25% by weight of at least one compound of the invention are ground with the addition of 3-10% by weight surfactant (for example sodium lignosulfonate), 1-5% by weight binder ( for example carboxymethylcellulose) and such an amount of water to give a total amount of 100% by weight. This results in a fine suspension of the active substance. Dilution with water results in a stable suspension of the active substance. ix) Micro emulsion (ME) 5-20% by weight of at least one compound of the invention are added to 5-30% by weight mixture of organic solvents (for example fatty acid dimethylamide and cyclohexanone), 10-25% by weight of surfactant mixture (for example example polyoxyethylene ether and fatty alcohol and arylphenol ethoxylate), and such an amount of water to give a total amount of 100% by weight. This mixture is stirred for 1 h to spontaneously produce a thermodynamically stable microemulsion. x) Microcapsules (CS) An oily phase comprising 5-50% by weight of at least one compound of the invention, 0-40% by weight water-insoluble organic solvent (for example aromatic hydrocarbon), 2-15% by weight acrylic monomers (for example methyl methacrylate , methacrylic acid and a di- or triacrylate) are dispersed in an aqueous solution of protective colloid (for example polyvinyl alcohol). Radical polymerization initiated by a radical initiator leads to the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50% by weight of at least one compound of the invention, 0-40% by weight water-insoluble organic solvent (for example aromatic hydrocarbon), and an isocyanate monomer (for example diphenylmethene- 4,4'-di¡socyanatae) are dispersed in the aqueous solution of a protective colloid (for example polyvinyl alcohol), which gives rise to the formation of polyurea microcapsules. Optionally, the addition of a polyamine (for example hexamethylenediamine) is also used to give rise to the formation of polyurea microcapsules. The amount of monomers is 1-10% by weight of the total CS formulation. x¡) Powders (DP, DS) -10% by weight of at least one compound of the invention is finely ground and intimately mixed with such an amount of solid carrier, for example finely divided kaolin, to give a total amount of 100% by weight. xii) Granules (GR, FG) 0.5-30% by weight of at least one compound of the invention is finely ground and associated with such an amount of solid carrier (for example silicate) to give a total amount of 100% by weight. xiii) Ultra Low Volume Liquids (UL) 1-50% by weight of at least one compound of the invention are dissolved in such an amount of an organic solvent, for example aromatic hydrocarbon, to give a total amount of 100% by weight. Formulation types i) to xiii) may optionally comprise other auxiliaries, such as 0.1-1% by weight preservatives, 0.1-1% by weight antifoams, 0.1-1% by weight inks and / or pigments, and 5-10% by weight of antifreeze. Mixtures The compounds having the formula (I) can also be used as a mixture with one or more fungicides, bactericides, acaricides, molluscicides, nematicides, insecticides, microbiological, beneficial species, herbicides, fertilizers, bird repellents, phytonics, sterilizers, protectors, etc semiochemicals and / or plant growth regulators, in order to, for example, broaden the spectrum of action, prolong the duration of action, increase the speed of action, prevent rejection or prevent the evolution of resistance. Furthermore, such combinations of active compounds can improve plant growth and / or tolerance to abiotic factors, for example, high or low temperatures, drought or high water content or soil salinity. It is also possible to improve flowering and fruiting performance, optimize germination capacity and root development, facilitate harvesting and improve yields, influence ripening, improve quality and / or nutritional value of harvested products. , prolong storage life and / or improve the processability of harvested products. Furthermore, the compounds of formula (I) may be present in a mixture with other active compounds or semiochemicals such as bird attractants and / or repellents and / or plant activators and / or growth regulators and / or fertilizers. Similarly, compounds having formula (I) can be used to improve plant properties such as growth, yield and quality of harvested material. In a particular embodiment according to the invention, the compounds having the formula (I) are present in formulations or the use forms prepared from these formulations in a mixture with other compounds, preferably those described below. If one of the compounds mentioned below can be found in different tautomeric forms, these forms are also included, even if they are not explicitly mentioned in each case. Furthermore, all named mixing pairs can, if their functional groups permit, optionally form salts with suitable bases or acids. Insecticides / miticides / nematicides The active compounds identified herein by their common names are known and are described, for example, in the pesticide manual (“The Pesticide Manual” 16th Ed., British Crop Protection Council 2012) or can be found on the Internet (e.g. http: / / www.alanwood.net / pesticides). The classification is based on the current version of the IRAC Mode of Action Classification Scheme at the time of filing this patent application. (1) Acetylcholinesterase (AChE) inhibitors, preferably carbamates to be selected from alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, etiofencarb, fenobucarb, formethanate, furatiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, tiofanox, triazamate, trimetacarb, , coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, etion, ethoprophos, famfur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenofos, imiciaphos, isofenphos, isopropyl O- (methoxyaminothiophosphor¡l) salicylate, isoxation, malathion, mecarbam, methamidophos, metidathion, mevinphos, monocrotofos, naled, omethoate, oxidemeton-methyl, parathion-methyl, fenthoate, phorate, fosalone, phosmet, fosfamidon, phoxim, pirimifos-methyl, profenophos , propetamphos, protiophos, pyraclophos, pyridafenthion, quinalfos, sulfotep, tebupirimphos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, trichlorfon and vamidothion. (2) Blockers of GABA-regulated chloride channels, preferably organochlorines of cyclodienes selected from chlordane and endosulfan, or phenylpyrazoles (fiprols) selected from etiprol and fipronil. (3) Sodium channel modulators, preferably pyrethroids selected from acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioalletrin, s-cyclopentenyl isomer of bioalletrin, bioresmethrin, cycloprothrin, cyfluthrin, beta -cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(1R)-trans isomer], deltamethrin, empentrin [(EZ)-(1R) isomer )], esfenvalerate, etofenprox, fenpropatrin, fenvalerate, flucitrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin [(1R)-trans isomer], pralletrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R) isomer)], tralometrin and transfluthrin or DDT or methoxychlor. (4) Competitive modulators of the nicotinic acetylcholine receptor (nAChR), preferably neonicotinoids selected from acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam, or nicotine, or sulfoximines selected from sulfoxaflor, or butenolides selected from from flupyradifurone, or mesoionics selected from triflumezopyrim. (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR), preferably spinosyns selected from spinetoram and spinosad. (6) Allosteric modulators of glutamate-regulated chloride channels (GluCI), preferably avermectins / milbemycins to be selected from abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone mimics, preferably juvenile hormone analogues selected from hydroprene, kinoprene and methoprene, or phenoxycarb or pyriproxyfen. (8) Miscellaneous non-specific (multi-site) inhibitors, preferably alkyl halides selected from methyl bromide and other alkyl halides, or chloropicrin or sulfuryl fluoride or borax or tartar emetics or methyl isocyanate generators selected from of diazomet and metam. (9) Modulators of the TRPV channels of the chordotonal organs, preferably pyridine azomethanes to be selected from pymetrozine and pyrifluquinazone, or pyropenes to be selected from afidopyropene. (10) Mite growth inhibitors affecting CHS1 to be selected from clofentezine, hexythiazox, diflovidazine and etoxazole. (11) Microbial disruptors of insect intestinal membranes to be selected from Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and B.t. of plant proteins to be selected from CrylAb, CrylAc, CrylFa, Cry1A,105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb and Cry34Ab1 / 35Ab1. (12) Inhibitors of mitochondrial ATP synthase, preferably ATP disruptors selected from diafenthiuron, or organotin compounds selected from azocyclotin, cyhexatin and fenbutatin oxide, or propargite or tetradifon. (13) Uncouplers of oxidative phosphorylation by proton gradient disruption to be selected from chlorfenapyr, DNOC and sulframid. (14) Blockers of channels regulated by the nicotinic acetylcholine receptor to be selected from bensultap, cartap hydrochloride, thiocylam and thiosultap-sodium. (15) Chitin biosynthesis inhibitors that affect CHS1, preferably benzoylureas to be selected from bistrifluron, chlorfluazuron, diflubenzuron, flucicloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. (16) Chitin biosynthesis inhibitors, type 1 to be selected from buprofezin. (17) Moult disruptor (particularly for Diptera, i.e. dipteranes) to be selected from cyromazine. (18) Ecdysome receptor agonists, preferably diacylhydrazines to be selected from chromafenozide, halofenozide, methoxyfenozide and tebufenozide. (19) Octopamine receptor agonists to be selected from amitraz. (20) Inhibitors of electronic transport in mitochondrial complex III to be selected from hydramethylnonone, acequinocyl, fluacripyrim and bifenazate. (21) Inhibitors of electronic transport in mitochondrial complex I, preferably METI acaricides and insecticides to be selected from fenazaquine, fenpyroximate, pyrimidifene, pyridaben, tebufenpyrad and tolfenpyrad, or rotenone (Derris). (22) Voltage-gated sodium channel blockers, preferably oxadiazines to be selected from indoxacarb or semicarbazones to be selected from metaflumizone. (23) Acetyl CoA carboxylase inhibitors, preferably derived from tetronic and tetramic acids to be selected from spirodiclofen, spiromesifen, spiropyridion and spirotetramat. (24) Inhibitors of electron transport in mitochondrial complex IV, preferably phosphides to be selected from aluminum phosphide, calcium phosphide, phosphine and zinc phosphide, or cyanides to be selected from calcium cyanide, potassium cyanide and cyanide of sodium. (25) Inhibitors of electronic transport in mitochondrial complex II, preferably beta-ketonitrile derivatives to be selected from cynopyrafen and cyflumethofen, or carboxanilides to be selected from piflubumide. (28) Ryanodine receptor modulators, preferably diamides to be selected from chlorantraniliprole, cyantraniliprole, cyclaniliprol, flubendiamide and tetraniliprole. (29) Modulators of chordotonal organs (with undefined target site) to be selected from flonicamide. (30) GABA-gated chlorid channel allosteric modulators, preferably meta-diamides selected from broflanilide, or isoxazoles selected from fluxametamide. (31) Baculovisuses, preferably Granuloviruses (GVs) selected from Cydia pomonella GV and Thaumatotibia leucotreta (GV), or Nucleopolyhedroviruses (NPVs) selected from Anticarsia gemmatalis MNPV and Helicoverpa armigera NPV. (32) Nicotinic acetylcholine receptor allosteric modulators (Site II) selected from GSomega / kappa HXTX-Hv1a peptide. (30) Other active compounds to be selected from acinonapepepropic, Afoxolaner, azadiractin, benchlotiaz, benzoxyxy, benzpiimoxan, bromopropilate, quinometionat, chloropralletrin, Creole, cyclobutrifuram, cicloxaprid -88-4), dichloromezotiaz , Dicofol, Dimpropyridaz, epsilonMetofluthrin, epsilon-Momfluthrin, Flomethoquine, Fluazaindolizine, Flucipyriprole (CAS 1771741-86-6), Fluensulfone, Flufenerim, Flufenoxystrobin, Flufiprol, Fluhexafon, Fluopyram, Flupirimine, Fluralaner, Fufenozide, Fluperntiofenox, Guadipir, He Ptafluthrin, Imidaclotiz , Iprodione, Isocycloseram, kappa-Bifentrine, kappa-Tefluthrin, Lotilaner, Meperfluthrin, Nicofluprol (CAS 1771741-86-6), Oxazosulfil, Paichongding, Pyridalyl, Pyrifluquinazon, Pyriminostrobin, Sarolaner, Spidoxamat, Spirobudiclofen, Tetramethylfluthrin, Tetrachlorantraniliprole, Tigolan er, Thioxazaphene , Thiofluoximate Ticlopyrazoflor, lodomethane; and also preparations based on Bacillus firmus (1-1582, Votivo) and azadirachtin (BioNeem), and also the following compounds: 1 -{2-fluoro-4methyl-5-[(2,2,2-trifluoroethyl )sulf¡n¡l]phen¡l}-3-(trifluoromethyl)-1 H-1,2,4-thazol-5-amine (disclosed in WO2006 / 043635) (CAS 885026-50-6), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1yl]piperidin-4-yl}-4-(trifluoromethyl)phenyl]isonicotinamide (disclosed in WO2006 / 003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxyl-8-methoxyl-1,8-diazaspiro[4.5]dec -3-en2-one (disclosed in WO 2010052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8methox¡-2-oxo-1,8-diazaspiro[ 4.5]dec-3-en-4-¡l ethyl carbonate (disclosed in EP2647626) (CAS 1440516-42-6), PF1364 (disclosed in JP2010 / 018586) (CAS 1204776-60-2), (3E)-3 [1-[(6-chloro-3-pyrid¡l)methyl]-2-pyrid¡l¡dene]-1,1,1-trifluoro-propan-2-one (disclosed in WO2013 / 144213 ) (CAS 1461743-15-6), N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3(pentafluoroethyl)-4-(trifluoromethyl)-1 H-pyrazole-5- carboxamide (disclosed in WO2010 / 051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N-[4-chloro-2-methyl-6(methylcarbamo¡l)phen¡l]-2-( 3-chloro-2-pyridyl)pyrazole-3-carboxamide (disclosed in CN103232431) (CAS 1449220-44-3), 4-[5-(3,5-dichlorophenyl)-4, 5-dihydro-5-(trifluoromethyl)-3-soxazolyl]-2-methyl-N-(cis-1-oxido-3-thiethane)-benzamide , 4-[5-(3,5-dichlorophenyl)-4,5-d¡hydro-5(trifluoromethyl)-3-isoxazol¡l]-2-methyl-N-(trans-1 -oxide-3-thiethan¡l)-benzamide and 4-[(5S)-5-(3,5dichlorophen¡l)-4,5-dih¡diO-5-( trifluoiOmethyl)-3-¡soxazol¡l]-2-methyl¡l-N-(c¡s-1-oxide-3thietanyl)benzamide (disclosed in WO 2013 / 050317 A1) (CAS 1332628-83-7), N -[3-chloro-1(3-pyridín¡l)-1 H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoroprop¡l)sulfányl]- propanamide, (+)-N-[3chloro-1 -(3-pyridin¡l)-1 H-pyrazol-4-¡l]-N-ethyl-3-[(3,3,3- trifluoropropyl)sulfinyl]-propanamide and (-)N-[3-chloro-1 -(3-pyridinyl)-1 H-pyrazol-4-yl]-N-ethyl-3 -[(3,3,3-trifluoropropyl)sulfin¡l]-propanamide (disclosed in WO 2013 / 162715 A2, WO 2013 / 162716 A2, US 2014 / 0213448 A1) (CAS 1477923-37-7) , 5-[[(2E)-3-chloro-2-propen-1-yl]amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4 [(trifluoromethyl)sulf¡n¡l]-1 H-pyrazole-3-carbonitrile (disclosed in CN 101337937 A) (CAS 1105672-77-2), 3-bromo-N-[4-chloro-2-methyl- 6-[(methylamino)thioxomethyl]phenyl]-1-(3-chloro-2pyridinyl)-1H-pyrazole-5-carboxamide, (Liudaibenjiaxuanan, disclosed in CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro-2-[[(1,1-dimet¡leth¡l)amino]carbonyl]-6-methylphen¡l]-1-(3-chloro2-pyridín¡l)- 3-(fluoromethoxy¡)-1 H-pyrazole-5-carboxamide (disclosed in WO 2012 / 034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3,4-thiadiazole -2-¡l)-4-chloro-6-methylphenyl]-3-bromo-1 -(3chloro-2-pyridínyl)-1H-pyrazole-5-carboxamide (disclosed in WO 2011 / 085575 A1) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propen-1 -yl)oxy]phenoxy¡]propoxy¡ ]-2-methoxy¡6-(trifluoromethyl)-pyrimídine (disclosed in CN 101337940 A) (CAS 1108184-52-6); (2E)- and 2(Z)-2-[2-(4-cyanophenyl)-1 -[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(difluoromethoxy)phenyl]hydrazinecarboxamide (disclosed in CN 101715774 A) (CAS 1232543-85-9); 3-(2,2-dichloroethenyl)-2,2-dimethyl-4-(1 H-benzimidazol-2-yl)phenyl-cyclopropanecarboxylic acid ester (disclosed in CN 103524422 A) (CAS 1542271-46-4); (4aS)-7chloro-2,5-dihydro-2-[[(methoxycarbon¡l)[4-[(tnfluoromethyl)thio]phen¡l]amino]carbon acid methyl ester l]-endene[1,2e][1,3,4]oxadiazine-4a(3H)-carboxylic acid (disclosed in CN 102391261 A) (CAS 1370358-692); 6-deoxy-3O-ethyl-2,4-d¡O-methyl-, 1 -[N-[4-[1 -[4-(1,1,2,2,2-pentafluoroethoxy)phenyl] -1 H-1,2,4tr¡azol-3-¡l]phen¡l]carbamate]-a-L-mannop¡ranose (disclosed in US 2014 / 0275503 A1) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3yl)-3-aza-bicyclo[3.2 .1 ]octane (CAS 1253850-56-4), (8-anti)-8-(2-cyclopropylmethoxy¡-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza -bicyclo[3.2.1 ]octane (CAS 933798-27-7), (8-syn)-8-(2-cyclopropílmethoxy¡-4-trifluoromethyl-phenoxy¡)-3-(6- trifluoromethylpyridazín-3-yl)-3-aza-bicyclo[3.2.1]octane (disclosed in WO 2007040280 A1, WO 2007040282 A1) (CAS 934001-66-8), N-[4-( aminothioxomethyl)-2-met¡l-6[(methylamino)carbon¡l]phen¡l]-3-bromo-1-(3-chloro-2-pyrid¡nyl)-1 H-pyrazole-5- carboxamide (disclosed in CN 103265527 A) (CAS 1452877-50-7), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy¡1-methyl-1,8-diazaspiro[4.5]decane -2,4-dione (disclosed in WO 2014 / 187846 A1) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy acid ethyl ester -1-methyl-2-oxo1,8-diazaspiro[4.5]dec-3-en-4-¡l-carbon¡co (disclosed in WO 2010 / 066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), Λ / -[1-(2,6-difluorophenyl )-1 H-pyrazol-3-yl]-2(trifluoromethyl)benzamide (known from WO 2014 / 053450 A1) (CAS 1594624-87-9), Λ / -[2-(2, 6-difluorophenyl) -2 / 7-1,2,3-triazol-4-yl]-2-(trifluoromethyl)benzamide (known from WO 2014 / 053450 A1) (CAS 1594637-65-6), N- [1-(3,5-difluoro-2-pyrid¡nyl)-1H-pyrazol-3-yl]-2(trifluoromethyl)benzamide (known from WO 2014 / 053450 A1) (CAS 1594626-19-3) , (3F?)-3(2-chloro-5-thiazolyl)-2,3-dihydro-8-methyl-5,7-dioxo-6-phenyl-5H-thiazolo[3 ,2-a]pyr¡m¡d¡n¡um inner salt (known from WO 2018 / 177970 A1) (CAS 2246757-58-2); 3-(2-chloro-5-thiazolyl)2,3-dihydro-8-methyl-5,7-dioxo-6-phenyl-5 / - / -thiazolo[3,2- a]pyr¡m¡din¡um inner salt (known from WO 2018 / 177970 A1) (CAS 2246757-56-0); A / -[3-chloro-1 -(3-pyridinyl)-1 H-pyrazol-4-yl]2-(methylsulfonyl)-propanamide (known from WO 2019 / 236274 A1) (CAS 2396747-83-2), N[2-bromo-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-6-(trifluoromethyl)phenyl]-2-fluoro-3-[(4fluorobenzoyl )amino]-benzamide (known from WO 2019059412 A1) (CAS 1207977-87-4). Fungicides. The active ingredients specified herein by their common names are known and are described, for example, in The Pesticide Manual (16th Ed.British Crop Protection Council) or can be found on the Internet (for example www.alanwood.net / pesticides). All named fungicide mixture pairs of classes (1) to (15) may, if their functional groups permit, optionally form salts with suitable bases or acids. All named mixture pairs of classes (1) to (15) may include tautomeric forms, where they exist. 1) Inhibitors of ergosterol biosynthesis, for example (1,001) cyproconazole, (1,002) difenoconazole, (1,003) epoxiconazole, (1,004) fenhexamid, (1,005) fenpropidine, (1,006) fenpropimorph, (1,007) fenpyrazamine, (1,008) fluquincon azole , (1,009) flutriafol, (1,010) imazalyl, (1,011) imazalyl sulfate, (1,012) ipconazole, (1,013) metconazole, (1,014) frCRnnn / zznz / B / YiAi myclobutanil, (1,015) paclobutrazol, (1,016) prochloraz, ( 1,017) propiconazole, (1,018) prothioconazole, (1,019) pyrisoxazole, (1,020) spiroxamine, (1,021) tebuconazole, (1,022) tetraconazole, (1,023) triadimenol, (1,024) tridemorph, (1,025) triticonazole, (1,026) (1R, 2S,5S)5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1 -(1H-1,2,4-triazol-1 -ylmethyl)-icyclo-ipentanol, (1.027) ( 1 S,2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1 -(1 H-1,2,4-triazol-1-ylmethyl)cyclopentanol, ( 1.028) (2R)-2-(1-chlorocyclopropyl)-4-[(1 R)-2,2-dichloro-iCÍclopropyl]-1 (1 H-1,2,4-triazole-1 - i I) butane -2-01, (1.029) (2R)-2-(1 -chloro-iC¡clopropyl)-4-[(1 S)-2,2di-ichlorocycloprop¡l]-1 -(1 H-1,2 ,4-triazol-1 -yl)butan-2-ol, (1.030) (2R)-2-[4-(4-chlorophenoxy¡)-2(trifluoromethyl)phenyl]-1 -(1 H-1,2 ,4-triazol-1 -yl)--propan-2-ol, (1.031) (2S)-2-(1 -chlorocyclopropyl)4-[(1 R)-2,2-d ichlorocyclopropyl]-1 -( 1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.032) (2S)-2-(1 chlorocyclopropyl)-4-[( 1 S)-2,2-dichloro-iC ¡clo-ipropyl]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.033) (2S)-2-[4-(4-chlorophenoxy)-2- (trifluoromethyl)phenyl]-1 -(1 H-1,2,4-triazol-1 -yl)propan-2-ol, (1.034) (R)-[3-(4-chloro -2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.035) (S)-[3 -(4-chloro-2-fluorophenyl)-5-(2,4-difluoro-iphen¡l)-1,2-oxazol-4-yl](pyrdín-3-¡l)methanol , (1,036) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridín-3-yl)methanol, (1.037) 1-({(2R,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H1 ,2,4-triazole, (1,038) 1-({(2S,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan -2yl}methyl)-1 H-1,2,4-triazole, (1,039) 1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)ox¡ran2-yl]methyl thiocyanate}-1 H-1,2,4-triazol-5-yl, (1.040) 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluoro-iphenyl) thiocyanate oxiran-2-yl]methyl}-1 H-1,2,4-triazol-5-yl, (1.041) 1-{[rel(2R,3S)-3(2-chlorophen¡ I)-2 thiocyanate - (2,4-difluorophenyl)oxy ran-2-yl]methyl}-1 H-1,2,4-triazol-5-yl, (1.042) 2[(2R,4R,5R)-1 -( 2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4triazol-3-thione, (1,043) 2-[(2R ,4R,5S)-1 -(2,4-dichlorophen¡l)-5-hydroxy¡-2,6,6-tnmet¡lheptan-4-yl]2,4-dihydro-3H-1,2,4 -triazol-3-thione, (1,044) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy¡2,6,6-trimethylheptan-4-yl ]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1.045) 2-[(2R,4S,5S)-1-(2,4dichlorophenyl )-5-hydroxy¡-2,6,6-trimet¡lheptan-4-¡l]-2,4-di¡hydro-3H-1,2,4-triazol-3-thione , (1,046) 2-[(2S,4R,5R)-1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-d¡ hydro-3H-1,2,4triazol-3-thione, (1.047) 2-[(2S,4R,5S)-1 -(2,4-dichlorophenyl)-5-hydroxy¡-2,6 ,6-trimethylheptan-4-yl]2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,048) 2-[(2S,4S,5R)-1 -(2,4- dichlorophenyl)-5-hydrox¡2,6,6-trimethyl-.heptan-4-¡l]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,049 ) 2-[(2S,4S,5S)-1-(2,4dichlorophenyl)-5-hydroxy¡-2,6,6-trimethylheptan-4-¡l]-2,4-d hydro-3H-1,2,4-triazol-3-thione, (1,050) 2-[1-(2,4-dichlorophenyl)-5-hydroxy¡-2,6,6- trimethylheptan-4-¡l]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,051) 2-[2-chloro-4-(2 ,4-dichlorophenoxy)phenyl]-1 -(1 H-1,2,4-triazol-1 -yl)propan-2-ol, (1,052) 2[2-chloro-4-(4-chlorophenoxy) phenyl]-1 -(1 H-1,2,4-triazol-1 -yl) butan-2-ol, (1,053) 2-[4-(441 chlorof e noxy)-2-(trif I ororomethyl )f e n i I] -1 -(1H-1,2,4-triazol-1 -II) butan-2-ol, (1.054) 2-[4-(4chlorof e noxy)-2-(trif I or oromethi l)f e n i I] -1 -(1 H-1,2,4-triazol-1 -yl)pentan-2-ol, (1.055) Mefentrifluconazole, (1,056) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4dihydro-3H-1,2,4-triazole-3 -thione, (1,057) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H -1,2,4-triazol-3-thione, (1,058) 2-{[rel(2R,3S)-3(2-chlorophenyl)-2-(2,4-difluoro—iphenyl)—toxiran-2- yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,059) 5-(4-chlorobenzyl)-2-(chloro-imethyl)-2-methyl- 1 -(1 H-1,2,4-triazol-1 -ylmethyl)cyclopentanol, (1,060) 5-(allyl-iSulfanyl)-1 -{[3-(2-chlorophenyl)-2-(2 ,4-difluorophenyl)oxiran-2-yl]methyl}-1 H-1,2,4triazole, (1.061) 5-(allylsulfanyl)-1 -{[rel(2R,3R)-3-(2-chlorophenyl) -2-(2,4-difluorophen¡l)oxiran-2yl]—,methyl}-1 H-1,2,4-triazole, (1.062) 5-(allylsulfanyl)-1 -{[rel (2R,3S)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-¡l]methyl}-1 H-1,2,4-triazole, (1,063) N'- (2,5-dimet¡l-4-{[3-(1,1,2,2tetrafluoroethoxy)phen¡l]sulfan¡l}phen¡l)-N-ethyl¡l-N-methyl¡m¡doformam ¡da, (1,064) N'-(2,5-dimethyl-4{[3-(2,2,2-trifluoroethoxy)phen¡l]sulfan¡l}phen¡l)-N-ethyl¡l-N -methylamide-iform-iamide, (1.065) N'-(2,5dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl) ]sulfan¡l}phen¡l)-N-ethyl¡l-N-methyl¡m¡doformamide, (1.066) N'-(2,5-dimethyl-4-{[3-(pentafluoroethoxy¡)- ifen¡l]-isulfan¡l}phen¡l)-N-ethyl-Nmethylimidoformamide, (1,067) N'-(2,5-dimethyl-4-{3-[(1,1,2,2tetrafluoroethyl) sulfan¡l]phenoxy¡}phen¡l)-N-ethyl¡l-N-methyl¡m¡doformamide, (1.068) N'-(2,5-dimethyl-4{3-[(2 ,2,2-trifluoroethyl)sulfan¡l]phenoxy¡}phenyl)-N-ethyl-N-met¡limide-iform-iamide, (1.069) N'-(2, 5d¡methyl¡l-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfan¡l]phenoxy¡}phen¡l)-N-ethyl-N-methyl¡m¡doformamide , (1,070) N'-(2,5-dimethyl-4-{3-[(pentafluoroethyl)-iSulfan¡l]-ifenoxy¡}phen¡l)-N-ethyl-Nmethylimidoformamide, ( 1.071) N'-(2,5-dimethyl-4-phenoxy-iphenyl)-N-ethyl-N-methylamide, (1.072) N'-(4-{[3-(difluoromethoxy)-iphenyl]-sulfanyl}-2,5-dimet¡iphenyl)-N-ethyl-Nmethylimidoformamide, (1,073) N'-(4-{3-[(difluoro-methyl)sulfan¡l] phenoxy¡}-2,5-dimet¡lfen¡l)-N-ethyl¡lN-methylimidoformamide, (1.074) N'-[5-bromo-6-(2,3-dihydro-1 H-inden- 2-yloxy)-2-methylpyridin3-íl]-N-ethyl-N-methylímído-iform-iamide, (1,075) N'-{4-[(4,5-dichloro-1, 3-thiazol-2-yl)ox¡]-2,5dimethyl¡lphenyl}-N-ethyl-N-methyl¡m¡doformamide, (1,076) N'-{5-bromo-6-[( 1 R)-1-(3,5difluorophen¡l)ethoxy¡]-2-met¡lp¡r¡din-3-¡l}-N-ethyl¡l-N-met¡l¡m¡doformamide , (1,077) N'-{5-bromo-6[(1 S)-1 -(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.078) N'{5-bromo-6-[(c¡s-4-¡sopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimido-iformamide, (1.079) N,-{5-bromo-6-[(trans-4-¡soprop¡lcyclohex¡l)ox¡]-2-met¡lpyrid¡n-3-¡l}-N-et¡ l-Nmethylimidoformamide, (1,080) N'-{5-bromo-6-[1 -(3,5-difluorophenyl)ethoxy]-2-methylimidoformamide, ( 1081) Ipfentrifluconazole, (1082) 2-[4-(4-chlorophenoxy¡)-2(trifluoromethiI)phenyl]-1 -(1 H-1,2,4-triazol-1 -yl)propan-2-ol, (1,083) 2-[6-(4-bromophenoxy¡)-2(trifluoromethyl)-3-pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol, (1,084) 2 -[6-(4-chlorophenox¡)-2 (trifluoromethyl)-3-pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol, (1.085) 3-[2- (1-chlorocyclopropyl)3-(3-chloro-2-fluoro-phenyl)-2-hydrox¡-propyl]im¡dazole-4-carbon¡tr¡le and (1.086) 4-[[6-[rac( 2R)-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4-triazol-1-yl)propyl]3- pyridyl]oxy]benzonitrile. 2) Respatone chain inhibitors in complex I or II, for example (2001) benzovindiflupyr, (2002) bixaphene, (2003) boscalid, (2004) carboxin, (2005) fluopyram, (2006) flutolanil, (2007) fluxapyroxad , (2008) furametpyr, (2009) Isofetamid, (2010) isopyrazam (1R,4S,9S anti-epimeric enantiomer), (2011) isopyrazam (1S,4R,9R anti-epimeric enantiomer), (2012) isopyrazam (anti-epimeric racemate 1 RS,4SR,9SR), (2013) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1 RS,4SR,9SR), (2014) isopyrazam (syn-epimeric enantiomer 1R,4S, 9R), (2015) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2016) isopyrazam (synepimeric racemate 1 RS,4SR,9RS), (2017) penflufen, (2018) penthiopyrad, (2019) pidiflumetofen, ( 2,020) Pyraziflumid, (2,021) sedaxane, (2,022) 1,3-dimethyl-N-(1,1,3-thmethyl-2,3-dihydro-1 Hinden-4-yl)-1 H- pyrazole-4-carboxamide, (2,023) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro1 H-inden-4-i l]-1 H-pyrazole-4 -carboxamide, (2,024) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3dihydro-1 H-inden-4-yl]-1 H-pyrazole-4-carboxamide, (2.025) 1 -methyl-3-(trifluoromethyl)-N-[2'(trifluoromethyl)biphenyl-2-yl]-1 H-pyrazole-4-carboxamide, (2.026) 2 -fluoro-6-(trifluoromethyl)-N(1,1,3-trimethi l-2,3-dihydro-1 H-inden-4-yl)benzamide, (2.027) 3-(difluoromethyl )-1 -methyl-N- (1,1,3-trimethi l-2,3-dih idro-1 H-inden-4-yl)-1 H-pyrazole-4-carboxamide, (2,028) inpyrfluxam, ( 2029) 3-(difluoromethyl)-1 -methyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazole4-carboxamide, (2.030) Fluindapir, (2.031) 3-(difluoromethyl)-N-[(3R)-7-fluoro-1,1,3-trimethyl2,3-dihydro-1 H-inden-4-yl]-1 -met 1-1 H-pyrazole-4-carboxamide, (2.032) 3-(difluoromethyl)-N[(3S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1 H-inden-4 -yl]-1 -methyl-1 H-pyrazole-4-carboxamide, (2,033) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl) ]oxy}-iphenyl)ethyl]quinazolin-4amine, (2.034) N-(2-cyclopentyl-5-f luorobenzyl)-N-cyclopropyl-3-(dif luoromethyl)-5-f luoro-1 methyl-1 H- pyrazole-4-carboxamide, (2.035) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3(difluoromethyl)-5-fluoro-1 -methyl-1 H-pyrazole-4 -carboxamide, (2,036) N-(2-tert-butylbenzyl)-Ncyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1 H-pyrazole-4-carboxamide, (2,037) N- (5-chloro-2ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1 H-pyrazole-4-carboxamide, (2.038) N-(5-chloro -2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1 H-pyrazole4-carboxamide, (2.039) N-[(1 R,4S)-9- (dichloromethylene)-1,2,3,4-tetrahydro-1,4methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1 H-pyrazole-4-carboxamide, (2,040) N [(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoro-imethyl)43 -methyl-1 H-pyrazole-4-carboxamide, (2.041) N-[1 -(2,4-dichlorophenyl)-1 -methoxypropan-2-yl]-3(difluoromethiI)-1 -methyl-1 H-pyrazole -4-carboxamide, (2.042) N-[2-chloro-6-(trif luoromethyl)benzyl]N-cyclopropyl-3-(dif luoromethyl)-5-f luoro-1 -methyl-1 H-pyrazole-4 -carboxamide, (2.043) N-[3chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclo-ipropyl-3-(difluoromethyl)-5-fluoro-1-methyl -1 Hpyrazole-4-carboxamide, (2.044) N-[5-chloro-2-(trifluoromethyl)benzyl]-N-cyclopropyl-3(dif luoromethi l)-5-f luoro-1 -methyl- 1 H-pyrazole-4-carboxamide, (2,045) N-cyclopropyl-3(difluoromethyl)-5-fluoro-1-methyl-N-[5-methyl-2-(trifluoromethyl)benzyl ]-1 H-pyrazole-4-carboxamide, (2.046) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-sopropylbenzyl) -1 -methyl-1 Hpyrazole-4-carboxamide, (2.047) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5methylbenzyl)-1- methyl-1 H-pyrazole-4-carboxamide, (2,048) N-cyclopropyl-3-(difluoromethyl)-5fluoro-N-(2-isopropylbenzyl)-1-methyl-1 H-pyrazole-4 -carbothioamide, (2,049) N-cyclopropyl-3(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1 -methyl-1 H-pyrazole-4-carboxamide, (2,050) Nc¡ cloprop¡l-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2-isoprop¡lbenzyl)-1 -methyl-1 H-pyrazole-4carboxamide, (2.051) N- cycloprop¡l-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1 methyl-1 H-pyrazole-4-carboxamide, (2.052) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1 H-pyrazole-4-carboxamide, (2.053) N-cyclopropyl-3(difluoromethyl )-N-(2-ethyl-5-methylbenzyl)-5-fluoro-1 -methyl-1 H-pyrazole-4-carboxamide, (2.054) Nc¡cloprop¡l-N-(2-c¡clopropyl-5-fluorobenz ¡l)-3-(difluoromethyl)-5-fluoro-1-methyl-1 H-pyrazole-4carboxamide, (2.055) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3- (difluoromethyl)-5-fluoro1 -methyl-1 H-pyrazole-4-carboxamide, (2.056) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3(difluoromethyl)-5-fluoro-1 -methyl-1 H-pyrazole-4-carboxamide, (2.057) pyrapropoin. 3) Complex III respiratory chain inhibitors, for example (3.001) ametoctradine, (3.002) amisulbrom, (3.003) azoxystrobin, (3.004) coumethoxystrobin, (3.005) coumoxystrobin, (3.006) cyazofamid, (3.007) dimoxystrobin, ( 3.008) enoxastrobin, (3.009) famoxadone, (3.010) fenamidone, (3.011) fluphenoxystrobin, (3.012) fluoxastrobin, (3.013) kresoxim-methyl, (3.014) metominostrobin, (3.015) orysastrobin, (3.016) picoxystrobin, (3.01) 7) pyraclostrobin , (3,018) pyrametostrobin, (3,019) pyroxystrobin, (3,020) trifloxystrobin, (3,021) (2E)-2-{2-[({[(1 E)-1-(3-{[(E)-1- fluoro-2-phenylvinyl]oxyphenyl)ethylideneamino}oxy)methyl]phenyl}-2-(methoxy-imino)-N-methylacetamide, (3.022) (2E,3Z) -5-{[1 -(4-chlorophenyl)-1 H-pyrazol-3-¡l]ox¡}-2-(methox¡m¡no)-N,3-dimet¡lpent-3enamide, (3.023 ) (2R)-2-{2-[(2,5-dimethylphenoxy¡)methyl]phen¡l}-2-methoxy¡-N-methylacetamide, (3.024) (2S)-2-{2 -[(2,5-dimet¡lfenoxy¡)met¡l]phen¡l}-2-methoxy¡-N-methyl¡acetamide, (3.025) fenpicoxamid, (3.026) mandestrobin, (3.027) N-(3- ethyl-3,5,5-trimethylcyclohexyl)-3formamido-2-hydroxybenzamide, (3.028) (2E,3Z)-5-{[1-(4-chloro-2-fluorophenyl)-1 H -pyrazol-3 ¡l]oxy¡}-2-(methoxyim¡no)-N,3-dimethylpent-3-enam¡de, (3.029) methyl {5-[3-(2,4- dimethylphenyl)-1Hpyrazol-1-yl]-2-methylbenzyl}carbamate, (3.030) methyltetraprol, (3.031) florylpicoxamid. 4) Inhibitors of mitosis and cell division, for example (4.001) carbendazim, (4.002) diethofencarb, (4.003) ethaboxam, (4.004) fluopicolide, (4.005) pencicuron, (4.006) thiabendazole, (4.007) thiophanate-methyl, (4.008) zoxamide, (4.009) 3-chloro-4-(2,6-difluorophen¡I)- 6-methyl-5-phenylpindazine, (4.010) 3-chloro-5-(4-chloroph en i 1)-4-(2,6-d if I uorof en i l)-6methylpyridazine, (4.011) 3-chloro-5-(6-chloropyridín-3-íl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (4.012) 4-(2-bromo- 4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.013) 4-(2-bromo-4-fluorophenyl)-N-( 2-bromo-6-fluorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.014) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophenyl)-1 ,3-dimethyl-1 H-pyrazole-5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1 H- pyrazole-5-amine, (4.016) 4 (2-bromo-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.017) 4-(2 -bromo4-fluorophenyl)-N-(2-f luorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.018) 4-(2-chloro-4f luorofen ¡I)-N-( 2,6-dif luorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.019) 4-(2-chloro-4 f luorophenyl)-N-(2-chloro-6-f luorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.020) 4-(2-chloro-4f luoro-ifeni I)-N-(2-chlorophenyl)-1,3-dimethyl- 1 H-pyrazole-5-amine, (4.021) 4-(2-chloro-4-fluoro-iphenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4.022 ) 4-(4-chlorophenyl)-5-(2,6difluorophenyl)-3,6-dimethylpyridazine, (4.023) N-(2-bromo-6-fluorophenyl)-4- (2-chloro-4f luorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine, (4,024) N-(2-bromophenyl)-4-(2-chloro-4fluorophenyl)-1,3 -dimethyl-1 H-pyrazole-5-amine, (4.025) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4f luorophen ¡l)-1,3-dimethyl-1 H-pyrazole-5-amine. 5) Compounds capable of multisite action, for example (5.001) Bordeaux mixture, (5.002) Captafol, (5.003) Captan, (5.004) Chlorothalonil, (5.005) Copper hydroxide, (5.006) Copper naphthenate, (5.007) Oxide copper, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianon, (5.011) dodine, (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram , (5,016) metiram zinc, (5,017) oxine-copper, (5,018) propineb, (5,019) sulfur and sulfur preparations including calcium polysulfide, (5,020) thiram, (5,021) zineb, (5,022) ziram, (5,023 ) 6-ethyl-5,7-dioxo-6,7-dihydro-5Hpyrrolo[3',4':5,6][1,4]dithyno[2,3-c][1,2]thiazole -3-carbonitrile. 6) Compounds capable of inducing host defense, for example (6.001) acibenzolar-S-methyl, (6.002) isotianyl, (6.003) probenazole, (6.004) thiadinyl. 7) Inhibitors of amino acid and / or protein biosynthesis, for example (7.001) cyprodinil, (7.002) kasugamycin, (7.003) kasugamycin hydrochloride hydrate, (7.004) oxytetracycline, (7.005) pyrimethanyl, (7.006) 3-(5- fluoro-3,3,4,4-tetramethyl-3,4dihydroisoquinolin-1 -yl)quinoline. 8) Inhibitors of ATP production, for example (8.001) silthiofam. 9) Cell wall synthesis inhibitors, e.g. (9.001) bentiavalicarb, (9.002) dimethomorph, (9.003) flumorf, (9.004) iprovalicarb, (9.005) mandipropamid, (9.006) pirimorph, (9.007) valifenalate, (9.008) ) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-¡I)-1 -(morpholin-4yl)prop-2-en-1 -one, (9.009) (2Z )-3-(4-tert-butylene i l)-3- (2-chloroprídiη-4-i I)-1 -(morpholin-4yl)prop-2-en-1-one. 10) Inhibitors of lipid and membrane synthesis, for example (10,001) propamocarb, (10,002) propamocarb hydrochloride, (10,003) tolclofos-methyl. 11) Inhibitors of melanin biosynthesis, for example (11.001) tricyclazole, (11.002) {3methyl-1-[(4-methylbenzo¡l)amino]butan-2-¡l}carbamatode 2,2,2- trifluoroethyl. 12) Inhibitors of nucleic acid synthesis, for example (12,001) benalaxyl, (12,002) benalaxyl-M (kiralaxyl), (12,003) metalaxyl, (12,004) metalaxyl-M (mefenoxam). 13) Signal transduction inhibitors, for example (13,001) fludioxonil, (13,002) iprodione, (13,003) procymidone, (13,004) proquinazid, (13,005) quinoxyfen, (13,006) vinclozolin. 14) Compounds capable of acting as uncouplers, for example (14,001) fluazinam, (14,002) meptyldinocap. 15) Other fungicides to be selected from the group of, for example (15,001) abscisic acid, (15,002) benthiazole, (15,003) bethoxazine, (15,004) capsimycin, (15,005) carvone, (15,006) quinometionat, (15,007) cufraneb, (15.008) cyflufenamid, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianyl, (15.012) fosetyl aluminum, (15.013) fosetyl calcium, (15.014) fosetyl sodium, (15.015) methyl isothiocyanate, (15.0 16 ) metrafenone, (15,017) mildiomycin, (15,018) natamycin, (15,019) nickel dimethyldithiocarbamate, (15,020) nitrotal-isopropyl, (15,021) oxamocarb, (15,022) oxathiapiproline, (15,023) oxyfenthiin, (15,024) pen tachlorophenol and salts, ( 15,025) phosphorous acid and its salts, (15,026) propamocarb-phosethylate, (15,027) pyriophenone (clazafenone), (15,028) tebufloquine, (15,029) teclofthalam, (15,030) tolnifanide, (15,031) 1-(4-{4-[ (5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)- 2-[5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1-yl]ethanone, (15.032) 1 -(4-{4-[(5S)-5-(2,6-difluorophenyl )-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2- ¡l}piper¡din-1 -yl)-2-[5-methyl] 3-(trifluoromethyl)-1 H-pyrazole-1 -yljetanone, (15.033) 2-(6benzylpyr¡din-2-¡l)quinazoline, (15.034) dipimethrone, (15.035) 2-[ 3,5-bis(difluoromethyl)-1 Hpyrazol-1 -yl]-1 -[4-(4-{5-[2-(prop-2-yn-1 -yloxy)phenyl]-4, 5-d i hydro-1,2-oxazol-3-yl}-1,3-thiazol-2 i l)--pi pe rid in-1 -i l]ethan one, (15,036) 2-[3,5- bis(d if I uo ro metí I) -1 H-pyrazol-1 -yl]-1 -[4-(4-{5-[2chloro-6-(prop-2-in-1 -yloxy)phenyl] -4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidi n-1yl]ethanone, (15,037) 2-[3,5-bis(difluoromethyl )-1 H-pyrazol-1 -yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2in-1 -yloxy)pheníl]-4,5-dihydro- 1,2-oxazol-3-yl}-1,3-thiazol-2-íl)piperidin-1 -yl]-iethanone, (15,038) 2[6-(3-fluoro-4-methoxypheníl)- 5-methylpyridin-2-yl]quinazoline, (15,039) 2{(5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1 H-pyrazol-1-yl) methanesulfonate ]acetyl}p¡perídin-4-yl)-1,3-thiazol-4-yl]-4,5dihydro-1,2-oxazol-5-yl}-3-chlorophenyl, (15,040) methanesulfonate 2-{(5S)-3-[2-(1-{[3,5bis(difluoromethyl)-1 H-pyrazol-1 -yl]acetyl}piperidin-4-¡l)-1,3-thiazole -4-yl]-4,5-dih idro-1,2-oxazol5-yl}-3-chlorophenyl, (15,041) Ipflufenoquine, (15,042) 2-{2-fluoro-6-[(8-fluoro-2 -methylquinol¡n3-yl)oxy]phenyl}propan-2-ol, (15.043) fluoxapiprolin, (15.044) 2-{3-[2-(1{[3,5-bis(difluoromethyl)-1 H) methanesulfonate -pyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-íl]-4,5-dihydro-1,2oxazol-5-yl}phenyl, (15,045) 2 -phenylphenol and salts, (15,046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4dihydroisoquinolin-1 -yl)quinoline, (15,047) quinofumeline, (15,048) 4-amino -5fluoropyrimidin-2-ol (tautomeric form: 4-amino-5-fluoropinm¡din-2(1 H)-one), (15.049) 4-oxo-4-[(2-phenylethyl)am acid ¡no]butano¡co, (15,050) 5-amino-1,3,4-thiad¡azol-2-thiol, (15,051) 5-chloro-N'-phenyl-N'-(prop-2-¡n -1 -yl)thiophene-2-sulfonohydrazide, (15.052) 5-fluoro-2-[(4fluorobenzyl)oxy]pyrimidin-4-amine, (15.053) 5-f luoro-2- [(4-methylbenzyl)->oxy]-ipyrimidin-4amine, (15,054) 9-f luoro-2,2-dimethyl-5-(quino¡n-3-yl)-2,3-dihydro-1 ,4-benzoxazepine, (15,055) {6-[({[(Z)-(1 -methyl-1 H-tetrazol-5-yl)-i(phenyl)--methylene]am inoxoxy)methyl]pyridin- 2!IJbut-3-¡n-1-ílcarbamate, (15.056) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15.057) phenazine-1-carboxylic acid , (15,058) propyl 3,4,5-trihydroxybenzoate, (15,059) quinolin-8-ol, (15,060) quinolin-8-ol sulfate (2:1), (15,061) {6-[({[( tert-butyl 1-methyl-1 H-tetrazol-5yl)(phenyl)methylene]amino}ox¡)methyl]pyridín-2-yl}-icarbamate, (15.062) 5 -fluoro-4im¡no-3-methyl¡l-1-[(4-met¡lphenyl)sulfonyl]-3,4-dihydropyrimidin-2(1 H)-one, (15,063) aminopyrifen, (15,064) (N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-Nmethylimidoformamide), (15.065) (N'-(2-chloro-5-methyl-4-phenoxyphenyl )-N-ethyl-Nmethylimido-iformamide), (15.066) (2-{2-[(7,8-difluoro-2-methylqui noli n-3-yl)oxy]-6fluorophenyl}propan-2 -ol), (15,067) (5-bromo-1 -(5,6-dimethylpyridin-3-y I) -3,3-dimethyl-3,4dihydroisoquinoline), (15,068) (3-(4,4-difluoro -5,5-dimethyl-4,5-dihydrothieno[2,3-c]pyridin-7yl)quinoline), (15.069) (1 -(4,5-dimethyl-1 H-benzimidazol-1 -yl)- 4,4-difluoro-3,3-dimethyl-3,4d¡hydro¡soquino¡ne), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimet ¡l-3,4-d¡hydroisoquinolin¡n-1 yl)quinolone, (15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydro¡soqu¡ nolin-1 yl)quinolone, (15,072) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydro¡soquinolin-1 -yl)-8fluoroquinoline, (15,073) (N-methyl-N-phenyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamide), (15.074) (methyl{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}carbamate), (15.075) (N-{4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]benzyl}-iC¡clopropane-icarboxamide), (15.076) N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxad¡azol-3-yl ]-ibenzam¡de, (15.077) N-[(E)methoxy¡m¡nomethyl]-4-[5-(tri¡fluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, ( 15.078) N-[(Z)methoxy¡m¡nomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15.079) N-[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-cyclopropane-icarboxamide, (15,080) N-(2fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]benzamide, (15,081) 2,2-difluoro-Nmethyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-acetamide , (15.082) N-allyl-N-[[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl]methyl]acetamide, (15.083) N-[(E)- N-methoxy-Cmethyl-carbon¡m¡doyl]-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-benzamide, (15.084) N-[(Z) N-methoxy-C-methyl-carbon¡midoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15.085) N-allyl-N -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-methyl]-ipropanamide, (15,086) 4,4-dimethyl-1 -[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-ipyrrolidin-2one, (15.087) N-methyl-4-[5-(trifluoromethyl) )-1,2,4-oxadiazol-3-yl]-benzenecarbothioamide, (15,088) 5-methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]pyrrolidin-2-one, (15,089) N-((2,3-difluoro-4-[5-(trif luoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]-3,3,3trifluoro-propanamide, (15,090) 1 -methoxy¡-1 -methyl-3-[[4-[5-(trifIuorometiI}-1,2,4-oxadiazol-3yl]phenyl]-imethyl] urea, (15,091) 1,1-diethyl-3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, (15,092) N-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phen-iyl]methyl]propanamide, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, (15,094) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, (15,095) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]->methyl) -iC¡clopropane-icarboxamide, (15.096) N,2-dimethoxy-N-[[4-[5(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]-imethyl]- ipropanamide, (15,097) N-ethyl-2-methyl-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl]methyl]-ipropanamide, (15,098 ) 1 -methoxy¡-3methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-imethyl]-iurea, (15.099) 1,3dimethoxy¡-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxad¡azol-3-yl]phenyl]methyl]urea, (15,100) 3-ethyl-1-methoxy-1 -[[ 4-[5-(t rif I or orom ethyl I)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) 1 -[[4-[5(trifluoromethyl)-l , 2,4-oxadiazol-3-yl]phenyl]methyl]p¡per¡d¡n-2-one, (15.102) 4,4-dimethyl-2-[[4[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]¡sooxazol¡din-3-one, (15.103) 5,5dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]isoxazoldin-3-one, (15.104) 3,3-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxad¡zol-3-yl]-iphenyl]-imeth¡l]-ipiper¡din-2-one, (15.105) 1-[[3-fluoro-4-(5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]-iphenyl]-imethyl]-iazepan-2one, (15.106) 4,4-dimethyl-2-[[4-(5-(trifluoromethyl)-1,2, 4-oxadiazol-348 yl]-iphenyl]-imethyl]¡soxazol¡din-3-one (15.107) 5,5-dimethyl-2-[[4-[5-(t¡fluoromethyl)1,2,4 -oxadiazol-3-yl]-iphenyl]methyl]isoxazol¡din-3-one, (15.108) ethyl (1-{4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl] benzyl}-1 H-pyrazol-4-yl)acetate, (15.109) N,N-dimethyl-1 -{4-[5(thfluoromethyl)-l ,2,4-oxadiazol-3-yl]benzyl}-1 H-1,2,4-triazol-3-amine and (15.110) N-{2,3difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}butanamide. Biological pesticides as mixing components Compounds having formula (I) can be combined with biological pesticides. Biological pesticides include in particular bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites. Biological pesticides comprise bacteria such as spore-forming bacteria, root-colonizing bacteria, and bacteria that act as biological insecticides, fungicides, or nematicides. Examples of such bacteria that are or can be used as biological pesticides are: Bacillus amyloliquefaciens, strain FZB42 (DSM 231179), or Bacillus cereus, in particular B. cereus strain CNCM 1-1562 or Bacillus firmus, strain 1-1582 (Registration Number CNCM I1582) or Bacillus pumilus, in particular strain GB34 (Registration Number ATCC registration 700814) and strain QST2808 (NRRL registration number B-30087), or Bacillus subtilis, in particular strain GB03 (ATCC registration number SD-1397), or Bacillus subtilis strain QST713 (NRRL registration number B-21661) or Bacillus subtilis strain OST 30002 (NRRL registration number B50421) Bacillus thuringiensis, in particular B. thuringiensis subspecies israelensis (serotype H-14), strain AM65-52 (ATCC registration number 1276), or B. thuringiensis subspecies aizawai, in particular strain ABTS-1857 (SD-1372), or B. thuringiensis subspecies kurstaki strain HD-1, or B. thuringiensis subspecies tenebrionis strain NB 176 (SD-5428), Pasteuria penetrans, Pasteuria spp. (nematode Rotylenchulus reniformis)-PR3 (ATCC registration number SD-5834), Streptomyces microflavus strain AQ6121 (= QRD 31.013, NRRL B-50550), Streptomyces galbus strain AQ 6047 (NRRL registration number 30232). Examples of fungi and yeasts that are or can be used as biological pesticides are: Beauveria bassiana, in particular strain ATCC 74040, Coniotirium minitans, in particular strain CON / M / 91-8 (Registration number DSM-9660), Lecanicillium spp., in particular strain HRO LEC 12, Lecanicillium lecanii, (previously known as Verticillium lecanii), in particular strain KV01, Metarhizium anisopliae, in particular strain F52 (DSM3884 / ATCC 90448), Metschnikowia fructicola, in particular strain NRRL Y-30752, Paecilomyces fumosoroseus (now: Isaria fumosorosea), in particular strain IFPC 200613, or strain Apopka 97 (ATCC registration number 20874), Paecilomyces lilaciñus, in particular P. lilacinus strain 251 (AGAL 89 / 030550), Talaromyces flavus, in particular strain V117b, Trichoderma atroviride, in particular strain SC1 (CBS registration number 122089), Trichoderma harzianum, in particular T. harzianum rifai T39. (NCCM registration number I-952). Examples of viruses that are used or can be used as biological pesticides are: Adoxophyes orana granulosis virus (GV), Cydia pomonella granulosis virus (GV), Helicoverpa armigera nuclear polyhedrosis virus (NPV), mNPV of Spodoptera exigua (green donut or armyworm), mNPV of Spodoptera frugiperda (corn bollworm), NPV of Spodoptera littoralis (black donut). Also included are bacteria and fungi that are added as “inoculants” to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and plant health. Examples that can be mentioned are: Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (previously known as Pseudomonas cepacia), Gigaspora spp., or Gigaspora monosporum, Glomus spp., Lacearia spp. , Lactobacíllus buchneri, Paraglomus spp., Pisolithus tínctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp., Streptomyces spp. Examples of plant extracts and products formed by microorganisms including proteins and secondary metabolites that are or can be used as biological pesticides are: Allium sativum, Artemisia absinthium, azadirachtin, Biokeeper WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, Armor-Zen, Dryopteris filixmas, Equisetum arvense, Fortune Aza, Fungastop, Heads Up (Chenopoin quino extract) / Pyrethrins, Quassia amara , Quercus, Quillaja, Regalía, Insecticide Requiem™, rotenone, ryania / ryanodina, Symphytum officinale, Tanacetum vulgare, thymol, Triact 70, TriCon, Tropaeulum majus, Urtica dioica, Veratrina, Viscum album, Brassicaceae extract album, in particular powder rapeseed or mustard powder, as well as bioinsectoicidal / acaricidal active substances obtained from olive oil, in particular unsaturated fatty / carboxylic acids having carbon chain lengths C16 frCRnnn / zznz / B / YiAi C20 as active ingredients, such as, for example, contained in the product with the trade name FLIPPER®. Antidotes as mixing components Compounds having formula (I) can be combined with antidotes such as, for example, benoxacor, cloquintocet (-mexil), cyometrinil, cyprosulfamide, dichlormid, fenchlorazole (-ethyl), fenchlorim, flurazole, fluxofenim, furilazole, isoxadifen (- ethyl), mefenpyr (-diethyl), naphthalic anhydride, oxabetrinyl, 2-methoxy-N-({4[(methylcarbamo¡l)amino]phenyl}sulfon¡l)benzamide (CAS 129531-12-0) , 4-(dichloroacetyl)-1 oxa-4-azaspiro[4.5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3oxazolidine (CAS 52836 -31-4). Plants and plant parts All plants and plant parts can be treated according to the invention. In this context, plants should be understood to refer to all plants and plant parts such as desired and unwanted wild plants or crop plants (including natural crop plants), for example, cereals (wheat, rice, triticale, barley, rye, oats), corn, soybeans, potato, sugar beet, sugar cane, tomatoes, bell pepper, cucumber, melon, carrot, watermelon, onion, lettuce, spinach, leek, beans, Brassica oleracea (e.g. cabbage) and other plant species, cotton, tobacco, rapeseed, and also fruit plants ([where] the fruits [are] apples, pears, citrus fruits and vines). Crop plants may be plants that can be obtained by conventional breeding and optimization methods or by genetic and biotechnological engineering methods or combinations of these methods, including transgenic plants and plant varieties that may or may not be protected by rights. varietal property. It should be understood that plants refer to all stages of development, such as seeds, seedlings, young (immature) plants to mature plants. Plant parts should be understood as all parts and organs of plants located above and below the ground, such as shoots, leaves, flowers and roots, such as leaves, needles, main and secondary stems, flowers, clusters of fruits, fruits and seeds. Also tubers, roots and rhizomes. Plant parts also include harvested plants or parts of harvested plants and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds. The treatment of plants and plant parts with the compounds of formula (I) according to the invention is carried out directly or by allowing the compounds to act on the environment, the environment or the storage space by conventional treatment methods, for example, by immersion, spraying, evaporation, misting, dispersion, painting, injection and, in the case of propagation material, in particular in the case of seeds, also by applying one or more layers. As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional methods of biological reproduction, such as crossing or fusion of protoplasts, and also parts of [plants of said species and cultivars] are treated. . In another preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (genetically modified organisms), and parts of [plants of said species or cultivars] are treated. The term parts or parts of a plant or parts of plants has been explained above. The invention is used with particular preference to treat plants of the respective cultivars commonly available or those in use. Plant cultivars should be understood to mean plants that have new properties (traits) and that have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, biotypes or genotypes. Transgenic plants, seed treatment and integration events The transgenic plants or plant cultivars (those or those obtained by genetic engineering) to be treated in accordance with the invention preferably include all plants that, through genetic modification, received genetic material that imparts certain useful properties (traits) [ that are advantageous] for these plants. Examples of such properties are better plant growth, greater tolerance to high or low temperatures, greater tolerance to drought or soil water levels or salinity, greater flowering performance, easier harvest, accelerated maturation, higher yields, greater quality and / or greater nutritional value of harvested products, better storage life and / or processability of harvested products. Additional and particularly prominent examples of such properties are an increase in the resistance of plants against microbial and animal pests, such as against insects, arachnids, nematodes, mites, slugs and snails due to, for example, toxins formed in the plants, in particularly those formed in plants by the genetic material of Bacillus thuringiensis (for example, by the genes CrylA (a), CrylA (b), CrylA (c), CryllA, CrylllA, CrylllB2, Cry9c Cry2Ab, Cry3Bb and CrylF and also combinations of the same), as well as an increase in the resistance of plants against fungi, bacteria and / or phytopathogenic viruses, for example, due to a systemic acquired resistance (SAR), systemin, phytoalexins, inducers and also resistance genes and the corresponding expressed proteins and toxins, and also an increase in the tolerance of plants to certain compounds that have herbicidal activity, for example imidazolinones, sulfonylureas, glyphosate or phosphinothricin (for example, the PAT gene). The genes that impart the desired traits in question may also be present in combinations with each other in transgenic plants. Examples of transgenic plants that can be mentioned are important crop plants, such as cereals (wheat, rice, triticale, barley, rye, oats), corn, soybeans, potatoes, sugar beets, sugar cane, tomatoes, peas and other types of vegetables, cotton, tobacco, rapeseed and also fruit trees (where the fruits are apples, pears, citrus fruits and grapes), with special emphasis on corn, soybeans, wheat, rice, potatoes, cotton, sugar cane, tobacco and rapeseed. Traits that particularly stand out are the plants' increased resistance to insects, arachnids, nematodes, and slugs and snails. Among the DNA sequences that encode proteins that confer properties of resistance or tolerance to such microbial and animal pests, in particular to insects, mention will be made in particular of the genetic material of Bacillus thuringiensis that encodes the Bt proteins widely described in the literature and well known to experts, in art. Proteins extracted from bacteria such as Photorhabdus (WO97 / 17432 and WO98 / 08932) will also be mentioned. in particular, Bt Cry or VIP proteins will be mentioned which include the proteins CrylA, CrylAb, CrylAc, CryllA, CrylllA, CrylllB2, Cry9c Cry2Ab, Cry3Bb and CrylF or toxic fragments thereof and also hybrids or combinations thereof, especially the CrylF protein or hybrids derived from a CrylF protein (for example, CrylA-CrylF hybrid proteins or toxic fragments thereof), CrylA-like proteins or toxic fragments thereof, also the CrylAc protein or hybrids derived from the CrylAc protein (for example example hybrid proteins CrylAb (CrylAc) or the CrylAb or Bt2 protein or its toxic fragments, the Cry2Ae, Cry2Af or Cry2Ag proteins or its toxic fragments, the CrylA.105 protein or its toxic fragment, the VIP3Aa19 protein, the VIP3Aa20 protein, the VIP3A proteins produced in the COT202 or COT203 cotton events, the VIP3Aa protein or a toxic fragment thereof as described in Estruch et al. (1996), Proc Nati Acad Sci US A.28; 93 (11): 5389-94, Cry proteins as described in WO2001 / 47952, insecticidal proteins from Xenorhabdus (as described in WO98 / 50427), Serratia (particularly from S. entomophila) or strains of Photorhabdus species, such as Photorhabdus Te proteins as described in WO98 / 08932. Furthermore, any variant or mutant of any of these proteins differs in some amino acids (1-10, possibly 1-5) from any of the above-mentioned sequences, particularly The sequence of its toxic fragment, or that fuses with a transit peptide, such as a plastid transit peptide, or other protein or peptide, is included here. Another particularly prominent example of such properties is the tolerance conferred to one or more herbicides, for example, imidazolinones, sulfonylureas, glyphosate or phosphinothricin. Among the DNA sequences that encode proteins that confer tolerance properties to certain herbicides in transformed plant cells and plants, special mention will be made of the rod or the PAT gene or the Streptomyces coelicolor gene described in WO2009 / 152359 that confers tolerance to glufosinate herbicides, a gene encoding a suitable EPSPS (5-Enolpyruvylshikimat-3-phosphat-synthase) that confers tolerance to EPSPS-targeting herbicides, special herbicides such as glyphosate and its salts, a gene encoding the glyphosate-n-acetyltransferase, a gene encoding glyphosate oxidoreductase Other suitable herbicide tolerance traits include at least one ALS (acetolactate synthase) inhibitor (e.g. WO2007 / 024782), a mutated Arabidopsis ALS / AHAS gene (e.g. example, US Patent 6,855,533), genes encoding 2,4-D-monooxygenases that confer tolerance to 2,4-D (2,4-dichlorophenoxyacetic acid) and genes encoding Dicamba monooxygenases that confer tolerance to dicamba (3,6-dichloro-2-methoxybenzoic acid). Furthermore, particularly prominent examples of such properties are increased resistance against phytopathogenic fungi, bacteria and / or viruses due to, for example, systemic acquired resistance (SAR), systomin, phytoalexins, inducers and also resistance genes and proteins and correspondingly expressed toxins. Particularly useful transgenic events in transgenic plants or plant cultivars that can be treated in accordance with the invention include Event 531 / PVGHBK04 (cotton, insect control, described in WO2002 / 040677), Event 1143-14A (cotton, insect control, insect, undeposited, described in WO2006 / 128569); Event 114351B (cotton, insect control, non-deposited, described in WO2006 / 128570); Event 1445 (cotton, herbicide tolerance, non-deposited, described in US-A 2002-120964 or WO2002 / 034946); Event 17053 (rice, herbicide tolerance, deposited as PTA9843, described in WO2010 / 117737); Event 17314 (rice, herbicide tolerance, deposited as PTA-9844, described in WO2010 / 117735); Event 281-24-236 (cotton, insect control - herbicide tolerance, deposited as PTA-6233, described in WO2005 / 103266 or US-A 2005-216969); Event 3006-210-23 (cotton, insect control - herbicide tolerance, deposited as PTA-6233, described in US-A 2007-143876 or WO2005 / 103266); Event 3272 (corn, quality trait, deposited as PTA-9972, described in WO2006 / 098952 or US-A 2006-230473); Event 33391 (wheat, herbicide tolerance, deposited as PTA-2347, described in WO2002 / 027004), Event 40416 (maize, insect control - herbicide tolerance, deposited as ATCC PTA-11508, described in WO 11 / 075593); Event 43A47 (maize, insect control - herbicide tolerance, deposited as ATCC PTA-11509, described in WO2011 / 075595); Event 5307 (corn, insect control, deposited as ATCC PTA-9561, described in WO2010 / 077816); Event ASR-368 (bent grass, herbicide tolerance, deposited as ATCC PTA-4816, described in US-A 2006-162007 or WO2004 / 053062); Event B16 (corn, herbicide tolerance, non-deposited, described in US-A 2003-126634); Event BPSCV127-9 (soybean, herbicide tolerance, deposited as NCIMB No. 41603, described in WO2010 / 080829); Event BLRI (oilseed rape, male sterility restoration, deposited as NCIMB 41193, described in WO2005 / 074671), Event CE43-67B (cotton, insect control, deposited as DSM ACC2724, described in US-A 2009217423 or WO2006 / 128573) ; Event CE44-69D (cotton, insect control, non-deposited, described in US-A 2010-0024077); Event CE44-69D (cotton, insect control, non-deposited, described in WO2006 / 128571); Event CE46-02A (cotton, insect control, non-deposited, described in WO2006 / 128572); Event COT102 (cotton, insect control, non-deposited, described in US-A 2006-130175 or WO2004 / 039986); Event COT202 (cotton, insect control, non-deposited, described in US-A 2007-067868 or WO2005 / 054479); Event COT203 (cotton, insect control, non-deposited, described in WO2005 / 054480); ); Event DAS21606-3 / 1606 (soybean, herbicide tolerance, deposited as PTA-11028, described in WO2012 / 033794), Event DAS40278 (corn, herbicide tolerance, deposited as ATCC PTA-10244, described in WO2011 / 022469); Event DAS-44406-6 / pDAB8264.44.06.l (soybean, herbicide tolerance, deposited as PTA-11336, described in WO2012 / 075426), Event DAS-14536-7 / pDAB8291.45.36.2 (soybean, herbicide tolerance , deposited as PTA-11335, described in WO2012 / 075429), Event DAS-59122-7 (maize, insect control - herbicide tolerance, deposited as ATCC PTA 11384, described in US-A 2006-070139); Event DAS-59132 (maize, insect control - herbicide tolerance, not deposited, described in WO2009 / frCRnnn / zznz / B / YiAi 100188); Event DAS68416 (soybean, herbicide tolerance, deposited as ATCC PTA10442, described in WO2011 / 066384 or WO2011 / 066360); Event DP-098140-6 (maize, herbicide tolerance, deposited as ATCC PTA-8296, described in US-A 2009-137395 or WO 08 / 112019); Event DP-305423-1 (soybean, quality trait, not deposited, described in US-A 2008-312082 or WO2008 / 054747); Event DP-32138-1 (corn, hybridization system, deposited as ATCC PTA-9158, described in US-A 2009-0210970 or WO2009 / 103049); Event DP-356043-5 (soybean, herbicide tolerance, deposited as ATCC PTA8287, described in US-A 2010-0184079 or WO2008 / 002872); Event EE-I (brinjal, insect control, non-deposited, described in WO 07 / 091277); Event Fil 17 (maize, herbicide tolerance, deposited as ATCC 209031, described in US-A 2006-059581 or WO 98 / 044140); Event FG72 (soybean, herbicide tolerance, deposited as PTA-11041, described in WO2011 / 063413), Event GA21 (corn, herbicide tolerance, deposited as ATCC 209033, described in US-A 2005-086719 or WO 98 / 044140) ; Event GG25 (maize, herbicide tolerance, deposited as ATCC 209032, described in US-A 2005188434 or WO98 / 044140); Event GHB119 (cotton, insect control - herbicide tolerance, deposited as ATCC PTA-8398, described in WO2008 / 151780); Event GHB614 (cotton, herbicide tolerance, deposited as ATCC PTA-6878, described in US-A 2010-050282 or W02007 / 017186); Event GJ11 (maize, herbicide tolerance, deposited as ATCC 209030, described in US-A 2005-188434 or WO98 / 044140); Event GM RZ13 (sugar beet, virus resistance, deposited as NCIMB-41601, described in WO2010 / 076212); Event H7-I (sugar beet, herbicide tolerance, deposited as NCIMB 41158 or NCIMB 41159, described in US-A 2004-172669 or WO 2004 / 074492); JOPLIN1 event (wheat, disease tolerance, non-deposited, described in US-A 2008-064032); Event LL27 (soybean, herbicide tolerance, deposited as NCIMB41658, described in WO2006 / 108674 or US-A 2008-320616); Event LL55 (soybean, herbicide tolerance, deposited as NCIMB 41660, described in WO 2006 / 108675 or US-A 2008-196127); Event LLcotton25 (cotton, herbicide tolerance, deposited as ATCC PTA-3343, described in WO2003 / 013224 or US A 2003-097687); Event LLRICE06 (rice, herbicide tolerance, deposited as ATCC 203353, described in US 6,468.747 or WO2000 / 026345); Event LLRice62 (rice, herbicide tolerance, deposited as ATCC 203352, described in WO2000 / 026345), Event LLRICE601 (rice, herbicide tolerance, deposited as ATCC PTA-2600, described in US-A 2008-2289060 or WO2000 / 026356) ; Event LY038 (corn, quality trait, deposited as ATCC PTA-5623, described in US-A 2007-028322 or WO2005 / 061720); Event MIR162 (maize, control of frCRnnn / zznz / B / YiAi insect, deposited as PTA-8166, described in US-A 2009-300784 or WO2007 / 142840); Event MIR604 (corn, insect control, not deposited, described in US-A 2008-167456 or WO2005 / 103301); Event MON15985 (cotton, insect control, deposited as ATCC PTA-2516, described in US-A 2004-250317 or WO2002 / 100163); Event MON810 (corn, insect control, not deposited, described in US-A 2002-102582); Event MON863 (corn, insect control, deposited as ATCC PTA-2605, described in WO2004 / 011601 or US-A 2006-095986); Event MON87427 (corn, pollination control, deposited as ATCC PTA-7899, described in WO2011 / 062904); Event MON87460 (maize, stress tolerance, deposited as ATCC PTA-8910, described in WO2009 / 111263 or US-A 201 ΙΟΙ 38504); Event MON87701 (soybean, insect control, deposited as ATCC PTA-8194, described in US-A 2009-130071 or WO2009 / 064652); Event MON87705 (soybean, quality trait - herbicide tolerance, deposited as ATCC PTA-9241, described in US-A 20100080887 or WO2010 / 037016); Event MON87708 (soybean, herbicide tolerance, deposited as ATCC PTA-9670, described in WO2011 / 034704); Event MON87712 (soybean, yield, deposited as PTA-10296, described in WO2012 / 051199), Event MON87754 (soybean, quality trait, deposited as ATCC PTA-9385, described in WO2010 / 024976); Event MON87769 (soybean, quality trait, deposited as ATCC PTA-8911, described in US-A 2011-0067141 or WO2009 / 102873); Event MON88017 (maize, insect control - herbicide tolerance, deposited as ATCC PTA-5582, described in US-A 2008-028482 or WO2005 / 059103); Event MON88913 (cotton, herbicide tolerance, deposited as ATCC PTA-4854, described in WO2004 / 072235 or US-A 2006-059590); Event MON88302 (oilseed rape, herbicide tolerance, deposited as PTA-10955, described in WO2011 / 153186), Event MON88701 (cotton, herbicide tolerance, deposited as PTA-11754, described in WO2012 / 134808), Event MON89034 (maize, insect control, deposited as ATCC PTA-7455, described in WO 07 / 140256 or US-A 2008-260932); Event MON89788 (soybean, herbicide tolerance, deposited as ATCC PTA-6708, described in US-A 2006-282915 or WO2006 / 130436); MSI event 1 (rapeseed, pollination control - herbicide tolerance, deposited as ATCC PTA-850 or PTA-2485, described in WO2001 / 031042); Event MS8 (rapeseed, pollination control - herbicide tolerance, deposited as ATCC PTA-730, described in WO2001 / 041558 or US-A 2003-188347); Event NK603 (maize, herbicide tolerance, deposited as ATCC PTA-2478, described in US-A 2007-292854); Event PE-7 (rice, insect control, non-deposited, described in WO2008 / 114282); Event RF3 (rapeseed, pollination control - herbicide tolerance, deposited as ATCC PTA-730, described event 8264.44.06.1 (soybean, stacked herbicide tolerance, accession number PTA-11336, WO2012075426A2), event 8291.45.36.2 (soybean, stacked herbicide tolerance, accession number PTA-11335, WO2012075429A2), event SYHT0H2 (event SYHT0H2 (event SYHT0H2), Nede ATCC accession PTA-11226, WO2012 / 082548A2), event MON88701 (cotton, Nsde ATCC accession PTA-1175 4 , WO2012 / 134808AI), event KK179-2 (alfalfa, ATCC accession number PTA-11833, WO2013 / 003558AI), event pDAB8264.42.32.1 (soybean, stacked herbicide tolerance, ATCC accession number PTA11993, WO2013 / 010094AI) , event MZDT09Y (corn, ATCC accession number PTA13025, WO2013 / 012775AI). In addition, a list of such transgenic events is provided by the United States Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) and can be found on their website on the world wide web at aphis.usda.gov . For this application, the status of the list as it is / was on the date of submission of this application is relevant. The genes / events that impart the desired traits in question may also be present in combinations with each other in the transgenic plants. Examples of transgenic plants that can be mentioned are important crop plants, cereals such as (wheat, rice, triticale, barley, rye, oats), corn, soybeans, potatoes, sugar beets, cane sugar, tomatoes, peas and other types, of vegetables, cotton, tobacco, rapeseed and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), with special emphasis on corn, soybeans, wheat, rice, potatoes, cotton , sugar cane, tobacco and oilseed rape. Traits that particularly stand out are increased plant resistance to insects, arachnids, nematodes, and slugs and snails, as well as increased plant resistance to one or more herbicides. Commercially available examples of such plants, plant parts or plant seeds that can be treated in accordance with the invention include commercial products, plant seeds such as, sold or distributed under GENUITY®, DROUGHTGARD®, SMARTSTAX®, RIB COMPLETE®, ROUNDUP READY®, VT DOUBLE PRO®, VT TRIPLE PRO®, BOLLGARD II®, ROUNDUP READY 2 YIELD®, YIELDGARD®, ROUNDUP READY® 2 XTENDTM, INTACTA RR2 PRO®, VISTIVE GOLD®, and / or XTENDFLEX™. Crop protection - types of treatment The treatment of plants and plant parts with the compounds of formula (I) is carried out directly or by action on their environment, habitat or storage space using customized treatment methods, for example by immersion, spraying, atomization, irrigation , evaporation, dusting, misting, diffusing, foaming, painting, spreading, injecting, watering (soaking), drip irrigation and, in the case of propagation material, in particular in the case of seed, also as a powder for treatment of dry seeds, a solution for treating liquid seeds, a water-soluble powder for treating suspension, embedding, coating with one or more layers, etc. Furthermore, it is possible to apply the compounds of the formula (I) by the ultra-low volume method or to inject the application form or the compound of the formula (I) into the soil. A preferred direct treatment of plants is foliar application, i.e. the compounds of formula (I) are applied to foliage, where the treatment frequency and application rate should be adjusted according to the level of infestation with the pest. in question. In the case of systematically active compounds, the compounds of formula (I) also access plants through the root system. The plants are then treated by the action of the compounds of formula (I) in the plant habitat. This can be done, for example, by soaking, or mixing in the soil or nutrient solution, that is, the plant locus (e.g. soil or hydroponic systems) is impregnated with a liquid form of the compounds of the formula (I ), or by application to the soil, that is, the compounds of formula (I) according to the invention are introduced in solid form (for example in the form of granules) into the locus of the plants, or by drip application (often also referred to as chemigation), that is, the liquid application of the compounds of formula (I) according to the invention from surface or sub-surface droplets for a certain period of time, together with different amounts of water in defined locations in the vicinity of the plants. In the case of paddy rice crops, this can also be done by measuring the compound of formula (I) in a solid application form (e.g. as granules) in a rice field. flooded. Digital technologies The compounds of the invention can be used in combination with models for example integrated into computer programs for site-specific crop management, satellite agriculture, precision agriculture or precision agriculture. Such models support site-specific management of agricultural sites with data from various sources, such as soils, climate, crops (example type, growth stage, plant health), weeds (example type, growth stage), diseases, pests, nutrients, water, humidity, biomass, satellite data, yield, etc. with the aim of optimizing profitability, sustainability and environmental protection. In particular, these models can help optimize agronomic decisions, monitor the accuracy of pesticide applications, and record work performed. As an example, the compounds of the invention can be applied to a crop plant according to an appropriate dosage regimen if a model models the development of a pest and calculates that a threshold has been reached for which it is advisable to apply the compound of the invention. invention to the crop plant. Commercially available systems that include agronomic models are, for example, FieldScriptsTM from The Climate Corporation, XarvioTM from BASF, AGLogicTM from John Deere, etc. The compounds of the invention can also be used in combination with intelligent spraying equipment such as spot spraying or precision spraying equipment connected to an agricultural vehicle such as tractor, robot, helicopter, airplane, unmanned aerial vehicle (UAV). ) such as a drone, etc. Such equipment usually includes input sensors (such as a camera) and a processing unit configured to analyze the input data and configured to make a decision based on the analysis of the input data to apply the compound of the invention to crop plants (respectively weeds) in a specific and precise way. The use of such intelligent spray equipment usually also requires positioning systems (eg GPS receivers) to locate recorded data and guide or control agricultural vehicles; geographic information systems (GIS) to represent the information on intelligible maps, and appropriate agricultural vehicles to carry out the required agricultural action such as spraying. In one example, pests can be detected from images acquired by a camera. In one example, pests can be identified and / or classified based on those images. Such identification and / or classification may make use of image processing algorithms. Such image processing algorithms may use machine learning algorithms, trained neutral networks, decision trees, and artificial intelligence algorithms. In this way, the compounds described herein can only be applied where necessary. Seed treatment The control of animal pests by treating plant seeds has been known for a long time and is the subject of continuous improvements. However, seed treatment entails a series of problems that cannot always be solved satisfactorily frCRnnn / zznz / B / YiAi. Therefore, it is desirable to develop methods of protecting the seed and the germinating plant that dispense with, or at least considerably reduce, the additional application of pesticides during storage, after planting, or after plant emergence. In addition, it is desirable to optimize the amount of active compound employed in such a way that it provides optimal protection from attack by animal pests to the seed and germinating plant, but without the use of the active compound damaging the plant itself. In particular, seed treatment methods should also take into account the intrinsic insecticidal or nematicidal properties of pest resistant or tolerant transgenic plants in order to achieve optimal protection of the seed and also the germinating plant by using of the minimum amount of pesticides possible. Therefore, the present invention in particular also relates to a method for the protection of seeds and germinating plants against pest attack, by treating the seed with one of the compounds of formula (I). The method according to the invention for protecting seeds and germinating plants against attack by pests also comprises a method in which the seed is treated simultaneously in a single operation or sequentially with a compound having the formula (I) and a mix component. It also comprises a method in which the seed is treated at different times with a compound having the formula (I) and a mixture component. The invention also relates to the use of the compounds of formula (I) for the treatment of seeds so as to protect the seed and the resulting plant against animal pests. Furthermore, the invention relates to seeds that have been treated with a compound having formula (I) according to the invention to provide protection against animal pests. The invention also relates to seeds that have been treated simultaneously with a compound having formula (I) and a mixture component. The invention further relates to seeds that have been treated at different times with a compound having the formula (I) and a mixture component. In the case of seeds that have been treated at different times with a compound having the formula (I) and a mixture component, the individual substances may be present in the seed in different layers. In that context, layers comprising a compound having formula (I) and blend components may optionally be separated by an intermediate layer. The invention also relates to seeds in which a compound having formula (I) and a mixing component has been applied as a component of a coating or as an additional layer or layers in addition to a coating. Furthermore, the invention relates to seeds that, after treatment with a compound having formula (I), are subjected to a film coating process to prevent abrasion of the seed by the action of dust. One of the advantages achieved with a compound that has formula (I) of systemic action is the fact that, when treating the seed, not only the seed itself, but also the plants that result from it, after emergence, They are protected against animal pests. In this way, treatment of the crop can be dispensed with immediately at the time of sowing or shortly after. It should be considered an additional advantage that by treating the seed with a compound of the formula (I), the germination and emergence of the treated seed can be improved. It is considered advantageous that the compounds of formula (I) can in particular also be used for transgenic seeds. Furthermore, the compounds of formula (I) can be employed in combination with signaling technology compositions or compounds, which leads to improved colonization by symbionts such as, for example, rhizobia, mycorrhizae and / or endophytic bacteria or fungi, and / or to optimize nitrogen fixation. The compounds of formula (I) are suitable for the protection of seeds of any plant variety used in agriculture, greenhouse, forestry or horticulture, in particular this takes the form of cereal seeds (e.g. wheat, barley, rye, millet and oats), corn, cotton, soybeans, rice, potatoes, sunflowers, coffee, tobacco, rapeseed, rapeseed, beets (e.g. sugar beet and fodder beet), peanuts, vegetables (e.g. tomatoes , cucumbers, beans, cruciferous vegetables, onions and lettuces), fruit plants, grasses and ornamental plants. The treatment of seed of cereals (such as wheat, barley, rye and oats), corn, soybeans, cotton, canola, rapeseed, vegetables and rice is of particular importance. As already mentioned above, the treatment of transgenic seeds with a compound of formula (I) is also of particular importance. This takes the form of plant seeds which, as a rule, comprise at least one heterologous gene governing the expression of a polypeptide with in particular insecticidal and / or nematicidal properties. Heterologous genes in transgenic seeds can originate from microorganisms such as Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, frCRnnn / zznz / B / YiAi Clavibacter, Glomus or Gliocladium. The present invention is particularly suitable for the treatment of transgenic seeds comprising at least one heterologous gene originating from Bacillus sp. A heterologous gene derived from Bacillus thuringiensis is particularly suitable. In the context of the present invention, the compound of formula (I) is applied to the seed. Preferably, the seed is treated in a state where it is stable enough to avoid damage during treatment. In general, seed can be treated at any time between harvest and sowing. The seed usually used has been separated from the plant and freed from ears, shells, stems, coats, hairs or the flesh of the fruits. For example, it is possible to use seeds harvested, cleaned and dried to a moisture content that allows storage. Alternatively, it is also possible to use seeds that, after drying, have been treated with, for example, water and then dried again, for example, primer. In the case of rice seeds, it is also possible to use seeds soaked, for example in water, at a certain stage of the rice embryo (pigeon breast stage), stimulating germination and a more uniform emergence. When treating the seed, care should be taken that the amount of compound of formula (I) applied to the seed and / or the amount of additional additives is chosen in such a way that the germination of the seed is not adversely affected. or that the resulting plant is not damaged. This must be ensured especially in the case of active compounds that can exhibit phytotoxic effects at certain application doses. In general, the compounds of formula (I) are applied to the seed in a suitable formulation. Formulations and processes suitable for the treatment of seeds known to the person skilled in the art. The compounds of formula (I) can be converted to customized seed dressing formulations, solutions such as emulsions, suspensions, powders, foams, slurries or other seed coating compositions, and also ULV formulations. These formulations are prepared in a known manner, mixing the compounds of formula (I) with customized additives such as, for example, customized extenders and also solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary agents, thickeners, adhesives, gibberellins and also water. frCRnnn / zznz / B / YiAi The colorants that may be present in the seed dressing formulations that may be used in accordance with the invention are all colorants that are customized for such purposes. It is possible to use pigments, which are poorly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.L Pigment Red 112 and C.L Solvent Red 1. Useful wetting agents that may be present in seed dressing formulations usable according to the invention are all substances that promote wetting and that are conventionally used for the formulation of agrochemically active compounds. Preference is given to the use of alkylnaphthalenesulfonates, such as diisopropyl- or diisobutylnaphthalenesulfonates. Useful dispersants and / or emulsifiers that may be present in seed dressing formulations that may be used in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Preference is given to the use of nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Suitable nonionic dispersants include, in particular, ethylene oxide / propylene oxide block polymers, polyglycol alkylphenol ethers and tristerylphenol polyglycol ethers, and phosphated or sulfated derivatives thereof. Suitable ammonium dispersants are in particular lignosulfonates, polyacrylic acid salts and arylsulfonate / formaldehyde condensates. The antifoams that may be present in the seed dressing formulations usable according to the invention are all foam inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Preference is given to the use of silicone defoamers and magnesium stearate. The preservatives that may be present in the seed dressing formulations usable according to the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and hemiformal benzyl alcohol. The secondary thickeners that may be present in the seed dressing formulations usable according to the invention are all substances that can be used for such purposes in agrochemical compositions. Preferred are cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica. The adhesives that may be present in the seed dressing formulations usable according to the invention are all custom binders that can be used in seed dressing products. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose may be mentioned as preferred. Gibberellins that may be present in seed dressing formulations that may be used according to the invention are gibberellins Α1, A3 (= gibberellic acid), A4 and A7; Gibberellic acid is especially used. Gibberellins are known (see R. Wegler Chemie der Pflanzenschutz- and Schádlingsbekámpfungsmittel, vol. 2, Springer Verlag, 1970, pp. 401-412). The seed dressing formulations that can be used according to the invention can be used to treat a wide variety of different types of seeds, either directly or after prior dilution with water. For example, the concentrates of the preparations obtained by dilution with water can be used to dress the seeds of cereals, such as wheat, barley, rye, oats, and triticale, and also the seeds of corn, rice, rapeseed, peas, beans, cotton, sunflowers, soybeans and beets, or a wide variety of different vegetable seeds. Seed dressing formulations that can be used in accordance with the invention, or diluted use forms thereof, can also be used to dress transgenic seed plants. For the treatment of seeds with the seed dressing formulations usable according to the invention, or the use forms prepared therefrom by adding water, all mixing units usually used for seed dressing are useful. Specifically, the procedure in seed dressing is to place the seed in a mixer, operated in batches or continuously, to add the particular desired amount of seed dressing formulations, either as such or after prior dilution with water, and Mix everything until the formulation is homogeneously distributed in the seed. If appropriate, this is followed by a drying operation. The application rate of the seed dressing formulations usable according to the invention can be varied within a relatively wide range. It is guided by the particular content of the compounds of formula (I) in the formulations and by the seed. Application rates of the compound of formula (I) are generally between 0.001 and 50 g per kilogram of seed, and between 0.01 and 15 g per kilogram of seed. Animal health In the field of animal health, that is, in the field of veterinary medicine, the compounds of formula (I) are active against animal parasites, in particular ectoparasites or endoparasites. The term endoparasite includes in particular helminths and protozoa, such as coccidia. Ectoparasites are typically and preferably arthropods, particularly insects or mites. In the field of veterinary medicine, the compounds of formula (I) are suitable, with favorable toxicity in warm-blooded animals, for controlling parasites produced in animal husbandry and [the use] of animals in livestock animals. breeding, zoo, laboratory, experimental and domestic. They are active against all or specific stages of parasite development. Agricultural livestock includes, for example, mammals, such as sheep, goats, horses, donkeys, camels, buffaloes, rabbits, reindeer, fallow deer, and in particular cattle and pigs; or poultry, such as turkeys, ducks, geese, and in particular chickens; or fish or crustaceans, for example, in aquaculture; or, as the case may be, insects such as bees. Domestic animals include, for example, mammals, such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets or, in particular, dogs, cats; cage birds; reptiles; amphibians or aquarium fish. According to a particular embodiment, the compounds of formula (I) are administered to mammals. According to another particular embodiment, the compounds having formula (I) are administered to birds, namely cage birds or in particular poultry. By using the compounds that have formula (I) to control animal parasites, the aim is to reduce [the incidence of] or prevent diseases, cases of death and reductions in yield (in the case of meat, milk, wool, skins, eggs, honey and similar), so that a more economical and simple maintenance of the animals is possible and better animal welfare can be achieved. The term control or control, as used herein with respect to the field of animal health, means that the compounds possessing formula (I) are effective in reducing to harmless levels the incidence of the respective parasite in an animal infected with such parasites. More specifically, control, as used herein, means that the compounds possessing formula (I) are effective in killing the respective parasite, inhibiting its growth or inhibiting its proliferation. Examples of arthropods include, but are not limited to those of the order Anoplurida, for example, Haematopinus spp., Linognathus spp., Pediculus spp., Phtirus spp., Solenopotes spp.; frCRnnn / zznz / B / YiAi of the order Mallophagida and the suborders Amblycerina and Ischnocerina, for example Bovicola spp., Damalina spp., Felicola spp., Lepikentron spp., Menopon spp., Trichodectes spp., Trimenopon spp., Trinoton spp. , Werneckiella spp.; of the order Diptera and the suborders Nematocerina and Brachycerina, for example Aedes spp., Anopheles spp., Atylotus spp., Braula spp., Calliphora spp., Chrysomyia spp., Chrysops spp., Culex spp., Culicoides spp., Eusimulium spp. ., Fannia spp., Gasterophilus spp., Glossina spp., Haematobia spp., Haematopota spp., Hippobosca spp., Hybomitra spp., Hydrotaea spp., Hypoderma spp., Lipoptenaspp., Luciliaspp., Lutzomyia spp., Melophagus spp. ., Morellia spp., Musca spp., Odagmia spp., Oestrus spp., Philipomyia spp., Phlebotomus spp., Rhinoestrus spp., Sarcophaga spp., Simulium spp., Stomoxis spp., Tabanus spp., Típula spp., Wilhelmia spp., Wohlfahrtia spp. from the order Siphonapterida, for example Ceratophyllus spp.; Ctenocephalides spp., Pulex spp., Tunga spp., Xenopsylla spp.; from the order Heteropterida, for example Cimex spp., Panstrongylus spp., Rhodnius spp., Triátomoa spp.; as well as annoying and hygienic pests of the order Blattarida. Likewise, among arthropods, the following mites can be mentioned as an example, without being limited to them: from the subclass Acari (Acariña) and the order Metastigmata, for example, from the family Argasidae such as Argas spp., Ornithodorus spp., Otobius spp., from the family Ixodidae such as Amblyomma spp., Dermacentor spp., Haemaphysalis spp. , Hyalomma spp., Ixodes spp., Rhipicephalus (Boophilus) spp, Rhipicephalus spp. (the original genus of the multihost tick); from the order mesostigmata such as Dermanyssus spp., Ornithonyssus spp., Pneumonyssus spp., Raillietia spp., Sternostoma spp., Tropilaelaps spp., Varroa spp.; from the order Actinedida (Prostigmata), for example Acarapis spp., Cheyletiella spp., Demodex spp., Listrophorus spp., Myobia spp., Neotrombicula spp., Ornithocheyletia spp., Psorergates spp., Trombicula spp.; and from the order Acaridida (Astigmata), for example Acarus spp., Caloglyphus spp., Chorioptes spp., Cytodites spp., Hypodectes spp., Knemidocoptes spp., Laminosioptes spp., Notoedresspp., Otodectesspp., Psoroptesspp., Pterolichusspp., Sarcoptes spp., Trixacarus spp., Tyrophagus spp. Examples of parasitic protozoans include, but are not limited to: Mastigophora (Flagellata) such as: Metamonad: from the order Diplomonadida, for example, Giardia spp., Spironucleus spp. Parabasala: from the order Trichomonadida, for example, Histomonas spp., Pentatrichomonas spp., Tetratrichomonas spp., Trichomonas spp., Tritrichomonas spp. Euglenozoa: of the order Trypanosomatida, e.g. Leishmania spp., Trypanosoma spp Sarcomastigophora (Rhizopoda), such as Entamoebidae, e.g. Entamoeba spp., Centramoebidae, e.g. Acanthamoebasp., Euamoebidae, e.g. Hartmanella sp. Alveolata such as Apicomplexa (Sporozoa): for example Cryptosporidium spp.; from the order Eimeriida, for example, Besnoitia spp., Cystoisospora spp., Eimeria spp., Hammondia spp., Isospora spp., Neospora spp., Sarcocystis spp., Toxoplasma spp.; from the order Adeleida for example Hepatozoon spp., Klossiella spp.; from the order Haemosporida for example Leucocytozoon spp., Plasmodium spp.; from the order Piroplasmida for example Babesia spp., Ciliophora spp., Echinozoon spp., Theileria spp.; of the order Vesibuliferida for example Balantidium spp., Buxtonella spp. Microspora such as Encephalitozoon spp., Enterocytozoon spp., Globidium spp., Nosema spp., and also, for example, Myxozoa spp. Helminths pathogenic to humans or animals include, for example, acanthocephalans, nematodes, pentastomas and flatworms (for example monogeneous, cestodes and trematodes). Examples of helminths include, but are not limited to: Monogenea: for example: Dactylogyrus spp., Gyrodactylus spp., Mícrobothrium spp., Polistoma spp., Troglocephalus spp. Cestodes: from the order Pseudophyllidea, for example: Bothridium spp., Diphyllobothrium spp., Diplogonoporus spp., Ichtiobothrium spp., Lígula spp., Schistocephalus spp., Spirometra spp. of the order Ciclophyllida, for example: Andyra spp., Anoplocephala spp., Avitellina spp., Bertiella spp., Cittotaenia spp., Davainea spp., Diorchis spp., Diplopylidium spp., Dipylidium spp., Echinococcus spp., Echinocotyle spp. , Echinolepis spp., Hydatigera spp., Hymenolepis spp., Joyeuxiella spp., Mesocestoides spp., Moniezia spp., Paranoplocephala spp., Raillietina spp., Stilesia spp., Taenia spp., Tisaniezia spp., Tisanosoma spp. Trematodes: from the class Digenea, for example: Austrobilharzia spp., Brachylaima spp., Calicophoron spp., Catatropis spp., Clonorchis spp. Collyriclum spp., Cotylophoron spp., Ciclocoelum spp., Dicrocoelium spp., Diplostomum spp., Echinochasmus spp., Echinoparyphium spp., Echinostoma spp., Eurytrema spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp., Fischoederius spp., Gastrotilacus spp., Gigantobilharzia spp., Gigantocotyle spp., Heterophyes spp., Hypoderaeum spp., Leucochloridium spp., Metagonimus spp., Metorchis spp., Nanophyetus spp., Notocotylus spp., Opisthorchis spp., Ornithobilharzia spp., Paragonimus spp., Paramphistomum spp., Plagiorchis spp., Posthodiplostomum spp., Prosthogonimus spp., Schistosoma spp., Trichobilharzia spp., Troglotrema spp., Typhlocoelum spp. Nematodes: of the order Trichinellida, for example: Capillaria spp., Eucoleus spp., Paracapillaria spp., Trichinella spp., Trichomosoides spp., Trichuris spp. of the order Tylenchida, for example: Micronema spp., Parastrongyloides spp., Strongyloides spp. of the order Rhabditina, for example: Aelurostrongylus spp., Amidostomum spp., Ancylostoma spp., Angiostrongylus spp., Bronchonema spp., Bunostomum spp., Chabertia spp., Cooperia spp., Cooperioides spp., Crenosoma spp., Cyathostomum spp. , Ciclococercus spp., Cyclodontostomum spp., Cylicociclus spp., Cylicostephanus spp., Cylindropharynx spp., Cystocaulus spp., Dictyocaulus spp., Elaphostrongylus spp., Filaroides spp., Globocephalus spp., Graphidium spp., Gyalocephalus spp., Ha monchus spp., Heligmosomoid spp., Hyostrongylus spp., Marshaliagia spp., Metastrongylus spp., Muelleriusspp., necatorspp., Nematodirus spp., Neostrongylus spp., Nippostrongyluspp., Obeliscoides spp., Oesophagodontus spp. Ollulanus spp .; Ornithostrongylus spp., Oslerus spp., Ostertagia spp., Paracooperia spp., Paracrenosoma spp., Parafilaroides spp., Parelaphostrongylus spp., Pneumocaulus spp., Pneumostrongylus spp., Poteriostomum spp., Protostrongylus spp., Spicocaulus spp., Stephanurus spp ., Strongylus spp., Syngamus spp., Teladorsagia spp., Trichonema spp., Trichostrongylus spp., Triodontophorus spp., Troglostrongylus spp., Uncinaria spp. from the order Spirurida, for example: Acanthocheilonema spp., Anisakis spp., Ascaridia spp.; Ascaris spp., Ascarops spp., Aspiculuris spp., Baylisascaris spp., Brugia spp., Cercopithifilaria spp., Crassicauda spp., Dipetalonema spp., Dirofilaria spp., Dracunculus spp.; Draschia spp., Enterobius spp., Filaria spp., Gnathostoma spp., Gongylonema spp., Habronema spp., Heterakis spp.; Litomosoides spp., Loa spp., Onchocerca spp., Oxiuris spp., Parabronema spp., Parafilaria spp., Parascaris spp., Passalurus spp., Physaloptera spp., Probstmayria spp., Pseudofilaria spp., Setaria spp., Skjrabinema spp. ., Spirocerca spp., Stephanofilaria spp., Strongyluris spp., Syphacia spp., Thelazia spp., Toxascaris spp., Toxocara spp., Wuchereria spp. Acantocephala: from the order Oligacanthorhynchida, for example: Macracanthorhynchus spp., Prosthenorchis spp.; of the order Moniliformida, for example: Moniliformis spp. from the order Polimorphida, for example: Filicollis spp.; of the order Echinorhynchida, for example: Acanthocephalus spp., Echinorhynchus spp., Leptorhynchoides spp. Pentastoma: from the order Porocephalida, for example: Linguatula spp. In the veterinary field and in animal maintenance, the administration of the compounds of formula (I) is carried out by methods generally known in the art, such as enteral, parenteral, dermal or nasal, in the form of suitable preparations. Administration can be carried out prophylactically, metaphylactically or therapeutically. Therefore, one embodiment of the present invention relates to the compounds of formula (I) for use as a medicament. Another aspect refers to the compounds of formula (I) for use as an anti-endoparasitic agent. Another particular aspect relates to the compounds of formula (I) for use as an anthelmintic agent, more particularly for use as a nematicidal agent, a platyhelmintic agent, an anti-acanthocephalan agent, or an anti-pentastomid agent. Another particular aspect refers to the compounds of formula (I) for use as antiprotozoal agent. Another aspect relates to the compounds of formula (I) for use as an antiectoparasitic agent, in particular an arthropodicidal agent, more particularly an insecticidal agent or acaricidal agent. Other aspects of the invention are veterinary formulations, which comprise an effective amount of at least one compound having formula (I) and at least one of the following: excipient suitable for pharmaceutical use (for example, solid or liquid diluents) , pharmaceutical-grade auxiliary (e.g. surfactants), in particular a pharmaceutical-grade excipient and / or a pharmaceutical-grade auxiliary normally used in veterinary formulations. A related aspect of the invention is a method for preparing a veterinary formulation as described herein, which comprises the step of mixing at least one compound having formula (I) with excipients and / or auxiliaries suitable for pharmaceutical use, in particular with excipients suitable for pharmaceutical use and / or auxiliaries that are normally used in veterinary formulations. Another particular aspect of the invention is the veterinary formulations, selected from the group of ectoparasiticidal and endoparasiticidal formulations, more particularly selected from the group of anthelmintic, antiprotozoal and arthropodicidal formulations, even more particularly selected from the group of frCRnnn / zznz / B / YiAi nematicidal formulations, anti-flatworms, anti-acanthocephalans, anti-pentastomids, insecticides and acaricides, in accordance with the aforementioned aspects, as well as their preparation methods. Another aspect relates to a method for treating a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned herein, applying an effective amount of a compound having formula (I) to an animal, particularly a non-human animal, in need. Another aspect relates to a method for treating a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned here, applying a veterinary formulation as defined here to an animal, in particular a non-human animal. human, who needs it. Another aspect relates to the use of the compounds of formula (I) in the treatment of a parasitic infection, in particular an infection by a parasite selected from the group of ectoparasites and endoparasites mentioned herein, in an animal, in particular an non-human animal. In the current context of animal health or the veterinary field, the term treatment includes prophylactic, metaphylactic or therapeutic treatment. In a particular embodiment, mixtures of at least one compound having formula (I) with other active ingredients, particularly with endo- and ectoparasiticides, for the veterinary field are disclosed herein. In the field of animal health, mixture not only means that two (or more) different active ingredients are formulated in a joint formulation and, consequently, applied together, but also refers to products that comprise separate formulations for each active compound. . Accordingly, if more than two active compounds are applied, all the active compounds can be formulated in a joint formulation or all the active compounds can be formulated in separate formulations; Mixed forms are also possible in which some of the active compounds are formulated together and some of the active compounds are formulated separately. Separate formulations allow separate or successive application of the active compounds in question. The active compounds specified herein by their common name are known and are described, for example in the Pesticide Manual (see above) or can be searched on the Internet (for example http: / / www.alanwood.net / pesticides ). Examples of active ingredients to be selected from the set of ectoparasiticides, as components of the mixture, include, but are not limited to, the insecticides and acaricides listed in the previous list. Other active ingredients that can be used are listed below according to the aforementioned classification, which is based on the IRAC Mode of Action Classification Scheme: (1) Acetylcholinesterase (AChE) inhibitors; (2) Blockers of GABA-regulated chloride channels; (3) Sodium channel modulators; (4) Competitive modulators of the nicotinic acetylcholine receptor (nAChR); (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR); (6) Allosteric modulators of glutamate-gated chloride channels (GluCI); (7) Imitations of youth hormones; (8) Miscellaneous non-specific inhibitors (multisite); (9) Modulators of TRPV channels of chordotonal organs; (10) Mite growth inhibitors; (12) Mitochondrial ATP synthetase inhibitors, such as, ATP disruptors; (13) Uncouplers of oxidative phosphorylation through disruption of the proton gradient; (14) Blockers of channels regulated by the nicotinic acetylcholine receptor; (15) Chitin biosynthesis inhibitors, type 0; (16) Chitin biosynthesis inhibitors, type 1; (17) Moult disruptors (particularly for Diptera, i.e. dipteranes); (18) Ecdysone receptor agonists; (19) Octopamine receptor agonists; (21) Inhibitors of electronic transport in mitochondrial complex I; (25) Inhibitors of electronic transport in mitochondrial complex II; (20) Inhibitors of electronic transport in mitochondrial complex III; (22) Voltage-gated sodium channel blockers; (23) Acetyl CoA carboxylase inhibitors; (28) Ryanodine receptor modulators, (30) GABA-gated chloride channel allosteric modulators; Active compounds with unknown or non-specific mode of action, for example, fentrifanil, fenoxacrim, cycloprene, chlorobenzilate, chlordimeform, flubenzimine, dicyclanil, amidoflumet, quinomethionate, triaratene, clothiazobene, tetrasul, potassium oleate, petroleum, methoxadiazone, gossyplure, flutenzine, bromopropylate , cryolite; Compounds of other classes, for example butacarb, dimethylan, cloetocarb, fosfocarb, pirimiphos (-ethyl), parathion (-ethyl), metacryphos, isopropyl o-salicylate, trichlorfon, tigolaner, sulprofos, propaphos, sebufos, pyridathion, protoate, diclofenthion , demeton-S-methylsulfone, isazophos, cyanofenphos, dialyphos, carbofenothion, autathiofos, aromfenvinphos (-methyl), azinphos (ethyl), chlorpyrifos (-ethyl), fosmethylan, iodofenphos, dioxabenzophos, formotion, fonophos, flupyrazophos, fensulfothion, etrimphos; frCRnnn / zznz / B / YiAi organochlorines, for example camphechlor, lindane, heptachlor; or phenylpyrazoles, for example acetoprol, pyrafluprole, pyriprole, vaniliprole, sisapronil; or isoxazolines, for example sarolaner, afoxolaner, lotilaner, fluralaner; pyrethroids, e.g. (cis-, trans-), methofluthrin, profluthrin, flufenprox, flubrocitrinate, fubfenprox, fenfluthrin, protripenbute, pyresmethrin, RU15525, teralletrin, cis-resmethrin, heptafluthrin, bioethanemethrin, biopermethrin, fenpythrin, cis-cypermethrin, cis- permethrin, clocitrin, cyhalothrin (lambda-), clovaportrin, or halogenated carbon and hydrogen compounds (HCH), neonicotinoids, for example nithiazine dichloromezothiaz, triflumezopyrim macrocyclic lactones, for example nemadectin, ivermectin, latidectin, moxidectin, selamectin, eprinomectin, doramectin, emamectin benzoate; milbemycin oxime triprene, epofenonane, diofenolan; Biological compounds, hormones or pheromones, for example natural products, for example thuringiensin, codlemone or neem components dinitrophenols, for example dinocap, dinobuton, binapacryl; benzoylureas, for example fluazuron, penfluron, amidine derivatives, for example chlormebuform, cymiazole, demiditraz acaricides against colmenta varroa, for example oroganic acids, for example formic acid, oxalic acid. Examples of active ingredients to be selected from the set of endoparasiticides, as mixing pairs, include, but are not limited to, compounds with anthelmintic activity and compounds with antiprotozoal activity. Compounds with anthelmintic activity, including, but not limited to, the following compounds with nematicidal, trematicidal and / or cestocidal activity: from the class of macrocyclic lactones, for example: eprinomectin, abamectin, nemadectin, moxidectin, doramectin, selamectin, lepimectin , latidectin, milbemectin, ivermectin, emamectin, milbemycin; from the class of benzimidazoles and probenzimidazoles, for example: oxibendazole, mebendazole, triclabendazole, thiophanate, parbendazole, oxfendazole, netobimine, fenbendazole, febantel, thiabendazole, cyclobendazole, cambendazole, albendazole-sulfoxide, albendazole, flubendazole; from the class of depsipeptides, preferably cyclic depsipeptides, in particular 24-membered cyclic depsipeptides, for example: emodepside, PF1022A; from the class of tetrahydropyrimidines, for example: morantel, pyrantel, oxantel; from the class of imidazothiazoles, for example: butamisole, levamisole, tetramisole; from the class of aminophenylamidines, for example: amidantel, deacylated amidantel (dAMD), tribendimidine; from the aminoacetonitrile class, for example: monepantel; from the class of parahercuamides, for example: parahercuamide, derquantel; from the class of salicylanilides, for example: tribromsalan, bromoxanide, brotianide, clioxanide, closantel, niclosamide, oxyclozanide, rafoxanide; from the class of substituted phenols, for example: nitroxinil, bithionol, disophenol, hexachlorophene, niclofolan, meniclofolan; from the organophosphate class, for example: trichlorfon, naphthalofos, dichlorvos / DDVP, crufomate, coumaphos, haloxon; from the piperazinone / quinoline class, for example: praziquantel, epsiprantel; from the class of piperazines, for example: piperazine, hydroxyzine; from the tetracycline class, for example: tetracycline, chlorotetracycline, doxycycline, oxytetracycline, rolitetracycline; of several other classes, for example: bunamidine, niridazole, resorantel, omfalotine, oltipraz, nitroscanate, nitroxynil, oxamniquin, mirasan, miradlo, lucantone, hycantone, hetolin, emetine, diethylcarbamazine, dichlorophene, diamfenetide, clonazepam, bephenium, amoscanate, clorsulon. Compounds with antiprotozoal activity, including, but not limited to, the following active compounds: from the class of triazines, for example: diclazuril, ponazuril, letrazuril, toltrazuril; from the class of polyether ionophores, for example: monensin, salinomycin, maturemycin, narasin; from the class of the class of the class of the class of macrocyclic lactones, for example: milbemycin, erythromycin; quinolones, for example: enrofloxacin, pradofloxacin; quinines, for example: chloroquine; as pyrimidines, for example: pyrimethamine; as sulfonamides, for example: sulfaquinoxaline, trimethoprim, sulfaclozine; of the class of of the class of of the class of asthiamines, for example: amprolium; lincosamides, for example: clindamycin; as carbanilides, for example: imidocarb; nitrofurans, for example: nifurtimox; from the class of quinazolinone alkaloids, for example: halofuginon; of various other classes, for example: oxamniquine, paromomycin; of the class of vaccines or antigens from microorganisms, for example: Babesia canis rossi, Eimeria tenella, Eimeria praecox, Eimeria necatrix, Eimeria mitis, Eimeria maxima, Eimeria brunetti, Eimeria acervulina, Babesia canis vogeli, Leishmania infantum, Babesia canis canis, Dictyocaulus viviparus. All listed mixing pairs can, if their functional groups permit, optionally form salts with suitable bases or acids. Vector control Compounds having formula (I) can also be used in vector control. For the purposes of the present invention, a vector is an arthropod, in particular an insect or arachnid, capable of transmitting pathogens such as, for example, viruses, worms, unicellular organisms and bacteria from a reservoir (plant, animal, human, etc.). .) to a host. Pathogens can be transmitted mechanically (eg, trachoma by non-biting flies) to a host, or by injection (eg, malaria parasites by mosquitoes) into a host. Examples of vectors and the diseases or pathogens they transmit are: 1) Mosquitoes - Anopheles: malaria, filariasis; - Culex: Japanese encephalitis, other viral diseases, filariasis, transmission of other worms; - Aedes: yellow fever, dengue, other viral diseases, filariasis; - Simuliidae: transmission of worms, in particular Onchocerca volvulus; - Psychodidae: transmission of leishmaniasis. 2) Lice: skin infections, epidemic typhus; 3) Fleas: plague, endemic typhus, cestodes; 4) Flies: sleeping sickness (trypanosomiasis); cholera, other bacterial diseases; 5) Mites: acariasis, epidemic typhus, rickettsialpox, tularaemia, Saint Louis encephalitis, tick-borne encephalitis (TBE), Crimean-Congo hemorrhagic fever, borreliosis; 6) Ticks: borellioses such as Borrelia burgdorferi sensu lato., Borrelia duttoni, tick-borne encephalitis, Q fever (Coxiella burnetii), babesiosis (Babesia canis canis), ehrlichiosis. Examples of vectors for the purposes of the present invention are insects, for example aphids, flies, grasshoppers or thrips, which are capable of transmitting plant-to-plant viruses. Other vectors capable of transmitting plant viruses are mites, lice, beetles and nematodes. Other examples of vectors for the purposes of the present invention are insects and arachnids such as mosquitoes, in particular of the genera Aedes, Anopheles, for example A. gambiae, A. arabiensis, A. funestus, A. dirus (malaria) and Culex. , psychods such as Phlebotomus, Lutzomyia, lice, fleas, flies, mites and ticks capable of transmitting pathogens to animals and / or humans. Vector control is also possible if the compounds having formula (I) allow resistance-breaking. The compounds of formula (I) are suitable for use in the prevention of vector-borne diseases and / or pathogens. Therefore, a further aspect of the present invention is the use of compounds of formula (I) for the control of vectors, for example, in agriculture, in horticulture, in gardens and in leisure facilities, and also in the protection of stored materials and products. Protection of industrial materials. Compounds having formula (I) are suitable for protecting industrial materials against attack or destruction by insects, for example from the orders Coleoptera, Hymenoptera, Isoptera, Lepidoptera, Psocoptera and Zygentoma. In the current context, industrial materials are understood to mean inanimate materials, such as, preferably, plastics, adhesives, sizes, papers and cards, leather, wood, processed wood products, and coating compositions. Particularly preferred is the use of the invention to protect wood. In a further embodiment, the compounds having formula (I) are used together with at least one additional insecticide and / or at least one fungicide. In a further embodiment, the compounds having formula (I) are present as a ready-to-use pesticide, ie they can be applied to the material in question without further modification. Other suitable insecticides or fungicides are, in particular, those mentioned above. Surprisingly, it has also been found that compounds having formula (I) can be used to protect against fouling objects that come into contact with salt or brackish water, in particular helmets, screens, nets, buildings, moorings and signaling systems. . Likewise, compounds of formula (I), alone or in combination with other active compounds, can be used as antifouling agents. Control of animal pests in the hygiene sector. The compounds having formula (I) are suitable for controlling animal pests in the hygiene sector. In particular, the invention can be applied in the domestic sector, in the hygiene sector and in the protection of stored products, especially to control insects, arachnids, ticks and mites found in closed spaces such as homes, industrial warehouses, offices. , vehicle cabins, animal farms. To control animal pests, the compounds of formula (I) are used alone or in combination with other active and / or auxiliary compounds. They are preferably used in household insecticide products. The compounds having formula (I) are effective against sensitive and resistant species, and against all stages of development. These pests include, for example, pests of the class Arachnida, of the orders Scorpiones, Araneae and Opiliones, of the classes Chilopoda and Diplopoda, of the class Insecta, of the order Blattodea, of the orders Coleoptera, Dermaptera, Diptera, Hipoptera, Hymenoptera , Isoptera, Lepidoptera, Phthiraptera, Psocoptera, Saltatoria or Orthoptera, Siphonaptera and Zygentoma and the class Malacostraca of the order Isopoda. They are used, for example, in aerosols, non-pressure spray products, e.g. pump sprayers and atomizers, automatic misting systems, nebulizers, foams, gels, evaporator products with evaporator tablets made of cellulose or plastic, liquid evaporators , gel and membrane evaporators, propeller-driven evaporators, unpowered or passive evaporation systems, moth papers, moth bags, and moth gels, as granules or powders, in baits for spreading or [placing at a given location]. Preparation examples Synthesis of 3-chloro-M-{1-[1-(6-cyano-3-pyridín¡l)-3-(difluoromethyl)-1H-1,2,4-triazol-5yl]ethyl} -5-(trifluoromethyl)benzamide (Example I-9) frCRnnn / zznz / B / YiAi Step 1 2-[6-cyano-3-pyridinyl]hydrazide-2,2-difluoro-ethanimidic acid CN or HN F To 2.33 g (17.4 mmol) 5-hydrazin¡l-2-pyridinecarbonitrile in methanol (30 mL) was added 3.15 g (24.3 mmol) ethyl 2,2-difluoroethanecarboximidate (purchased from Enamine Building Blocks), and the mixture The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was then stirred with n-hexane (30 mL) and ethyl acetate (3 mL). The brownish precipitator was separated and dried to give 3.38 g (purity: 90.4%; yield: 83.0%) 2-[6-cyano-3-pyrid¡n¡l]hydraz acid de-2,2-difluoro-ethane! ESI mass [m / z]: 211.1 [M+H]+ Step 2 2-[1 -[3-(difluoromethyl)-1 -(6-cyano-3-pyridinyl)-1 / 7-1,2,4-triazol-5-¡l)ethyl]-1 / 7 -¡so¡ ndol-1 diona frCRnnn / zznz / B / YiAi A 3.28 g (14.0 mmol) 2-[6-cyano-3-pyridin¡l]hydraz¡de-2,2-difluoro-ethanymic acid in pyridine (20 mL), 3.32 g (14.0 mmol) (aS)-1,3-dihydro-a-methyl-1,3-dioxo-2Hisoindole-2-acetyl chloride were added (see preparation below). starting from (aS)-1,3-dihydro-a-methyl-l ,3dioxo-2 / 7-ísoíndole-2-acetic acid (Pht-Ala-OH purchased from ABCR) and oxalyl chloride: D. A. Gruzdev etal., Tetrahedron: Asymmetry, 21(8), 936-942, 2010), and the reaction mixture was stirred at room temperature overnight. Water (200 mL) was then added and the mixture was extracted with dichloromethane (200 mL). The organic phase was extracted twice with a saturated aqueous NaHCOs solution (100 mL), dried over Na2SO4, and evaporated under reduced pressure. The remaining solid residue was analyzed by chromatography with a cyclohexane / acetone gradient on silica gel to give 1.09 g (purity: 95.7%; yield: 18.8%) of the racemic title compound in the form of a colorless solid. ESI mass [m / z]: 395.2 [M+H]+ Step 3 6-[5-(1-aminoethyl)-3-(difluoromethyl)-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (INT-4) A 1.0 g (2.5 mmol) 2-[1 -[3-(difluoromethyl)-1 -(6-cyano-3-pyridiníl)-1 / 7-1,2,4-triazol-5-yl)et l]-1 Hisoindol-1,3(2H)-dione in ethanol (20 mL), 577 mg (6.34 mmol) hydrazinehydrate was added, and the reaction mixture was heated under reflux. After 30 minutes a colorless precipitate formed. The reaction mixture was stirred and heated under reflux for another hour, acetone (15 mL) was added and heating continued for another 30 minutes. The reaction mixture was concentrated and the solid residue was treated with ethanol. After filtration, the filtrate was evaporated under reduced pressure to give 663 mg of 6-[5-(1-aminoethyl)3-(difluoromethyl)-1,2,4-triazol-1-yl]pyridine-3- carbonitrile (IT-4), which was used in step 4 without purification. ESI mass [m / z]: 265.2 [M+H]+ List of 1H-NMR peaks see Table 2 (INT-4). Step 4 3-chloro-A / -{1 -[1 - (6-cyano-3-pyridi n i l)-3- (d if I uorom eti I) -1 / 7-1,2,4-triazole-5 -¡ I] eti l}-5(trifluoromethyl)benzamide At 222 mg (0.84 mmol) 6-[5-(1-aminoethyl)-3-(difluoromethyl)-1,2,4-triazol-1-yl]pyridine-3carbonitrile (INT-4), added 194 mg (0.84 mmol) 3-chloro-5-(trifluoromethyl)benzoic acid, 141 mg (1.09 mmol) A / ,A / -diisopropylethilamine (Hünig's Base) in N,Ndimethylformamide (DMF) ( 5 mL), 383 mg (1.00 mmol) [O-(7azabenzotriazol-1-¡l)- / V, / V, / V', / V'-tetramethyluron¡o hexafluorophosphate] (HATU), and the Reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and the solid residue was treated with dichloromethane and then extracted with a saturated aqueous solution of NaHCOs and water. The organic phase was separated, dried over Na2SO4 and the solvent evaporated under reduced pressure. The remaining solid residue was analyzed by chromatography with a cyclohexane / acetone gradient on silica gel followed by spraying with diethyl ether and filtration to give 259 mg (purity: 100%; yield: 65.4%) of the racemic title compound. ESI mass [m / z]: 471.1 [M+H]+ List of 1H-NMR peaks see Table 1. Synthesis of 6-{5-[(1S)-1-aminoethyl]-3-isopropyl-1 H-1,2,4-triazol-1-yl}nicotinonitrile (INT2) Step 1 6-{5-[( 1S)-1 -(1,3-dioxo-1,3-dihyd ro-2H-isoindol-2-¡l)et¡ l]-3-isopropyl-1H-1,2, 4-triazol-1yljnicotinonitrile A solution of 5.00 g (95% purity, 21.6 mmol) (2S)-2-(1,3-dioxo-1,3-dihydro-2H¡soindol-2-¡l)propanoic acid and 0.08 mL ( 1 mmol) DMF in 30 mL absolute CH2CI2 was treated with 3.78 mL (43.3 mmol) oxalyl chloride at 0 °C. The reaction mixture was stirred for 2 d at room temperature. All volatiles were removed under reduced pressure and the residue was used for the next step without further purification. To a solution of 3.13 g (95% purity, 21.6 mmol) methyl 2-methylpropanimidate hydrochloride (1:1) in 40 mL absolute THF, 15.1 mL (86.4 mmol) absolute DIPEA were added at 0 °C. The acid chloride prepared in the first step was dissolved in 20 mL absolute THF and added dropwise over 25 min to the imidate solution. After 30 min of stirring at 0 °C, 3.19 g (23.7 mmol) 6-hydrazinonicotinonitrile and 10 mL absolute THF were added. The reaction mixture was stirred for 30 min at 0 °C and overnight at room temperature. All volatiles were removed under reduced pressure. 200 mL water was added to the residue and the mixture was extracted with 200 mL EtOAc. The phases were separated and the aqueous phase was extracted several times with EtOAc. The combined organic phases were washed with brine and dried over Na?SO4. The solvent was removed under reduced pressure and the residue was purified by silica chromatography (cyclohexane / ethyl acetate) to give 5.57 g of 6-{5-[(1 S)-1 -(1,3-dioxo-1, 3-dihydro-2H-ísoindol-2-íl)ethyl]3-ísopropyl-1 H-1,2,4-triazol-1 -yl} nicotinonitrile. ESI mass [m / z]: 387.5 [M+H]+ Step 2 6-{5-[(1 S)-1 -aminoethyl]-3-¡soprop¡l-1 H-1,2,4-triazol-1 -iI}nicotinonitrile (INT-2) frCRnnn / zznz / B / YiAi A solution of 2.00 g (5.17 mmol) 6-{5-[(1S)-1-(1,3-dioxo-1,3-dihydro-2H-¡soindol-2-yl)ethyl]3 -ísopropyl-1 H-1,2,4-triazol-1 -yl}nicotinonitrile and 0.38 mL hydrazine hydrate in 40 mL ethanol were heated for 2 h at 80 °C. The resulting suspension was stirred overnight at room temperature and then cooled to 10 °C. The mixture was filtered and the residue was washed with ice-cold ethanol. The filtrate was concentrated under reduced pressure to give 1.57 g (70% mash) of 6-{5-[(1S)-1-aminoethyl]-3-isopropyl-1H-1,2, 4-thazol-1IJnicotinonitrile. ESI mass [m / z]: 257.2 [M+H]+ Synthesis of 3-chloro-N-{(1 S)-1 -[1 -(5-cyanopyridiη-2-iI)-3-cyclopropyI-1 H-1,2,4-triazol-5yl]ethyl}-5 -(trifluoromethyl)benzamide (example I-6) Step 1 {(1 S)-1 -[1 -(5-cyanopyridin-2-yl)-3-cyclopropyl-1 H-1,2,4-triazol-5-yl]ethyl}tert-butyl carbamate frCRnnn / zznz / B / YiAi To a solution of 2.0 g (10.5 mmol) N-(tert-butoxycarbon¡l)-L-alanine in N,Ndimethylformamide (37.5 ml) was added 1.91 g (15.9 mmol) cyclopropylamidine followed by 4.42 g (11.63 mmol) of HATU and 5.52 ml (31.7 mmol) of Ν,Ν-diisopropylethylamine and the reaction mixture was stirred at room temperature for 3 h. Then 6.05 ml (105.7 mmol) of acetic acid and 2.13 g (15.8 mmol) of 6-hydrazinonicotinonitrile were added and the reaction mixture was stirred for 5 h at 80 °C and then at room temperature overnight. The reaction mixture was cooled to room temperature, saturated aqueous Na2CO3 solution was added, and then the mixture was extracted with EtOAc. The combined organic layers were washed with water, a 5% NaH2PO4 aqueous solution, brine and finally dried over Na2SO4. After filtration and evaporation of the solvent under vacuum, the crude oil was purified by preparative HPLC (water / acetonitrile). The combined product fractions were evaporated to give the title compound (0.77 g, 21%). ESI mass [m / z]: 355.3 [M+H]+ 1H-NMR peak list (400.2 MHz, CD3CN): δ= 8.8116 (6.3); 8.8100 (6.6); 8.8062 (6.7); 8.8046 (5.9); 8.2628 (4.8); 8.2573 (4.6); 8.2412 (5.5); 8.2357 (5.4); 7.9980 (7.0); 7.9964 (6.6); 7.9764 (5.9); 7.9747 (5.6); 5.8766 (0.8); 5.7388 (0.5); 5.7213 (1.4); 5.7031 (1.9); 5.6849 (1.3); 5.6682 (0.4); 2.1614 (41.0); 2.0585 (1.0); 2.0462 (2.0); 2.0378 (2.2); 2.0344 (1.4); 2.0255 (3.5); 2.0194 (1.3); 2.0132 (2.1); 2.0049 (2.2); 1.9926(1.1); 1.9648 (4.6); 1.9528 (18.4); 1.9467 (34.9); 1.9405 (49.0); 1.9343 (33.6); 1.9281 (17.1); 1.4498 (14.5); 1.4328 (14.5); 1.3608 (16.0); 1.2685 (1.1); 1.2388 (0.7); 1.1974 (0.7); 1.0334 (0.4); 1.0281 (0.4); 1.0173 (1.7); 1.0106 (5.0); 1.0083 (4.1); 1.0049 (6.3); 0.9990 (1.5); 0.9901 (6.0); 0.9848 (6.4); 0.9754 (1.5); 0.9669 (2.7); 0.9546 (1.2); 0.9464 (3.2); 0.9446 (3.1); 0.9403 (2.8); 0.9385 (2.8); 0.9342 (3.2); 0.9324 (3.0); 0.9274 (4.6); 0.9204 (2.9); 0.9154 (3.3); 0.9084 (2.6); 0.9047 (1.3); 0.9014 (1.4); 0.8974 (1.0); 0.8927 (0.8); 0.8872 (0.7); 0.8837 (0.6); 0.1459 (0.8); 0.0080 (6.7); -0.0002 (166.9); -0.0086 (6.2); -0.0171 (0.6); -0.1495 (0.8) Step 2 6-{5-[(1 S)-1 -aminoethyl]-3-cyclopropyl-1H-1,2,4-triazol-1 -yl}nícotinonitrile hydrochloride (1:1) (INT-3) A solution of 830 mg (2.34 mmol) {(1 S)-1 -[1 -(5-cyanop¡r¡din-2-¡l)-3-cycloprop¡l-1 H-1,2, Tert-butyl 4-triazol-5-l]ethyl carbamate in dioxane (22 ml) was treated with 4N HCl in dioxane (10.9 ml). The reaction mixture was stirred at room temperature overnight. The resulting precipitate was separated by filtration and air dried to give the title compound (0.71, 100%). ESI mass [m / z]: 255.1 [M+H-HCI]+ Step 3 3-chloro-N-{(1 S)-1 -[1 -(5-cyanopyridi n-2-yl)-3-cyclopropyl-1 H-1,2,4-triazol-5-yl]ethyl} -5- (trifluoromethyl)benzamide To a solution of 100 mg (0.34 mmol) 6-{5-[(1S)-1-aminoethyl]-3-cyclopropyl1 H-1,2,4-triazol-1-ylnicotinonitrile hydrochloride (1: 1) in anhydrous dichloromethane (4.65 ml) 0.01 ml (0.48 mmol) Ν,Ν-diisopropylethylamine was added followed by a solution of 0.06 ml (0.37 mmol) 3-chloro-5-(tnfluoromethyl)benzoyl chloride in 1.5 ml anhydrous dichloromethane. The mixture was stirred at room temperature overnight. The reaction mixture was quenched with 5% NaH2PO4 aqueous solution and then extracted with dichloromethane. The organic phase was dried over Na2SO4, filtered and after evaporating the solvent under vacuum the crude oil was purified by preparative HPLC (water / acetonitrile, 0.1% formic acid). The combined product fractions were evaporated to give the title compound (115 mg, 73%). ESI mass [m / z]: 461.2 [M+H]+ List of 1H-NMR peaks see Table 1. Synthesis of 3-chloro-N-{(1S)-1-[1-(5-cyanopyridin-2-yl)-3-methoxy-1H-1,2,4-triazol-5-yl]ethyl}5- (trifluoromethyl)benzamide (Example 1-10) Step 1: O-methyl [(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-l)propanoyl]carbamothioate To a solution of 1.0 g (4.6 mmol) (2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) propanoic acid in toluene (15 ml) was added 0.80 ml ( 9.12 mmol) oxalyl chloride and one drop of Ν,Ν-dimethylformamide. The reaction mixture was stirred for 3 h at room temperature and then hexane (15 ml) was added and stirring was continued overnight. After that, oxalyl chloride (0.5 ml) was added again and the reaction mixture was stirred for 3 h and finally evaporated. The crude residue was dissolved in acetone (15 ml) and then 0.44 g (4.56 mmol) KSCN was added in the form of a solution in acetone (5 ml) and the mixture was stirred at 60 °C for 2 h. Then 0.46 ml (11.4 mmol) of methanol was added and the mixture was stirred at 60 °C overnight, cooled to room temperature and evaporated under reduced pressure. The resulting residue was dissolved in EtOAc, washed with water and brine respectively and finally the organic layer was dried over anhydrous Na2SO4 and then concentrated under reduced pressure. The crude product was purified by silica gel chromatography to give the title compound (0.82 g, 59%). ESI mass [m / z]: 293.1 [M+H]+ Step 2: 6-{5-[( 1 S)-1 -(1,3-dioxo-1,3-dihyd ro-2H-isoindol-2-¡l)et¡ l]-3- methoxy-1 H-1, 2,4-triazol-1 IJnicotinonitrile To a solution of 1.5 g (5.1 mmol) O-methyl [(23)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2¡l)propanoyl]carbamothioate in ethanol (30 ml ) 0.69 g (5.1 mmol) 6hydrazinonicotinonitrile was added and the reaction mixture was stirred at 90 °C overnight. The mixture was cooled to room temperature, evaporated under reduced pressure and the resulting residue was dissolved in EtOAc, washed with water and brine respectively. The organic layer was dried over anhydrous Na2SCU and then concentrated under reduced pressure. The crude product was purified by silica gel chromatography to give the title compound (1.23 g, 58%). ESI mass [m / z]: 375.1 [M+H]+ Step 3: 6-{5-[(1S)-1 -aminoethyl]-3-methoxy¡-1 H-1,2,4-triazol-1 -yl}nicotinonitrile (INT-5) either- To a solution of 1.20 g (3.20 mmol) 6-{5-[(1 S)-1-(1,3-dioxo-1,3-dihydro-2H-isoindol-2yl)ethyl]-3-methoxy-1 H-1,2,4-triazol-1-IJnicotinonitrile in ethanol (30 ml), 0.39 ml (8.01 mmol) hydrazine hydrate was added and the reaction was heated to reflux temperature overnight. After cooling the mixture to room temperature, acetone (10 ml) was added and heated again at reflux temperature for 3 h. The resulting precipitate was filtered and the filtrate was evaporated under reduced pressure to give a residue that was used in the next step without further purification (1.05 g, 44% purity, 59% yield). ESI mass [m / z]: 245.1 [M+H]+ Step 4: 3-chloro-N-{(1 S)-1 -[1 -(5-cyanopyridi n-2-yl)-3-methoxy¡-1 H-1,2,4-triazol-5-yl]et¡ l}-5(trifluoromethyl)benzamide To a solution of 200 mg (0.82 mmol) 6-{5-[(1S)-1-aminoethyl]-3-methoxy¡-1H-1,2,4-thazol-1¡IJnicotinonitrile in dichloromethane (4.5 ml ) 0.74 ml (1.15 mmol) N,Ndiisopropylethylamine were added followed by a solution of 0.15 ml (0.90 mmol) 3-chloro-5-(trifluoromethyl) benzoyl chloride in 1.5 ml dichloromethane. The mixture was stirred at room temperature overnight. The reaction mixture was quenched with 5% aqueous NaH2PO4 solution and then extracted with dichloromethane. The organic phase was dried over Na2SO4, filtered, and evaporated under reduced pressure. The crude material was purified by preparative HPLC (water / acetonitrile, 0.1% formic acid). The combined product fractions were evaporated and the residue was then purified by silica gel chromatography to give the title compound (75 mg, 20%). ESI mass [m / z]: 451.2 [M+H]+ List of 1H-NMR peaks see Table 1. Synthesis of 6-{5-[(1S)-1-aminoethyl]-1H-1,2,4-triazol-1-¡l}nícotinonitrile hydrochloride Step 1: tert-butyl {(1S)-1 -[1 -(5-cyanopyrid¡n-2-¡l)-1 H-1,2,4-thazol-5-yl]ethyl}carbamate To a solution of 2.00 g (10.6 mmol) N2-(tert-butoxycarbonyl)-L-alaninamide in 40 mL CH2CI2 was added 2.1 mL (16 mmol) Ν,Ν-dimethylformamide dimethylacetal. The solution was heated at reflux for 2 h after which the solvent was removed under reduced pressure. The residue was dissolved in a mixture of 20 mL 1,4-dioxane and 20 mL glacial acetic acid. 1.7 g (13 mmol) 6-hydrazinonicotinonitrile was added and the mixture was stirred at 50 °C for 60 min. The solvents were removed under reduced pressure, a saturated aqueous solution of NaHCOs was added and the mixture was extracted several times with ethyl acetate. The combined organic layers were washed with brine, dried with Na2SO4 and the solvent was removed under reduced pressure. The residue was purified by reverse phase chromatography (H2O / acetonitrile) to give 3.0 g of {(1 S)-1 -[1 -(5-cyanopyridin-2-yl)-1 H-1,2,4-triazole tert-butyl -5yl]ethyl}carbamate. Wp0= +89 (c = 1.0; ethanol)1H NMR (DMSO-d6, 400 MHz): 9.10 (s, 1 H), 8.57 (dd, 1 H), 8.21 (s, 1H), 8.05 (d, 1H ), 7.52 (d, 1 H), 5.63 (m, 1 H), 1.43 (d, 3 H), 1.31 (s, 9 H). ESI mass [m / z]: 259.2 [M-C4H8+H]+ Step 2: 6-{5-[(1 S)-1 -aminoethyl]-1 H-1,2,4-triazol-1 -yl}nicotinonitrile hydrochloride N II frCRnnn / zznz / B / YiAi To a solution of 2.9 g (9.2 mmol) {(1 S)-1-[1-(5-cyanopyrid¡n-2-¡l)-1 H-1,2,4-triazol-5yl]ethyl}tert-butyl carbamate in 40 mL 1,4-dioxane, 23 mL of a 4 M HCl solution in 1,4-dioxane was added. The mixture was stirred for 4 h at 50 °C and overnight at room temperature. The solvent was removed under reduced pressure to give 2.81 g of a residue containing 6-{5-[(1 S)-1-aminoethyl]-1 H-1,2,4-triazol-1-ylnicotinonitrile hydrochloride. This was used without further purification. 1H NMR (DMSO-d6, 400 MHz): 9.11 (d, 1H), 8.80 (brd, 3H), 8.61 (dd, 1H), 8.45 (s, 1H), 8.13 (d, 1H), 5.39 (m, 1H), 1.63 (d, 3H). ESI mass [m / z]: 215.2 [M+H-HCI]+ Synthesis of 5-(difluoromethoxy)-2-hydrazinopyrimidine F I H A solution of 500 mg (2.60 mmol) 5-(difluoromethox¡)-2-(methylsulfan¡l)pyrmidine in 2 mL ethanol was treated with 0.52 mL (11 mmol) hydrazine hydrate. The mixture was heated at reflux overnight. The reaction mixture was then cooled to 5 °C from which a white precipitate formed. The suspension was filtered and the precipitate was washed with ethanol. The residue was dried under reduced pressure to give 125 mg of 5-(difluoromethoxy)-2hydrazinopyrimidine. 1H NMR (DMSO-d6, 400 MHz): 8.35 (s, 1 H), 8.28 (S, 2 H), 7.06 (t, J= 74 Hz, 1 H), 4.17 (br S, 2H). ESI mass [m / z]: 177.2 [M+H]+ Synthesis of 3-chloro-5-(difluoromethyl)benzoic acid (INT-10) Step 1: 3-chloro-5-(difluoromethyl)benzonitrile F CL A solution of 5.00 g (30.1 mmol) 3-chloro-5-formylbenzoníthlo in 150 mL CH2CI2 was treated with 5.84 g (36.2 mmol) diethylaminosulfur trifluoride (DAST) and stirred for 2 h at room temperature. The reaction was stopped by cautious addition of a saturated NaHCOs solution and the mixture was extracted several times with CH2CI2. The combined organic layers were washed with brine and dried with Na2SO4. The solvent was removed under reduced pressure to give 5.31 g 3-chloro-5-(difluoromethyl)benzonitrich which was used without further purification. Mass El [sic] [m / z]: 187 [M]+ Step 2: 3-Chloro-5-(difluoromethyl)benzoic acid (INT-10) frCRnnn / zznz / B / YiAi A solution of 300 mg (1.59 mmol) 3-chloro-5-(difluoromethyl)benzonitetrile in a mixture of 6.5 mL THF and 3.5 mL methanol was treated with 1.92 g (23.9 mmol) of an aqueous solution of hydroxide. 50% sodium. The mixture was heated to reflux and stirred for 45 min at that temperature. All volatiles were then removed under reduced pressure. Water was added and the pH was brought to pH 1 using concentrated hydrochloric acid. The mixture was extracted several times with EtOAc. The combined organic layers were washed with brine, dried with Na2SÜ4 and the solvent was removed under reduced pressure to give 278 mg of 3chloro-5-(difluoromethyl)benzoic acid which was used without further purification in the synthesis of Example 11-12. 1H NMR (DMSO-de, 400 MHz): 13.65 (brs, 1 H), 8.06 (s, 2 H), 7.93 (s, 1 H), 7.14 (t, J= 55 Hz, 1 H). ESI mass [m / z]: 207.1 [M+H]+ Synthesis of 3-chloro-5-(difluoromethyl)benzoic acid (INT-09) Step 1: O-(3-chloro-5-cyanophenyl) dimethylcarbamothioate 38.9 mL (279 mmol) triethylamine, 1.14 g (9.3 mmol) N,N-dimet¡lprídin-4-amine (DMAP) and 13.8 g (112 mmol) dimethylcarbamothioyl chloride were successively added to a suspension vigorously stirred 14.3 g (93 mmol) 3-chloro-5-hydroxybenzonitrile in 450 mL anhydrous EtOAc. The reaction mixture was brought to 55-60°C and stirred at this temperature for 24 h. After cooling to room temperature, the reaction mixture was washed with 450 mL water and 450 mL brine. The organic layer was separated, dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo to a volume of about 50 mL. The concentrate was diluted with 150 mL n-hexane, the precipitate formed was separated by filtration, washed with 150 mL of a 1:1 mixture of diethyl ether and n-hexane and dried under vacuum at 60 °C (1 tor, 3 h) to give 9.3 g (86%) of O-(3-chloro-5cyanophenyl) dimethylcarbamothioate in the form of colorless crystals. 1H NMR (400 MHz, CDCI3) δ: 3.35 (s, 3H), 3.46 (s, 3H), 7.30 (s, 1H), 7.35 (s, 1H), 7.53 (s, 1H) (recorded on a device Varies Gemini 2000). Step 2: S-(3-chloro-5-cyanophenyl) dimethylcarbamothioate frCRnnn / zznz / B / YiAi A solution of 2.41 g (10 mmol) O-(3-chloro-5-cyanophenyl) dimethylcarbamothioate in 20 mL anhydrous dimethyl acetamide was heated in a Biotage Initiator microwave for 35 min at 220 °C. The reaction mixture was brought to room temperature and diluted with 40 ml of water. The precipitate formed was separated by filtration, washed with hot (ca. 70 °C) water and n-hexane and dried under vacuum at 60 °C (1 tor, 3 h) to give 2.05 g (85%) of dimethylcarbamothioate. of S-(3-chloro-5-cyanophenyl) in the form of a white powder. 1H NMR (400 MHz, CDCI3) δ: 3.05 (S, 3H), 3.10 (S, 3H), 7.64 (s, 1H), 7.69 (S, 1H), 7.73 (S, 1H) (recorded on a device Varies Gemini 2000). Step 3: 3-chloro-5-sulfanylbenzoic acid A hot (ca. 70 °C) solution of 68.5 g (1.71 mol) NaOH in 300 mL water was added to a suspension of 27.5 g (114 mmol) S-(3-chloro-5-cyanophenyl) dimethylcarbamothioate in 700 mL of warm methanol (approx. 40 °C). The reaction mixture was stirred under reflux (20 h). Methanol was removed in vacuo and the aqueous solution was washed with 2 x 200 mL diethyl ether. The aqueous layer was separated and added dropwise to a suspension of 300 g of ice in concentrated aqueous HCl (under argon, ice bath cooling). The solution formed was separated by filtration, washed with 2 x 50 mL water, 50 mL n-hexane and dried under vacuum at °C (1 tor, 3 h) to give 21.2 g (98%) of 3-chloro acid. -5-sulfanylbenzoic acid in the form of a white powder. 1H NMR (400 MHz, CDCI3) δ: 3.65 (s, 1H), 7.50 (s, 1H), 7.86 (s, 1H), 7.89 (s, 1H), 10.80 (brs, 1H) (recorded on a device Varies Gemini 2000). Step 4: 3-chloro-5-[(difluoromethyl)sulfanyl]benzoic acid (INT-09) OH 12.44 g (90 mmol) K2CO3 and 18.3 g (120 mmol) sodium chloro(difluoro)acetate were successively added to a solution of 11.32 g (60 mmol) 3-chloro-5-sulfanylbenzoic acid in anhydrous DMF under argon atmosphere. The reaction mixture was stirred at 95-100°C for 3 h. Caution: At 90 - 95 °C CO2 evolved vigorously! Volatiles were removed in vacuo and the residue was diluted with water to a volume of 500 ml. The product was extracted with diethyl ether. The aqueous layer was separated and added dropwise to the ca. 100 g of ice in 200 mL 5% hydrochloric acid. The suspension was stirred at room temperature for 20 h, the precipitate was separated by filtration, washed with 2 x 50 mL water and a 1 / 1 mixture of n-hexane and diethyl ether. It was dried in vacuo at 60 °C (1 tor, 3 h) to give 11 g of crude product (85% purity according to 1H and 19F NMR). Sublimation at 90 - 95°C / 0.01 tor gave 7.7 g (54%) of 3-chloro-5[(difluoromethyl)sulfan¡l]benzoic acid in the form of a white powder. Ή NMR (400 MHz, CDCI3) δ: 6.90 (t, 1H, J = 74.4 Hz), 7.83 (t, 1H, J = 2 Hz), 8.14 (t, 1H, J = 2 Hz), 8.20 (s, 1H), 10.50 (brs, 1H). (recorded on a Varián Gemini 2000 computer). Synthesis 6-(5-{(1 S)-1 -[3,5-bis(trifluoromethyl)benzamido]ethyl}-1 H-1,2,4-triazol-1 -yl)-N-cyclopropyl- N-methylnicotinamide (example II-38) Step 1: 6-(5-{(1 S)-1 -[3,5-bis(thfluoromethyl)benzam¡do]ethyl}-1H-1,2,4-triazole-1¡ acid l)nícotiníco A solution of 2.00 g (6.09 mmol) N-[(2S)-1-amino-1-oxopropan-2-yl]-3,5bis(trifluoromethyl)benzamide and 1.21 mL (9.14 mmol) A / . / V-dimethylformamide dimethyl acetal in 40 mL dichloromethane was heated to reflux. After 1h the reaction mixture was concentrated under reduced pressure. To the residue were added 1.89 g (9.95 mmol) 6-hydrazinonicotinic acid hydrochloride (1:1) and 40 mL acetic acid. The mixture was heated for 1 h at 100 °C. The solvent was removed under reduced pressure. To the residue was added water and the mixture was extracted several times with EtOAc. The combined organic layers were washed with brine, dried over NasSCU, and filtered. The filtrate was concentrated under reduced pressure to give 3.1 g 6-(5-{(1 S)-1-[3,5-bis(trifluoromethyl)benzam¡do]ethyl}-1 H-1,2,4thazol- 1-yl)nicot¡nico that was used without further purification. ESI mass [m / z]: 474.2 [M+H]+ Step 2: 6-(5-{( 1 S)-1 -[3,5-bis(trifluoromethyl)benzamido]ethyl}-1 H-1,2,4-triazol-1 -yl)-N -cyclopropyl-Nmethylnicotinamide (example II-38) V TO F a solution of 250 mg (0.52 mmol) 6-(5-{(1 S)-1 -[3,5bis(thfluoromethyl)benzam¡do]ethyl}-1 H-1,2,4-thazol-acid 1-yl)nicotinic and 38 mg (0.52 mmol) Nmethylcyclopropanamine in 5 mL acetonitrile, 0.50 mL (2.9 mmol) Λ / ,Λ / diisopropylethylamine and 0.50 mL (0.85 mmol) of a solution of T3P (cyclic anhydride of propanephosphonic acid) were added. 50% in EtOAc. The reaction mixture was stirred at room temperature overnight. It was then concentrated and the residue was purified by silica chromatography (cyclohexane / EtOAc) to give 113 mg 6-(5-{(1S)-1-[3,5bis(trifluoromethyl)benzamido]ethyl}-1 H-1, 2,4-triazol-1 -yl)-N-cyclopropyl-N-methylnycotinamide. ESI mass [m / z]: 527.2 [M+H]+1H-NMR peak list see Table 3 Synthesis of 3-chloro-N-[(1 S)-1 -{1 -[5-(isobutyrylamino)pyrídin-2-¡l]-1 H-1,2,4-triazol-5yl}ethyl] -5-(trifluoromethyl)benzamide (example II-2) Step 1: Ν-{( 1 S)-1 -[1 -(5-am ¡nopyridin-2-yl)-1H-1,2,4-tnazol-5-¡l]ethyl}-3-chloro-5 -(thfluoromethyl)benzamide To a solution of 1.22 g (2.76 mmol) 3-chloro-N-{(1 S)-1 -[1 -(5-nitropyridin-2-yl)-1 H-1,2,4triazol-5- l]ethyl¡l}-5-(trifluoromethyl)benzamide in a mixture of 65 mL ethanol and 6.4 mL acetic acid, 0.62 g (11 mmol) of iron powder was added. The mixture was heated at 80 °C for 2 h. All volatiles were removed under reduced pressure. Water and a saturated aqueous solution of NaHCOs were added to the residue. The layers were separated and the aqueous layer was extracted several times with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give 1.19 g of N-{(1S)-1-[1-(5-aminopyridin-2-yl)- 1 H-1,2,4-thazol-5-yl]ethyl}-3-chloro-5(trifluoromethyl)benzamide. ESI Mass [m / z]: 411.2 [M+H]+ Step 2: 3-chloro-N-[(1 S)-1 -{1 -[5-(isobuty r i lamino)pyridin-2-yl]-1 H-1,2,4-tnazol-5-yl}et¡ 1]-5(thfluoromethyl)benzamide (example 11-2) A solution of 80 mg (0.19 mmol) N-{(1 S)-1 -[1 -(5-aminopyrid¡n-2-¡l)-1 H-1,2,4-thazol-5yl] ethyl}-3-chloro-5-(trifluoromethyl)benzamide in 0.3 mL THF was treated at 0 °C with 20 pL (0.19 mmol) 2-methylpropanoyl chloride and 30 pL (0.21 mmol) triethylam¡ na. The reaction mixture was stirred overnight at room temperature. All volatiles were removed under reduced pressure and the residue was purified by chromatography on silica (cyclohexane / EtOAc) to give 43 mg of 3-chloro-N-[(1S)-1-{1-[5-(isobutyr¡lam). ¡no)pyridn¡-2-yl]-1 H-1,2,4triazol-5-yl}ethyl]-5-(trifluoromethyl)benzamide. ESI Mass [m / z]: 481.2 [M+H]+ List of 1H-NMR peaks see Table 3 Synthesis N-{(1S)-1-[1-(5-bromo-1,3-thiazol-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}-3-chloro- 5(trifluoromethoxy)benzamide (example 11-15) frCRnnn / zznz / B / YiAi 0.50 g (1.2 mmol) 3-chloro-N-{(1 S)-1-[1-(1,3-thiazol-2-yl)-1 H-1,2,4-triazol-5-yl ]ethyl}-5-(trifluoromethoxy)benzamide and 0.73 g (4.1 mmol) N-bromo-succinimide were dissolved in 37 mL DMF and stirred overnight at room temperature. The conversion of the starting material was incomplete, so 0.73 g (4.1 mmol) N-bromo-succinimide was added and stirring was continued for 5 h. Aqueous sodium bisulfite solution was added and the mixture was extracted several times with EtOAc. The combined organic layers were washed with water, saturated aqueous NaHCOs solution and brine. All volatiles were removed under reduced pressure and the residue was purified by chromatography on silica (cyclohexane / EtOAc) to give 457 mg of N-{(1S)-1-[1-(5-bromo-1,3-thiazole -2-yl)-1 H-1,2,4-triazol-5-yl]ethyl}3-chloro-5-(trifluoromethoxy)benzamide. ESI Mass [m / z]: 497.9 [M+H]+ List of 1H-NMR peaks see Table 3 Synthesis of 3,5-di(trifluoromethyl)-N-{1-[3-chloro-1-(3-cyano-pyridin-6-yl)-1H-1,2,4-tr¡azol5-yl]ethyl}-benzamide (example I-39) Step 1 Λ / -[(Ε)-Λ / -[2-(1,3-dioxo¡so¡ndolin-2-yl)propan¡l]-C-methylsulfanyl-carbon¡m¡do¡ l] tert-butyl carbamate At 1.09 g (5.0 mmol) (aS)-1,3-dihydro-a-methyl-1,3-dioxo-2 / 7-iso¡ndole-2-acetic acid (Pht-AlaOH purchased from ABCR) and 0.95 g (5.0 mmol) 1-A / -Boc-2-methyl-isothiourea (purchased from ABCR) dissolved in tetrahydrofuran (30 ml), triethylamine (2.1 ml) and [0-hexafluorophosphate] were added. (7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronio] (HATU), and the reaction mixture was stirred for 2 h at a temperature of 80 °C. Water was then added and the mixture was extracted with sodium hydrogen carbonate and dichloromethane solution. The organic phase was separated, dried over Na2SO4, filtered and the solvent evaporated. The remaining solid residue was purified by chromatography with a cyclohexane / acetone gradient on silica gel to give 1.40 g (purity: 97.0%; yield: 69.6%) of the racemic title compound. ESI mass [m / z]: 392.2 [M+H]+ 1H-NMR peak list (400 MHz, DMSO-d6, ppm) δ = 11.8958 (0.5); 11.4353 (0.9); 7.9299 (0.5); 7.9221 (1.0); 7.9152 (1.2); 7.9102 (1.0); 7.9063 (1.2); 7.9000 (2.1); 7.8930 (1.1); 7.8847 (2.6); 7.8785 (1.3); 7.8744 (1.2); 7.8627 (0.8); 4.9976 (0.8); 4.9794 (0.8); 3.3230 (9.5); 2.5251 (0.4); 2.5204 (0.6); 2.5117 (8.2); 2.5072 (16.6); 2.5027 (21.9); 2.4981 (15.8); 2.4936 (7.6); 2.2949 (2.4); 1.9720 (6.0); 1.6029 (2.9); 1.5848 (3.0); 1.5719 (1.3); 1.5540 (1.1); 1.4430 (16.0); 1.3971 (11.0); 1.2665 (6.6); -0.0002 (0.5) Step 2 2-[1 -[3-(A / -Boc-amino)-1 -(3-cyano-pi ridin-6-yl)-1 H-1,2,4-triazol-5-yl)ethyl]- 1 / - / -¡ndol-1,3(2 / - / )dione frCRnnn / zznz / B / YiAi To a solution of 2.1 g (5.36 mmol) tert-butyl Λ / -[(Ε)-Λ / -[2-(1,3-dioxoisoindolin-2-yl)propanoyl]-Cmethylsulfanyl-carbonimidoyljcarbamate in pyridine (20 ml ), 1.0 g (7.45 mmol) 6-hydraz¡n¡l-3-pyrádinacarbonitrile was added and the reaction mixture was stirred at 80 °C for 2 h. Then another 250 mg tert-butyl Λ / -[(Ε)-Λ / -[2-(1,3-dioxoiso¡ndolin-2-yl)propan¡l]-Cmethylsulfanyl-carbonimidoyljcarbamate was added and the mixture The reaction mixture was stirred for another hour at a temperature of 80 °C. The solvent was then evaporated in vacuo and the crude product was purified by chromatography with a cyclohexane / acetic acid ethyl ester gradient on silica gel to give 1.7 g (purity: 98.5%; yield: 67.9%) of the racemic title compound. ESI mass [m / z]: 404.3 [M-H2C=(CH3)2]+ 1H-NMR peak list (400 MHz, DMSO-de, ppm) δ = 10.1893 (1.2); 8.7198 (1.0); 8.7155 (1.0); 8.4412 (0.7); 8.4357 (0.6); 8.4197 (0.7); 8.4142 (0.7); 7.8856 (1.0); 7.8642 (0.9); 7.8302 (9.0); 6.1248 (0.8); 6.1071 (0.8); 3.3201 (12.8); 2.5249 (0.7); 2.5113 (13.7); 2.5070 (27.3); 2.5026 (35.5); 2.4980 (25.3); 2.4936 (12.2); 1.9890 (0.4); 1.8230 (2.2); 1.8054 (2.2); 1.4459(16.0); 1.3977 (14.0);-0.0002 (3.0) Step 3 frCRnnn / zznz / B / YiAi 2-[1 -[3-amino-1 -(3-cyano-pyridín-6-íl)-1 / 7-1,2,4-triazol-5-yl)ethyl]- hydrochloride 1 / 7-isoindol1,3(2 / 7)-dione 1.9 g (4.14 mmol) 2-[1 -[3-(A / -Boc-amino)-1 -(3-cyano-pyridin-6-yl)-1 / 7-1,2,4-triazole -5-yl)ethyl]-1 Hisoindol-1,3(2 / 7)-dione was treated with 4N HCl solution in dioxane (50 ml) and the reaction mixture was stirred for 18 h at room temperature. The reaction mixture was then concentrated and the racemic solid residue was used for the introduction of halogen (step 4) without purification. ESI mass [m / z]: 360.3 [M-HCI]+ Ή-NMR peak list (400 MHz, DMSO-d6, ppm) δ = 8.6984 (0.6); 8.6942 (0.7); 8.3712 (0.5); 8.3656 (0.4); 8.3496 (0.5); 8.3439 (0.5); 7.8431 (2.4); 7.8409 (2.4); 7.7665 (0.6); 7.7448 (0.6); 6.1130 (0.5); 6.0953 (0.5); 3.8452 (0.6); 3.5682 (16.0); 2.5245 (0.8); 2.5109 (17.6); 2.5066 (35.5); 2.5021 (46.5); 2.4976 (33.8); 2.4932 (16.7); 1.8297 (1.6); 1.8120 (1.6); -0.0002 (2.4) Step 4 2-[1 -[3-chloro-1 -(3-cyano-pyridin-6-yl)-1 / 7-1,2,4-triazol-5-yl)ethyl]-1 / 7-¡ soindol-1,3(2 / 7)-dione CN > you 97c N N C A 1.14 g (3.17 mmol) 2-[1 -[3-amino-1-(3-cyano-pyridin-6-yl)-1 H-1,2,4-triazol-5-£yl)ethyl hydrochloride ]-1 H-isoindole-1,3(2H)-dione in acetonitrile (91.2 ml), 725.1 mg (5.39 2 mmol) Cu(ll) chloride was added, and then the reaction mixture was treated dropwise with 458.0 mg (4.44 mmol) tert-butyl nitrite at room temperature. Then the reaction mixture was stirred for 1 h at 70 °C and then treated with ethyl acetic acid ester and then extracted with a saturated solution of NaHCOs and water. The organic phase was separated, dried over Na2SO4, filtered and the solvent evaporated. The crude product was purified by silica gel cyclohexane / acetone gradient chromatography to give 670 mg (purity: 100%; yield: 55.7%) of the racemic title compound. ESI mass [m / z]: 379.1 [M+H]+ Step 5 6-[5-(1-aminoethyl)-3-chloro-1,2,4-triazol-1-yl]pyridine-3-carbonitrilo (INT-11) CN N^ CL At 650.0 mg (1.71 mmol) 2-[1 -[3-chloro-1 -(3-cyano-pyridin-6-íl)-1 H-1,2,4-triazol-5-yl)et l]-1 Hisoindol-1,3(2H)-dione in ethanol (36.1 mL), 390.5 mg (4.29 mmol) hydrazine hydrate was added, and the reaction mixture was heated under reflux. After 30 minutes a colorless precipitate formed. The reaction mixture was stirred and heated under reflux for another two hours, acetone (10 mL) was added and heating continued for another 30 minutes. The reaction mixture was concentrated and the solid residue was treated with ethanol. After filtration, the filtrate was evaporated under reduced pressure to give racemic 6-[5-(1-aminoethyl)-3-chloro1,2,4-triazol-1-yl]pyridine-3-carbonitrile (INT- 11), which was used in step 6 without purification. ESI mass [m / z]: 249.2 [M+H]+ Step 6 3,5-di(thfluoromethyl)-N-{1 -[3-chloro-1 -(3-cyano-pyridin-6-yl)-1 H-1,2,4-triazol-5-yl] ethyl}benzamide (example I-39) CN / 0I \ Y ΰ Y .N LJJHcf3Cl At 125.0 mg (0.50 mmol) 6-[5-(1-aminoethyl)-3-chloro-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (INT-11), 146.6 mg (0.55 mmol) 3,5-bis(thfluoromethyl)-benzoic acid, 100 mg (0.77 mmol) A / ,A / -diisopropylethilamine (Hünig's Base) in acetonitrile (6.25 mL) were added. , 258.3 mg (0.67 mmol) [0-(7-azabenzotriazol-1-yl)- / V,A / , / \ / ',A / '-tetramethyluron¡o hexafluorophosphate] (HATU), and the mixture The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and the solid residue was treated with dichloromethane and then extracted with a saturated aqueous solution of NaHCOs and water. The organic phase was separated, dried over Na2SO4 and the solvent evaporated under reduced pressure. The remaining brown oily substance was purified by preparative HPLC with a neutral gradient of water / acetonitrile to give 106.0 mg (purity: 100%; yield: 39.3%) of the racemic title compound. ESI mass [m / z]: 489.1 [M+H]+ List of 1H-NMR peaks see Table 1 Synthesis of 3,5-di(trifluoromethyl)-N-{1-[3-bromo-1-(3-cyano-pyridin-6-yl)-1H-1,2,4triazol-5-yl]ethyl}- benzamide (example I-48) Step 1 2-[1 -[3-bromo-1 - (3-cyano-pyridin-6-yl)-1 H-1,2,4-triazol-5-yl)ethyl]-1 H-isoindol-1,3 (2 / - / )-dione C.N. A 250.0 mg (0.69 mmol) 2-[1 -[3-amino-1 -(3-cyano-pyridin-6-yl)-1 H-1,2,4-triazol5-yl)ethyl]-1 hydrochloride H-isoindole-1,3(2H)-dione in acetonitrile (16.6 ml), 300.0 mg (1.34 mmol) Cu(ll) bromide was added, and then the reaction mixture was treated dropwise at room temperature with 110.0 mg (1.06 mmol) tert-butyl nitrite. Then the reaction mixture was stirred for 1 h at 70 °C, followed by treatment with ethyl acetic acid ester and extraction with a saturated solution of NaHCOs and water. The organic phase was separated, dried over NasSO^, filtered and the solvent evaporated. The crude product was analyzed by silica gel cyclohexane / acetone gradient chromatography to give 300 mg (purity: 96.2%) of the racemic title compound. ESI mass [m / z]: 423.3 [M+H]+ Step 2 6-[5-(1-aminoethyl)-3-bromo-1,2,4-triazol-1-yl]pyridine-3-carbonitrilo (INT-12) C.N. Br At 300.0 mg (0.70 mmol) 2-[1-[3-bromo-1-(3-cyano-pyridin-6-¡l)-1 H-1,2,4-triazol-5-yl)et l]-1 Hisoindol-1,3(2H)-dione in ethanol (10 mL), 160.0 mg (1.75 mmol) hydrazine hydrate was added, and the reaction mixture was heated under reflux. After 30 minutes a colorless precipitate formed. The reaction mixture was stirred and heated under reflux for another two hours, acetone (2 mL) was added and heating continued for another 30 minutes. The reaction mixture was concentrated and the solid residue was treated with ethanol. After filtration, the filtrate was evaporated under reduced pressure to give 210 mg (purity: 88%; yield: 88.9%) of 6-[5-(1-aminoethyl)-3-bromo-1,2,4-triazole- Racemic 1-yl]pyridine-3-carbonitrile (INT-12), which was used in the final step 3 without further purification. ESI mass [m / z]: 293.0 [M+H]+ 100 Step 3 3,5-di(trif luoromethyl)- / V-{1 -[3-bromo-1 - (3-cyano-pyridin-6-iI)-1H-1,2,4-triazol-5-yl]et ¡l}benzamide (example I-48) At 173.8 mg (0.59 mmol) 6-[5-(1-aminoethyl)-3-bromo-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (INT-12) , 170.0 mg (0.63 mmol) 3,5-bis(trifluoromethyl)-benzoic acid, 115.9 mg (0.89 mmol) / V, / V-diisopropylethilamine (Hünig's base) in acetonitrile were added ( 6.25 mL), 299.4 mg (0.78 mmol) [0-(7-azabenzotriazol-1-¡l)- / V,A / ,A / ',A / '-tetramethyluron¡o hexafluorophosphate] (HATU), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and the solid residue was treated with dichloromethane and then extracted with a saturated aqueous solution of NaHCOs and water. The organic phase was separated, dried over Na2SÜ4 and the solvent was evaporated under reduced pressure. The remaining brown oily substance was purified by preparative HPLC with a water / acetonitrile gradient to give 81.0 mg (purity: 94.8%; yield: 22.5%) of the racemic title compound. ESI mass [m / z]: 535.0 [M+H]+ List of 1H-NMR peaks see Table 1 Synthesis of 3-chloro-5-Ktr¡fluoromethyl)sulfan¡nbenzoic acid Step 1: [3-chloro-5-(methoxycarbonyl)phenyl]boronic acid To a suspension of 12 g (40 mmol) methyl 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2yl)benzoate in 30 mL acetone and 30 mL H2O 17.3 g (80.9 mmol) sodium periodate and 6.24 g (80.9 mmol) ammonium acetate were added. The mixture was stirred at 25 °C for 2 h and then filtered through Celite. The filtrate evaporated. The residue was diluted 101 with 200 mL ethyl acetate and washed with 100 mL H2O. The organic phase was washed with brine, dried over anhydrous Na2SÜ4, filtered and concentrated in vacuo. The crude product was triturated with 10 mL petroleum ether at 15 °C for 20 min. The mixture was filtered and the residue was dried under reduced pressure to give 7 g [3-Chloro-5(methoxycarbonyl)phenyl]boronic acid in the form of a white solid. Ή-NMR (400 MHz, CDCI3): δ = 8.72 (s, 1H), 8.35 (s, 1H), 8.27 (s, 1H), 4.02 (s, 3H). relative to the CHCh trace signal at 7.25 ppm. Measured on a device They vary 400MR NMR. Step 2: Methyl 3-chloro-5-[(trifluoromethyl)sulfanyl]benzoate frCRnnn / zznz / B / YiAi ci or g (61 mmol) [3-Chloro-5-(methoxycarbonyl)phen¡l]boronic acid, 43.1 g (303 mmol) thmet¡l(trifluoromethyl)silane, 33.4 g (121 mmol) Ag2CO3, 38.6 g (182 mmol) K3PO4, 762 mg (6.06 mmol) CuSCN, 2.2 g (12 mmol) 1,10-Phenanthroline, 46.7 g (1.46 mol) sulfur and 13 g of 4 Á molecular sieve in 500 mL DMF were stirred. at 25 °C for 16 h under N2. The mixture was filtered through celite. The filtrate was diluted with 1.5 L methyl tert-butyl ether and washed with 2 x 500 mL H2O. The organic phase was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by MPLC on silica gel (petroleum ether:ethyl acetate = 1:0 ~ 20:1) to give 5.5 g methyl 3-chloro-5[(tñfluoromethyl)sulfaníl]benzoate in the form of a light yellow oil. Ή-NMR (400 MHz, CDCI3): δ =8.20 (s, 1H), 8.10-8.15 (m, 1H), 7.83 (s, 1H), 3.96 (s, 3H). relative to the trace signal of CHCl3a 7.25 ppm. Measured on a device They vary 400MR NMR. Step 3: 3-chloro-5-[(trifluoromethyl)sulfan¡l]benzo¡ic acid CL OH 5.5 g (20 mmol) methyl 3-chloro-5-[(trifluoromethyl)sulfanyl]benzoate was dissolved in a mixture of 12 mL tetrahydrofuran and 12 mL H2O. 1.63 g (40.6 mmol) NaOH was added to the mixture which was then stirred at 25 °C for 2 h. The mixture was brought to pH 5 by 102 added 40 mL 1 M HCl and extracted with 150 mL ethyl acetate. The organic phase was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was triturated with 50 mL petroleum ether at 25 °C for 15 min. The mixture was filtered and the residue was dried under reduced pressure to give 3.0 g 3-chloro-5(tnfluoromethylsulfanyl)benzoic acid in the form of a yellow solid. Ή-NMR (400 MHz, CDCI3): δ =11.28 (brs, 1H), 8.29 (s, 1H), 8.20 -8.25 (m, 1 H), 7.91 (s, 1H). relative to the trace signal of CHCI3 at 7.25 ppm. Measured on a device They vary 400MR NMR. ESI mass [m / z]: 254.8 [M-H]' The LC-MS determination was carried out using the mobile phases acetonitrile and 10 mM aqueous ammonium bicarbonate solution; linear gradient from 15% acetonitrile to 90% acetonitrile, flow rate 0.80 ml / min; Instruments: Agilent 1200 and Agilent 6120. The column used for chromatography was a 2.1*50 mm (5 pm particles) Xbridge Shield RPC18 column. Detection methods are diode array detection (DAD) and evaporative light scattering (ELSD), as well as negative electrospray ionization. Synthesis of 3-chloro 5-(pentafluoroethyl)benzoic acid (INT-13 intermediate) Step 1: Methyl 3-chloro-5-(pentafluoroethyl)benzoate To methyl 3-chloro-5-iodo-benzoate (18.5 g, 62.4 mmol) in DMF (180 mL) was added the potassium salt of pentafluoropropionic acid (22.7 g, 112.3 mmol) and Cul (23.7 g, 124.8 mmol) and the mixture was stirred at 160 °C for 2 h, monitored by TLC. Water (200 mL) and EtOAc (300 mL) were added to the reaction mixture, the resulting suspension was filtered, and the organic phase was separated from the filtrate. The organic phase was washed with H2O (2 x 50 mL) and then concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 100 / 1). The title compound was obtained in the form of a red oil (10.0 g, 32.2 mmol, 51.6% yield, 93.0% purity). 1031H-NMR (400 MHz, CDCI3): δ = 8.24 (s, 1H), 8.17 (s, 1H), 7.78 (s, 1H),3.98 (s, 3H). Measured on a Bruker 400 MHz NMR equipment. Step 2: 3-chloro-5-(pentafluoroethyl)benzoic acid Methyl 3-chloro 5-(pentafluoroethyl)benzoate (10.0 g, 34.6 mmol) was dissolved in MeOH (50 mL). LiOH (1.66 g, 69.3 mmol) in H2O (50 mL) was added to the above solution, the mixture was stirred at 25 °C for 5 h, monitored by TLC. Water (100 mL) was added to the reaction mixture and the mixture was extracted with ethyl acetate (60 mL). The separated aqueous phase was acidified with 1N HCl to f=5-6, then the solution was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated. The title compound was obtained as a white solid (8.00 g, 29.1 mmol, 84.0% yield). 1H-NMR (400 MHz, MeOD): δ = 8.24 (s, 1H), 8.14 (s, 1H), 7.88 (s, 1H). Measured on a Bruker 400 MHz NMR equipment. ESI mass [m / z]: 272.9 [M]+ Synthesis of 3-(difluoromethyl)-5-(trifluoromethoxy)benzoic acid (INT-14 intermediate) Step 1: 1-bromo-3-(difluoromethyl)-5-(thfluoromethox¡)benzene frCRnnn / zznz / B / YiAi To a solution of 5.00 g (18.5 mmol) 3-bromo-5-(trifluoromethoxy)benzaldehyde in 100 ml CH2CI2 was added 3.0 mL (23 mmol) diethylaminosulfur trifluoride. The reaction mixture was stirred for 2 h at room temperature. Thereafter, the reaction mixture was quenched with a saturated aqueous NaHCO3 solution and extracted with CH2CI2. The combined organic layers were dried with Na2SO4, filtered and concentrated under reduced pressure. Analysis of the crude product by NMR revealed that the conversion of the starting material was incomplete. Therefore, the residue was redissolved in 100 ml CH2CI2 and 3.0 mL (23 mmol) diethylaminosulfur trifluoride was added. Stirring was continued until complete conversion of the starting material was observed by analytical HPLC. The reaction mixture was quenched with a saturated aqueous NaHCO3 solution. 104 and was extracted with CH2CI2. The combined organic layers were dried with Na2SO4, filtered and concentrated under reduced pressure to give 4.87 g of a residue containing 1-bromo-3-(difluoromethyl)-5-(trifluoromethoxy¡)benzene. A portion of this crude material was purified by silica chromatography (cyclohexane / EtOAc) to give 1.78 g of pure 1-bromo3-(difluoromethyl)-5-(trifluoromethox¡)-benzene, which was used for the following reaction. carbonylation. 1H-NMR (DMSO-de, 400 MHz): δ = 7.92 (s, 1 H), 7.88 (s, 1 H), 7.65 (s, 1 H), 7.10 (t, J = 55 Hz, 1 H) . The mass [m / z]: 290, 292 [M]+ Step 2: Methyl 3-(difluoromethyl)-5-(trifluoromethoxy¡)benzoate frCRnnn / zznz / B / YiAi To a solution of 1.78 g (6.11 mmol) 1-bromo-3-(difluoromethyl)-5-(trifluoromethoxy¡)benzene in 45 mL methanol, 1.51 g (18.3 mmol) sodium acetate and 0.15 g (0.18 mmol) of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(ll) acetone adduct. This solution was then stirred for 16 h at 80 °C in an autoclave under a carbon monoxide atmosphere (5 bar). Thereafter, complete conversion of the starting material to methyl 3(difluoromethyl)-5-(trifluoromethoxy)benzoate was observed. The reaction mixture was used directly in the next step. Mass El [m / z]: 270 [M]+ Step 3: 3-(difluoromethyl)-5-(trifluoromethoxy)benzoic acid To the solution from the first step, 70 mL THF and 5.3 mL of a 45% aqueous sodium hydroxide solution were added. The mixture was heated under reflux for 45 min after which it was acidified to pH 1-2 using concentrated hydrochloric acid. HE 105 formed a precipitate that was removed by filtration. The filtrate was evaporated to dryness. Water was added to the residue and the mixture was extracted several times with diethyl ether. The combined organic layers were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure to give 1.44 g methyl 3-(difluoromethyl)-5(thfluoromethoxy)benzoate. Ή-NMR (DMSO-d6, 400 MHz): δ = 13.8 (brs, 1 H), 8.15 (s, 1 H), 7.98 (s, 1 H), 7.89 (s, 1 H), 7.20 (t, J= 55Hz, 1H). ESI Mass [m / z]: 254.8 [M-H]- Synthesis of 3-(difluoromethoxy)-5-(difluoromethyl)benzoic acid (INT-15 intermediate) Step 1: Methyl 3-(chlorocarbonyl)-5-(difluoromethoxy¡)benzoate 3-(Difluoromethoxy)-5-(methoxycarbon¡l)benzoic acid (known from WO 2012019428 (7.38 g, 30 mmol) was suspended in dry toluene (30mL). Oxalyl chloride (5.71 g) was added. , 45 mmol) in one portion followed by a drop of DMF at room temperature. The reaction mixture was stirred at room temperature for 12 h and then at 60-70 °C for 2 h. The reaction mixture was evaporated to give 7.9 g of crude methyl 3-(chlorocarbonyl)-5(difluoromethoxy)benzoate which was used without further purification. Step 2: Methyl 3-(difluoromethoxy¡)-5-formylbenzoate 106 2,6-Lutidine (3.38 g, 3.68 mL, 31.5 mmol) and 3-(chlorocarbonyl)-5-(difluoromethoxy)benzoate from step 1 (7.94 g, 30 mmol) were dissolved in absolute THF (100 mL), Pd / C (Alpha, dry, 10%, 430 mg) was added and the mixture was hydrogenated for 48 h (balloon with H2). The resulting precipitate was separated by filtration, washed with diethyl ether (200 mL), and saturated aqueous NaHCOs solution (30 mL) was added to the filtrate and stirred for 12 h at room temperature. The solution was diluted with more diethyl ether (300 mL) and water (300 mL). The organic layer was separated, washed with water (2 x 300 mL), an aqueous solution of citric acid (5%, 200 mL), water (300 mL), and brine (300 mL). The volatiles were removed in vacuo to give crude methyl 3-(difluoromethoxy)-5-formylbenzoate (4.1 g, 59% yield). 1H-NMR (400 MHz, CDCI3): δ = 10.05 (d, J= 0.7 Hz, 1H), 8.41 -8.35 (m, 1H), 8.07-8.00 (m, 1H), 7.86 - 7.79 (m, 1H ), 6.62 (t, J = 72.4 Hz, 1H), 3.98 (d, J = 0.7 Hz, 3H). Measured on a Varian Gemini 2000 device. Step 3: Methyl 3-(difluoromethoxy)-5-(difluoromethyl)benzoate o^o Crude methyl 3-(difluoromethoxy)-5-formylbenzoate (4 g, 17.38 mmol) was dissolved in DCM (100 mL) and the solution was cooled to -20 °C. DAST (5.60 g, 34.8 mmol) was added in one portion and the reaction mixture was stirred for 12 h (warming slowly to room temperature). The reaction mixture was poured into a saturated NaHCOg aqueous solution (200 mL) and DCM (100 mL) was added, followed by separation of the organic layer, washing with water (100 mL) and drying over Na2SO4. The volatiles were removed in vacuo to give 4.5 g of crude methyl 3-(difluoromethoxy)-5-(difluoromethyl)benzoate as a brown oil. 1H-NMR (400 MHz, CDCI3): δ = 8.04 (t, J = 1.4 Hz, 1H), 7.92 -7.87 (m, 1H), 7.48 (s, 1H), 6.68 (t, J = 55.9 Hz, 1H ), 6.59 (t, J = 72.6 Hz, 1 H), 3.96 (s, 3H). Measured on a Varian Gemini 2000 device. 107 Step 4: 3-(difluoromethox¡)-5-(difluoromethyl)benzo¡ic acid frCRnnn / zznz / B / YiAi A solution of LiOH (1.43 g, 34 mmol) in water (10 mL) was added to a solution of crude methyl 3(difluoromethoxy)-5-(difluoromethyl)benzoate from step 3 (4.3 g, 17 mmol) in a mixture of THF (35mL) and MeOH (35mL). The reaction mixture was stirred at room temperature for 2 h. The volatiles were removed in vacuo, water (100 mL) was added, and the resulting mixture was extracted with diethyl ether (100 mL). The separated aqueous phase was added dropwise into dilute HCl (5%, 100 mL). The precipitate was separated by filtration, washed with water, dried at 100 °C for 2 h and finally sublimed at 105 °C (0.1 torr) to give the title compound (3.2 g, 79%). performance). 1H-NMR (DMSO-d6, 400 MHz): δ= 13.62 (s, 1H), 7.99 (t, J = 1.3 Hz, 1H), 7.82 (s, 1H), 7.70 -7.62 (m, 1H), 7.42 (t, J = 73.3 Hz, 1H), 7.15 (t, J = 55.4 Hz, 1H). Measured on a Vahan Gemini 2000 device. Analytical data of the compounds Determination of [M+H]+ or M- by LC-MS under acidic chromatographic conditions was carried out with 1 ml of formic acid per liter of acetonitrile and 0.9 ml of formic acid per liter of Millipore water as eluents. The Zorbax Eclipse Plus C18 50 mm * 2.1 mm column was used. The column oven temperature was 55 °C. Instruments: LC-MS3: Waters UPLC with SQD2 mass spectrometer and SampleManager autosampler. Linear gradient from 0.0 to 1.70 minutes from 10% acetonitrile to 95% acetonitrile, constant from 1.70 to 2.40 minutes with 95% acetonitrile, flow rate 0.85 ml / min. LC-MS6 and LC-MS7: Agilent 1290 LC, Agilent MSD, HTS PAL autosampler. Linear gradient from 0.0 to 1.80 minutes from 10% acetonitrile to 95% acetonitrile, constant from 1.80 to 2.50 minutes with 95% acetonitrile, flow rate 1.0 ml / min. Determination of [M+H]+ by LC-MS under neutral chromatographic conditions was carried out with acetonitrile and Millipore water containing 79 mg / L ammonium carbonate as eluents. 108 Instruments: LC-MS4: Waters ICIass Acquity with QDA mass spectrometer and FTN autosampler (Waters Acquity column 1.7 pm 50 mm * 2.1 mm, oven temperature 45°C). Linear gradient from 0.0 to 2.10 minutes from 10% acetonitrile to 95% acetonitrile, constant from 2.10 to 3.00 minutes with 95% acetonitrile, flow rate 0.7 ml / min. LC-MS5: Agilent 1100 LC system with MSD mass spectrometer and HTS PAL autosampler (column: Zorbax XDB C18 1.8 pm 50 mm * 4.6 mm, oven temperature 55°C). Linear gradient from 0.0 to 4.25 minutes from 10% acetonitrile to 95% acetonitrile, constant from 4.25 to 5.80 minutes with 95% acetonitrile, flow 2.0 ml / min. Determination of 1H NMR data was carried out on a Bruker Avance III 400 MHz equipped with a 1.7 mm TCI cryoprobe, a Bruker Avance III 600 MHz equipped with a 5 mm multinuclear cryoprobe or a Bruker Avance NEO 600 MHz equipped with a 5 mm reference cryoprobe with tetramethylsilane as reference (0.0) and the solvents CD3CN, CDCI3 or D6-DMSO. The NMR data of selected examples are listed either in the conventional form (5 values, multiplet splitting, number of hydrogen atoms) or as lists of NMR peaks. NMR peak list method The 1H NMR data of the selected examples are displayed in the form of 1H NMR peak lists. For each signal peak, the δ value in ppm is listed first and then the signal intensity is listed in curved parentheses. Pairs of numbers corresponding to the δ value and signal intensity for different signal peaks are listed separating them by using a semicolon. The peak list for an example therefore takes the form of: δ1 (intensityl); δ2 (intensity2);........; δί (intensity);......; δη (intensityn) The intensity of the sharp signals is correlated with the height of the signals in a printed example of an NMR spectrum in cm and shows the true relationships of the signal intensities. For wide signals, half the signal and the relative intensity of the signal compared to the strongest signal in the spectrum can be displayed. For chemical shift calibration of 1H NMR spectra, we use tetramethylsilane and / or solvent chemical shift, particularly in the case of spectra measured in DMSO. Therefore, the tetramethylsilane peak can but does not necessarily have to be found in the list of NMR peaks. 109 1H NMR peak lists are similar to conventional 1H NMR formats and therefore typically contain all peaks listed in a conventional NMR interpretation. On the other hand, like conventional 1H NMR formats, they can show the signals of the solvents, signals of the stereoisomers of the compounds investigated which the invention also discloses, and / or peaks of impurities. In reporting delta range compound signals from solvents and / or water, our 1H NMR peak lists show the peaks from the standard solvents, for example DMSO peaks in DMSO-D6 and the water peak, the which usually have a high intensity on average. The peaks of the stereoisomers of the investigated compounds and / or the peaks of the impurities usually have a lower intensity on average than the peaks of the investigated compounds (eg >90% pure). Said stereoisomers and / or impurities can be typical of certain preparation processes. Their peaks can therefore help to identify the reproduction of our preparation processes in terms of "by-product footprints". A person skilled in the art who calculates the peaks of the investigated compounds by known methods (MestreC, ACD simulation, but also with empirically evaluated expected values) can, if required, isolate the peaks of the investigated compounds, optionally using additional intensity filters. . This isolation would be similar to the [peak identification] in question in the conventional interpretation of 1H NMR. More information on the 1H NMR peak lists can be found in the Research Disclosure Database under the number 564025. The compounds according to the invention described in Table 1 below are also preferred compounds of formula (I) according to the invention which are prepared according to or analogously to the preparation examples described above. frCRnnn / zznz / B / YiAi 110 Table 1 Example Structure2) List of NMR peaks1) or m / z3 1-1 N υ η N-< 1-1: 1H-NMR(600.1 MHz, CD3CN lowT): δ= 8.8607 (4.5); 8.8573 (4.6); 8.3210 (12.7); 8.3067 (3.1); 8.3030 (3.1); 8.1814 (5.2); 8.0566 (4.8); 8.0422 (4.4); 6.2332 (0.4); 6.2216 (1.9); 6.2099 (2.9); 6.1981 (1.9); 6.1864 (0.5); 2.7472 (2.3); 2.7345 (7.3); 2.7219 (7.5); 2.7093 (2.5); 2.2999 (14.8); 2.0769 (0.4); 2.0729 (0.4); 2.0686 (0.4); 2.0641 (0.3); 1.9863 (2.8); 1.9782 (2.3); 1.9739 (3.0); 1.9703 (24.4); 1.9662 (44.6); 1.9621 (65.6); 1.9580 (45.7); 1.9539 (23.4); 1.9456 (0.5); 1.8470 (0.4); 1.6718 (11.5); 1.6601 (11.5); 1.2984 (7.9); 1.2857 (16.0); 1.2731 (7.7); 0.0053 (0.4); -0.0001 (13.4); -0.0056(0.4) I-2 O or ¿a IZ f' ζ-^Λ— / I-2: 1H-NMR(600.1 MHz, CD3CN lowT): 5= 8.8543 (4.9); 8.8507 (5.0); 8.3168 (2.7); 8.3133 (2.7); 8.3024 (3.0); 8.2989 (3.0); 8.0480 (5.2); 8.0336 (4.8); 7.9934 (1.7); 7.9815 (1.7); 7.7236 (11.4); 7.7206 (12.4); 7.6284 (3.2); 7.6255 (5.7); 7.6226 (3.0); 6.1811 (0.5); 6.1694 (2.0); 6.1576 (3.1); 6.1459 (2.1); 6.1341 (0.5); 2.7554 (2.4); 2.7428 (7.4); 2.7302 (7.6); 2.7175 (2.6); 2.3024 (9.4); 2.0730 (0.3); 2.0639 (0.4); 1.9864 (3.2); 1.9780 (2.0); 1.9703 (19.7); 1.9663 (35.8); 1.9621 (52.4); 1.9581 (36.7); 1.9540 (18.9); 1.9455 (0.4); 1.6326 (12.2); 1.6210 (12.2); 1.3050 (7.9); 1.2923 (16.0); 1.2797 (7.7); 0.0047 (0.4); -0.0001 (10.2); -0.0053 (0.4) I-3 ^Z, Q 2- / -¼—=2 I-3: 1H-NMR(600.1 MHz, CD3CN lowT): 5=8.8618 (5.0); 8.8582 (5.2); 8.3660 (1.3); 8.3551 (1.3); 8.3249 (2.8); 8.3214 (2.8); 8.3105 (3.1); 8.3070 (3.2); 8.0628 (5.4); 8.0484 (4.9); 8.0063 (5.2); 7.9857 (5.5); 7.8591 (4.9); 6.2398 (0.5); 6.2282 (2.0); 6.2164 frc«nnn / 77n7 / E / YiAi 111 (3.1); 6.2047 (2.0); 6.1930 (0.5); 2.7647 (2.4); 2.7521 (7.4); 2.7395 (7.6); 2.7269 (2.6); 2.3169 (11.0); 1.9882 (6.7); 1.9798 (0.8); 1.9721 (7.3); 1.9681 (13.3); 1.9640 (19.6); 1.9599 (13.8); 1.9558 (7.2); 1.6565 (12.0); 1.6449 (12.1); 1.3051 (8.0); 1.2925 (16.0); 1.2799 (7.9); -0.0001 (3.5) I-4 Π ιζ X 'z=^ I-4: 1H-NMR(600.1 MHz, CD3CN lowT): 5= 8.8433 (6.5); 8.8411 (5.9); 8.8398 (6.8); 8.3169 (15.1); 8.3065 (3.7); 8.3030 (3.7); 8.2920 (3.9); 8.2886 (4.0); 8.1814 (6.3); 8.1403 (1.7); 8.1292 (1.8); 8.0359 (7.1); 8.0215 (6.4); 6.2055 (0.6); 6.1939 (2.6); 6.1822 (4.1); 6.1705 (2.7); 6.1588 (0.6); 2.3035 (22.9); 2.2697 (0.3); 2.0474 (0.7); 2.0393 (1.5); 2.0327 (1.8); 2.0255 (3.2); 2.0178 (2.0); 2.0118 (1.7); 2.0037 (0.8); 1.9869 (2.1); 1.9787 (1.7); 1.9707 (18.5); 1.9668 (34.0); 1.9627 (50.2); 1.9586 (35.8); 1.9546 (18.8); 1.6413 (15.9); 1.6297 (16.0); 1.0063 (3.8); 1.0027 (5.5); 0.9925 (3.7); 0.9888 (5.7); 0.9705 (0.9); 0.9509 (1.1); 0.9435 (1.3); 0.9339 (2.5); 0.9317 (2.3); 0.9266 (2.8); 0.9091 (2.5); 0.9057 (1.9); 0.9019 (2.3); 0.8903 (1.4); 0.8839 (0.7); -0.0001 (9.5); -0.0051 (0.4) I-5 N I Cl Y 0ΙΉ Q XY I-5: 1H-NMR(600.1 MHz, CD3CN lowT): 5= 8.8352 (6.1); 8.8332 (5.9); 8.8317 (6.4); 8.3013 (3.3); 8.2978 (3.4); 8.2869 (3.6); 8.2835 (3.8); 8.0257 (6.7); 8.0113 (6.0); 7.8903 (2.5); 7.8782 (2.5); 7.7191 (13.4); 7.7165 (16.0); 7.6331 (6.8); 6.1456 (0.6); 6.1340 (2.6); 6.1223 (4.0); 6.1106 (2.6); 6.0989 (0.6); 2.3021 (16.9); 2.0765 (0.3); 2.0733 (0.4); 2.0678 (0.3); 2.0639 (0.3); 2.0507 (0.7); 2.0427 (1.5); 2.0359 (1.8); 2.0289 (3.0); 2.0213 (1.9); 2.0152 (1.6); 2.0072 (0.8); 1.9865 (2.6); 1.9783 (2.0); 1.9704 (20.6); 1.9664 (37.9); 1.9623 (55.9); 1.9583 (39.9); 1.9543 (20.9); 1.8472 (0.3); 1.6031 (15.4); 1.5915 (15.4); 1.4588 frc«nnn / 77n7 / E / YiAi 112 (0.4); 1.4475 (0.4); 1.1080 (0.4); 1.0970 (0.4); 1.0086 (5.2); 0.9946 (5.4); 0.9759 (0.7); 0.9544 (1.0); 0.9470 (1.1); 0.9372 (3.1); 0.9293 (3.2); 0.9205 (2.3); 0.9174 (2.4); 0.9126 (2.3); 0.9089 (2.3); 0.8990 (1.2); 0.8929 (0.6);-0.0001 (10.9) I-6 N Λ V 8.8370 (6.6); 8.8356 (7.1); 8.3040 (3.6); 8.3004 (3.8); 8.2896 (4.0); 8.2860 (4.3); 8.1811 (1.8); 8.1706 (1.9); 8.0304 (7.3); 8.0157 (12.8); 7.9921 (7.6); 7.8805 (6.7); 6.1917 (0.6); 6.1801 (2.7); 6.1684 (4.2); 6.1566 (2.7); 6.1450 (0.6); 2.3133 (11.3); 2.0520 (0.7); 2.0440 (1.6); 2.0371 (2.0); 2.0302 (3.2); 2.0226 (2.0); 2.0165 (1.7); 2.0084 (0.8); 1.9881 (1.4); 1.9800 (1.0); 1.9721 (9.7); 1.9680 (18.1); 1.9639 (26.7); 1.9598 (19.2); 1.9558 (10.1); 1.6258 (15.9); 1.6143 (16.0); 1.0181 (0.4); 1.0059 (5.2); 1.0016 (6.3); 0.9920 (4.9); 0.9877 (6.6); 0.9750 (0.8); 0.9716 (0.8); 0.9621 (0.4); 0.9535 (1.2); 0.9452 (1.3); 0.9379 (3.0); 0.9342 (2.7); 0.9299 (3.2); 0.9254 (3.4); 0.9198 (3.1); 0.9118 (2.8); 0.9018 (1.1); 0.8951 (0.8); -0.0001 (4.7) I-7 N u h N— I-7: 1H-NMR(600.1 MHz, CD3CN lowT): 5= 8.8537 (4.0); 8.8519 (4.1); 8.8504 (4.3); 8.3219 (10.1); 8.3136 (2.2); 8.3103 (2.3); 8.2990 (2.3); 8.2959 (2.5); 8.2020 (4.2); 8.0523 (4.4); 8.0379 (4.0); 8.0163 (1.8); 8.0044 (1.8); 6.2003 (0.4); 6.1889 (1.7); 6.1773 (2.6); 6.1657 (1.7); 6.1540 (0.4); 3.0523 (0.7); 3.0408 (1.7); 3.0293 (2.3); 3.0178 (1.7); 3.0061 (0.7); 2.2944 (73.0); 2.2614 (1.2); 2.0798 (0.7); 2.0760 (1.0); 2.0726 (1.1); 2.0672 (1.1); 2.0635 (1.0); 1.9856 (7.0); 1.9765 (6.3); 1.9694 (60.1); 1.9656 (110.0); 1.9615 (161.8); 1.9576 (117.2); 1.9537 (62.1); 1.8539 (0.4); 1.8504 (0.6); 1.8464 (0.9); 1.8426 (0.7); 1.8387 (0.4); 1.6637 frc«nnn / 77n7 / E / YiAi 113 (10.2); 1.6522 (10.2); 1.3103 (16.0); 1.2988 (15.7); - 0.0001 (31.4) 1-8 N φν Λ F0 V n^N / / υ H NVZ I-8: 1H-NMR(600.1 MHz, CD3CN lowT): δ= 8.8522 (3.8); 8.8489 (4.0); 8.3132 (2.0); 8.3101 (2.1); 8.2989 (2.2); 8.2958 (2.3); 8.0508 (4.1); 8.0367 (7.3); 7.9913 (5.3); 7.9074 (4.0); 6.1871 (0.4); 6.1754 (1.6); 6.1637 (2.5); 6.1520 (1.6); 6.1403 (0.4); 3.0552 (0.6); 3.0437 (1.6); 3.0321 (2.2); 3.0206 (1.7); 3.0091 (0.7); 2.3089 (9.2); 1.9867 (1.3); 1.9783 (1.1); 1.9705 (11.1); 1.9667 (20.3); 1.9627 (29.7); 1.9588 (21.3); 1.9548 (11.3); 1.6474 (9.5); 1.6358 (9.6); 1.3113 (16.0); 1.2997 (15.9); -0.0001 (5.8) 1-9 or z= / I-9: 1H-NMR(400.2 MHz, d6-DMSO): δ= 9.5079 (3.6); 9.4906 (3.7); 9.0941 (6.7); 9.0888 (6.6); 8.6228 (4.9); 8.6173 (4.7); 8.6014 (5.3); 8.5958 (5.2); 8.3154 (0.5); 8.1465 (6.9); 8.0904 (9.1); 8.0825 (11.2); 8.0706 (7.0); 8.0694 (6.9); 7.3625 (3.1); 7.2308 (7.6); 7.0992 (3.6); 6.1051 (0.6); 6.0879 (2.9); 6.0706 (4.6); 6.0533 (2.9); 6.0359 (0.6); 3.3244 (150.9); 3.3045 (0.5); 2.8919 (2.0); 2.7321 (1.7); 2.6906 (1.6); 2.6808 (0.5); 2.6765 (1.0); 2.6719 (1.4); 2.6674 (1.0); 2.6631 (0.5); 2.5254 (3.8); 2.5207 (5.6); 2.5120 (81.4); 2.5075 (168.0); 2.5030 (222.3); 2.4984 (158.0); 2.4939 (74.5); 2.3387 (0.4); 2.3344 (0.9); 2.3299 (1.3); 2.3252 (0.9); 2.3206 (0.4); 2.0868 (8.5); 1.6780 (16.0); 1.6606 (15.9); 1.3979 (12.9); 0.1459 (0.6); 0.0081 (4.6); -0.0001 (152.8); -0.0085 (4.7); -0.1495 (0.6) 1-10 N νΐί (í N 0- 1-10:1H-NMR(400.2 MHz, CD3CN): δ= 8.8127 (1.8); 8.8089 (1.8); 8.2774 (1.4); 8.2720 (1.3) ; 8.2558 (1.5); 8.2503 (1.4); 8.0352 (1.9); 7.9870 (3.3); 7.9652 (1.6); 7.8784 (1.7); 7.7990 (0.5); 7.7860 (0.5); 6.1764 (0.9); 6.1587 (1.3) ; 6.1408 (0.9); 4.0677 (0.5); 4.0498 (0.5); 3.9955 (16.0); 2.4674 (0.4); 2.4625 frCRnnn / zznz / B / YiAi 114 (0.6); 2.4581 (0.4); 2.1462 (83.4); 2.1192 (0.6); 2.1131 (0.9); 2.1070 (1.0); 2.1007 (0.7); 2.0945 (0.4); 1.9715 (2.5); 1.9639 (4.2); 1.9575 (6.7); 1.9520 (58.0); 1.9458 (109.7); 1.9396 (153.0); 1.9334 (104.8); 1.9273 (53.4); 1.7742 (0.6); 1.7681 (0.9); 1.7618 (0.6); 1.6495 (6.2); 1.6322 (6.2); 1.4369 (1.5); 1.2215 (0.6); 1.2037 (1.1); 1.1859 (0.6); 0.1458 (2.7); 0.0404 (0.4); 0.0177 (1.4); 0.0079 (26.0); -0.0002 (568.7); -0.0086 (24.2); -0.0303 (0.9); -0.1495 (2.7) 1-11 N 0- 1-11: 1H-NMR(400.2 MHz, CD3CN): 5=8.8157 (2.3); 8.8106 (2.3); 8.3125 (5.3); 8.2782 (1.3); 8.2732 (1.3); 8.2566 (1.5); 8.2516 (1.5); 8.1497 (2.2); 7.9904 (2.4); 7.9687 (2.1); 7.9112 (0.7); 7.8933 (0.7); 6.2068 (1.1); 6.1892 (1.6); 6.1714 (1.1); 3.9954 (16.0); 2.1340 (10.9); 2.0134 (1.0); 1.9713 (0.9); 1.9637 (0.9); 1.9518 (10.8); 1.9459 (20.3); 1.9399 (28.1); 1.9338 (19.7); 1.9276 (10.5); 1.6677 (7.0); 1.6503 (7.0); 1.4361 (9.8); 1.2034 (0.4); 0.1454 (0.6); -0.0003 (105.2); -0.1499 (0.6) 1-12 N 1-12:1H-NMR(400.2 MHz, CD3CN): 5=8.8100 (1.8); 8.8082 (1.9); 8.8045 (1.9); 8.8027 (1.7); 8.2677 (1.4); 8.2622 (1.4); 8.2461 (1.6); 8.2405 (1.6); 8.0296 (2.0); 7.9886 (2.0); 7.9720 (2.0); 7.9702 (2.0); 7.9504 (1.8); 7.9486 (1.7); 7.8744 (1.8); 7.7994 (0.5); 7.7825 (0.5); 6.1783 (1.0); 6.1605 (1.3); 6.1424 (1.0); 4.3823 (1.2); 4.3646 (3.9); 4.3470 (3.9); 4.3294 (1.2); 2.1350 (13.2); 1.9718 (0.4); 1.9642 (0.9); 1.9580 (1.6); 1.9523 (12.2); 1.9461 (22.8); 1.9400 (31.5); 1.9338 (21.5); 1.9276 (11.0); 1.6459 (6.6); 1.6286 (6.6); 1.4365 (16.0); 1.4086 (4.2); 1.3910 (8.6); 1.3734 (4.1); 0.1459 (0.5); 0.0079 (5.5); -0.0002 (115.2); 0.0086 (4.8); -0.1495 (0.5) frCRnnn / zznz / B / YiAi 115 1-13 N o^N O-\ 1-13:1H-NMR(400.2 MHz, CD3CN): δ=8.8118 (2.4); 8.8065 (2.4); 8.3153 (5.5); 8.2693 (1.4); 8.2643 (1.4); 8.2476 (1.6); 8.2427 (1.5); 8.1518 (2.3); 7.9756 (2.6); 7.9540 (2.2); 7.9013 (0.7); 7.8858 (0.7); 6.2054 (1.1); 6.1879 (1.7); 6.1703 (1.1); 4.3817 (1.3); 4.3641 (3.9); 4.3465 (3.9); 4.3290 (1.3); 2.1329 (19.4); 1.9710 (0.9); 1.9629 (1.4); 1.9513 (15.8); 1.9454 (29.1); 1.9395 (40.1); 1.9335 (27.9); 1.9273 (14.4); 1.6643 (7.2); 1.6469 (7.1); 1.4362 (16.0); 1.4065 (4.1); 1.3889 (8.1); 1.3713 (4.0); 1.2036 (0.3); 0.1453 (0.8); 0.0064 (9.1); -0.0002 (152.6); -0.1502 (0-8) 1-14 □ ZI or δ 1-14: 1H-NMR(400.2 MHz, CD3CN): δ= 8.8060 (1.9); 8.8017 (1.9); 8.2659 (1.3); 8.2604 (1.3); 8.2443 (1.5); 8.2388 (1.5); 7.9656 (2.0); 7.9440 (1.8); 7.7210 (5.4); 7.7163 (5.6); 7.6843 (0.5); 7.6798 (0.5); 7.6729 (0.5); 7.6154 (1.6); 7.6108 (2.6); 7.6062 (1.3); 6.1495 (1.0); 6.1315 (1.4); 6.1138 (1.0); 4.3821 (1.2); 4.3645 (3.7); 4.3468 (3.8); 4.3292 (1.2); 2.1456 (18.6); 1.9714 (0.4); 1.9638 (1.2); 1.9520 (15.6); 1.9458 (29.2); 1.9397 (40.4); 1.9335 (27.9); 1.9274 (14.3); 1.8850 (0.3); 1.6277 (6.6); 1.6104 (6.6); 1.4364 (16.0); 1.4108 (4.0); 1.3932 (8.0); 1.3755 (3.8); 0.1456 (0.8); 0.0200 (0.4); 0.0075 (7.4); -0.0003 (156.5); 0.0085 (7.2); -0.1498 (0.8) 1-15 N I Cl <A) C'Y1 Q Xu 1-15:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.3058 (1.2); 9.2886 (1.3); 9.0149 (2.3); 9.0095 (2.3); 8.5439 (1.6); 8.5384 (1.5); 8.5223 (1.7); 8.5168 (1.7); 7.9778 (2.4); 7.9562 (2.3); 7.8587 (5.8); 7.8539 (7.3); 7.8217 (1.9); 7.8170 (2.7); 7.8125 (1.3); 6.0550 (1.0); 6.0377 (1.6); 6.0204 (1.0); 3.9627 (16.0); 3.3225 (9.3); 2.5256 (0.7); 2.5120 (15.2); 2.5077 (30.6); 2.5032 (40.2); 2.4987 (29.1); 2.4943 (14.2); 2.0756 frc«nnn / 77n7 / E / YiAi 116 (2.5); 1.6048 (5.5); 1.5874 (5.5); 0.0079 (1.9); -0.0002 (48.8); -0.0085 (1.7) 1-16 N 0 η n-^ 1-16:1H-NMR(400.2 MHz, CD3CN): δ= 8.8067 (3.4); 8.8026 (3.4); 8.2637 (2.2); 8.2582 (2.2); 8.2420 (2.6); 8.2365 (2.5); 8.0367 (3.5); 7.9952 (3.6); 7.9694 (3.6); 7.9477 (3.1); 7.8736 (3.4); 7.8428 (0.8); 6.1963 (0.4); 6.1787 (1.5); 6.1606 (2.2); 6.1429 (1.6); 6.1254 (0.4); 5.0090 (0.7); 4.9936 (1.8); 4.9783 (2.4); 4.9629 (1.8); 4.9475 (0.7); 2.1614 (41.0); 1.9651 (0.9); 1.9532 (14.5); 1.9470 (27.9); 1.9409 (39.6); 1.9347 (27.2); 1.9285 (13.9); 1.6431 (11.5); 1.6258 (11.4); 1.3906 (12.0); 1.3760 (16.0); 1.3628 (11.9); 1.2682 (1.0); 0.0079 (0.8); -0.0002 (22.0); -0.0084 (0.8) 1-17 N O Η Νύθ^ / 1-17:1H-NMR(400.2 MHz, CD3CN): δ= 8.8098 (3.3); 8.8055 (3.4); 8.3218 (7.4); 8.2650 (2.3); 8.2595 (2.2); 8.2434 (2.6); 8.2379 (2.5); 8.1501 (3.0); 7.9753 (3.5); 7.9741 (3.5); 7.9536 (3.6); 7.9524 (3.6); 7.9350 (0.8); 6.2258 (0.4); 6.2080 (1.6); 6.1903 (2.2); 6.1722 (1.6); 6.1547 (0.4); 5.4469 (0.7); 5.0093 (0.7); 4.9938 (1.9); 4.9784 (2.5); 4.9630 (1.9); 4.9477 (0.8); 2.1495 (28.1); 2.0867 (0.6); 1.9644 (1.0); 1.9526 (15.7); 1.9464 (29.7); 1.9403 (41.2); 1.9341 (28.2); 1.9280 (14.3); 1.6622 (11.4); 1.6449 (11.3); 1.3891 (11.3); 1.3763 ​​(16.0); 1.3613 (11.8); 1.2683 (0.4); 0.0079 (0.8); -0.0002 (21.3); -0.0084 (0.8) 1-18 N 1 Cl Cl« Q ΎλΧν °A 1-18:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.2762 (2.4); 9.2592 (2.4); 9.0010 (4.3); 8.9970 (4.1); 8.5287 (2.5); 8.5234 (2.4); 8.5072 (2.6); 8.5017 (2.5); 8.3152 (0.5); 7.9550 (4.0); 7.9334 (3.8); 7.8548 (9.3); 7.8503 (11.5); 7.8238 (3.6); 7.8194 (4.6); 7.6479 (0.6); 7.6431 (0.5); 6.0579 (0.4); 6.0401 (1.6); 6.0228 (2.5); 6.0056 (1.6); 5.9890 (0.4); 5.4735 (0.6); 4.9476 frc«nnn / 77n7 / E / YiAi 117 (0.7); 4.9324 (1.8); 4.9170 (2.4); 4.9017 (1.8); 4.8861 (0.7); 3.3226 (108.3); 2.6714 (1.7); 2.5024 (285.4); 2.3290 (1.7); 1.9890 (0.4); 1.5981 (9.1); 1.5807 (9.0); 1.3979 (11.3); 1.3609 (11.4); 1.3433 (16.0); 1.3265 (11.4); -0.0001 (36.1) 1-19 N I Cl rA BO v ® n^un u |-| N-^ 1-19: 1H-NMR(400.2 MHz, d6-DMSO): 5= 9.2993 (2.3); 9.2815 (2.3); 9.0238 (4.1); 9.0200 (4.0); 9.0183 (4.1); 8.5404 (3.1); 8.5349 (3.0); 8.5189 (3.4); 8.5133 (3.4); 8.0298 (3.8); 8.0282 (4.3); 8.0084 (3.6); 8.0067 (4.1); 7.9629 (2.8); 7.9588 (5.5); 7.9550 (4.0); 7.9225 (3.2); 7.9178 (5.8); 7.9133 (3.2); 7.8581 (3.6); 7.8537 (5.0); 7.8498 (3.3); 6.0859 (0.3); 6.0685 (1.7); 6.0509 (2.7); 6.0333 (1.7); 6.0159 (0.4); 5.7574 (0.4); 3.3263 (28.3); 3.0531 (0.8); 3.0357 (2.1); 3.0184 (2.9); 3.0011 (2.2); 2.9838 (0.9); 2.6775 (0.3); 2.6728 (0.5); 2.6683 (0.4); 2.5263 (1.7); 2.5216 (2.6); 2.5128 (27.8); 2.5084 (56.1); 2.5038 (76.0); 2.4992 (58.6); 2.4948 (30.8); 2.3352 (0.3); 2.3307 (0.5); 2.3262 (0.4); 1.6130 (9.1); 1.5956 (9.2); 1.3972 (0.8); 1.2965 (15.5); 1.2904 (16.0); 1.2792 (15.6); 1.2731 (15.7); 0.0080 (0.9); -0.0002 (28.6); -0.0085 (1.3) I-20 N υ h N-\ I-20:1H-NMR(400.2 MHz, CD3CN): δ= 8.9047 (1.8); 8.8997 (1.9); 8.8685 (1.8); 8.8637 (1.9); 8.4677 (0.6); 8.4488 (0.5); 8.4077 (1.9); 8.4029 (2.0); 8.2911 (1.3); 8.2856 (1.3); 8.2695 (1.5); 8.2640 (1.5); 8.0477 (2.1); 8.0262 (1.8); 6.1965 (0.9); 6.1792 (1.1); 6.1768 (1.1); 6.1596 (1.0); 3.0869 (0.4); 3.0695 (1.1); 3.0521 (1.5); 3.0348 (1.1); 3.0176 (0.5); 2.1427 (49.7); 2.1076 (0.3); 1.9646 (1.6); 1.9584 (1.8); 1.9527 (16.3); 1.9465 (30.8); 1.9404 (43.7); 1.9342 (30.7); 1.9280(16.1); 1.6156 (6.9); 1.5986 (6.9); 1.4368 (0.4); 1.3337 (16.0); 1.3164 (15.7); -0.0002 (4.1) frCRnnn / zznz / B / YiAi 118 1-21 N U H NA_ 1-21:1H-NMR(400.2 MHz, CD3CN): δ=8.8313 (2.5); 8.8298 (2.8); 8.8260 (2.9); 8.8244 (2.7); 8.2814 (2.0); 8.2759 (2.0); 8.2599 (2.3); 8.2543 (2.3); 8.1611 (3.2); 8.0361 (2.9); 8.0346 (3.0); 8.0125 (8.2); 7.8221 (0.8); 7.8041 (0.8); 6.1879 (0.4); 6.1705 (1.5); 6.1526 (2.0); 6.1347 (1.5); 6.1173 (0.4); 5.4475 (0.7); 3.0714 (0.6); 3.0540 (1.5); 3.0367 (2.0); 3.0194 (1.6); 3.0021 (0.6); 2.6808 (0.3); 2.1583 (39.8); 1.9727 (0.6); 1.9657 (0.8); 1.9593 (1.0); 1.9537 (8.5); 1.9476 (16.1); 1.9414 (22.8); 1.9352 (16.1); 1.9291 (8.5); 1.6479 (9.2); 1.6306 (9.2); 1.4358 (2.2); 1.3252 (16.0); 1.3078(15.6); 1.2743 (0.6); 1.2581 (1.0); 1.2416(0.6); 1.2235 (0.6); 1.2046 (0.4); -0.0002 (1.6) I-22 N H NA_ I-22:1H-NMR(400.2 MHz, CD3CN): δ= 9.0760 (0.4); 9.0567 (0.4); 8.8845 (1.7); 8.8831 (1.8); 8.8791 (1.9); 8.8777 (1.8); 8.3151 (1.2); 8.2954 (1.7); 8.2880 (1.5); 8.2825 (1.4); 8.2664 (1.7); 8.2609 (1.7); 8.1979 (0.9); 8.1785 (1.7); 8.1589 (0.8); 8.0547 (2.0); 8.0531 (2.1); 8.0331 (1.7); 8.0315 (1.7); 7.9730 (1.6); 7.9710 (1.7); 7.9534 (1.4); 7.9515 (1.4); 6.1796 (1.0); 6.1624 (1.0); 6.1595 (1.1); 6.1423 (1.0); 3.1004 (0.4); 3.0830 (1.1); 3.0657 (1.4); 3.0484 (1.1); 3.0311 (0.4); 2.1424 (18.3); 1.9657 (0.7); 1.9596 (0.7); 1.9537 (6.8); 1.9476 (12.7); 1.9414 (18.0); 1.9352 (12.6); 1.9291 (6.5); 1.6571 (7.0); 1.6400 (7.0); 1.3432 (16.0); 1.3259 (15.8); -0.0002 (1.6) I-23 N 1 Br WÑ u H N-^ I-23:1H-NMR(400.2 MHz, CD3CN): 5=8.9129 (2.4); 8.9077 (2.5); 8.8939 (0.5); 8.2895 (1.3); 8.2840 (1.3); 8.2678 (1.6); 8.2624 (1.6); 8.0513 (2.7); 8.0366 (2.0); 8.0348 (2.0); 8.0294 (2.0); 7.8437 (1.2); 7.8243 (2.5); 7.8051 (1.6); 7.7437 (2.2); 7.7423 (2.2); 7.7238 (1.4); 6.1638 (1.0); 6.1465 (1.1); 6.1434 (1.1); 6.1261 (1.0); 3.1025 (0.4); 3.0851 (1.1); 3.0678 frCRnnn / zznz / B / YiAi 119 (1.5); 3.0504 (1.2); 3.0332 (0.5); 2.1464 (17.6); 1.9657 (0.6); 1.9595 (0.7); 1.9539 (6.2); 1.9477 (11.6); 1.9415 (16.4); 1.9353 (11.4); 1.9292 (6.0); 1.6367 (7.2); 1.6196 (7.2); 1.4358 (0.8); 1.3452 (16.0); 1.3279 (15.8); -0.0002 (1.5) I-24 N I-24: 1H-NMR(400.2 MHz, CD3CN): δ= 8.8293 (2.8); 8.8254 (2.9); 8.2826 (2.0); 8.2770 (2.0); 8.2610 (2.4); 8.2554 (2.3); 8.0310 (3.0); 8.0296 (3.0); 8.0094 (2.5); 8.0081 (2.6); 7.8926 (7.1); 7.8901 (13.1); 7.7639 (0.8); 7.7461 (0.8); 6.1562 (0.4); 6.1388 (1.5); 6.1210 (2.1); 6.1031 (1.5); 6.0857 (0.4); 3.0723 (0.6); 3.0550 (1.6); 3.0377 (2.2); 3.0203 (1.7); 3.0030 (0.7); 2.4713 (0.5); 2.4665 (0.6); 2.4620 (0.5); 2.1862 (122.7); 2.1147 (0.4); 2.1084 (0.4); 2.1024 (0.3); 1.9654 (2.2); 1.9591 (2.6); 1.9535 (22.4); 1.9474 (42.4); 1.9412 (59.7); 1.9350 (41.7); 1.9289 (21.5); 1.7696 (0.4); 1.6279 (9.9); 1.6106 (9.8); 1.3263 (16.0); 1.3089(15.7); 1.2669 (0.5); 1.2498 (0.6);-0.0002 (2.1) I-25 / =H ώ ZI r I-25:1H-NMR(400.2 MHz, CD3CN): δ= 8.8317 (2.8); 8.8301 (2.7); 8.8262 (2.9); 8.2836 (2.1); 8.2780 (2.0); 8.2620 (2.4); 8.2564 (2.3); 8.1783 (2.3); 8.1748 (3.4); 8.1708 (1.9); 8.0809 (3.7); 8.0625 (2.7); 8.0588 (3.5); 8.0545 (1.8); 8.0376 (3.2); 8.0160 (2.7); 7.7881 (0.7); 6.1813 (0.4); 6.1641 (1.5); 6.1464 (2.1); 6.1285 (1.4); 6.1111 (0.4); 5.4478 (2.7); 3.0721 (0.6); 3.0547 (1.6); 3.0374 (2.2); 3.0201 (1.6); 3.0028 (0.7); 2.6763 (0.4); 2.1687 (20.4); 2.1206 (0.3); 2.1146 (0.3); 2.1084 (0.4); 1.9653 (1.5); 1.9591 (1.8); 1.9534 (15.0); 1.9472 (28.0); 1.9410 (38.8); 1.9348 (26.3); 1.9287 (13.4); 1.6386 (9.7); 1.6213 (9.7); 1.3289 (16.0); 1.3116 (15.7); 1.2737 (0.9); 1.2610 (1.0); 1.2577 (1.0); 1.2445 (0.8); 1.2219 (0.4); -0.0002 (1.6) frc«nnn / 77n7 / E / YiAi 120 I-26 N 1 ° H N-í' 1-26:1H-NMR(400.2 MHz, CD3CN): δ= 8.8284 (2.6); 8.8268 (2.7); 8.8230 (2.8); 8.2817 (1.9); 8.2761 (1.8); 8.2601 (2.2); 8.2545 (2.1); 8.0342 (2.9); 8.0326 (2.8); 8.0126 (2.4); 8.0110 (2.3); 7.9276 (3.6); 7.7995 (0.7); 7.7867 (0.8); 7.6618 (2.4); 7.6409 (2.5); 6.1658 (0.4); 6.1483 (1.4); 6.1306 (2.0); 6.1126 (1.4); 6.0952 (0.4); 3.0722 (0.6); 3.0548 (1.5); 3.0374 (2.0); 3.0201 (1.5); 3.0028 (0.6); 2.4652 (0.4); 2.1714 (56.7); 2.1082 (0.3); 1.9652 (1.8); 1.9589 (2.4); 1.9533 (18.2); 1.9472 (34.0); 1.9410 (47.3); 1.9348 (32.8); 1.9287 (17.0); 1.6391 (8.9); 1.6218 (8.9); 1.3268 (16.0); 1.3095 (15.7); 1.2702 (0.5); 1.2544 (0.6); 1.2387 (0.4); -0.0002 (2.4) I-27 N -A »N 0 Η N— I-27:1H-NMR(400.2 MHz, CD3CN): δ= 8.8576 (2.8); 8.8532 (2.8); 8.8355 (2.4); 8.8316 (2.4); 8.7879 (2.7); 8.7823 (2.8); 8.2830 (1.6); 8.2775 (1.6); 8.2614 (2.0); 8.2557 (3.3); 8.2498 (2.9); 8.2450 (1.5); 8.0380 (2.6); 8.0164 (2.2); 7.7687 (0.6); 6.1774 (1.3); 6.1594 (1.8); 6.1417 (1.3); 6.1243 (0.3); 3.0740 (0.5); 3.0567 (1.3); 3.0394 (1.8); 3.0221 (1.4); 3.0048 (0.6); 2.1483 (17.6); 2.1201 (0.4); 2.1138 (0.3); 2.1076 (0.4); 1.9647 (1.6); 1.9527 (16.8); 1.9465 (31.5); 1.9404 (44.2); 1.9342 (30.7); 1.9280 (16.0); 1.6430 (8.4); 1.6257 (8.4); 1.3291 (16.0); 1.3117 (15.7); 0.0002 (2.2) I-28 N 1 A T / / ^ 0 H N I-28:1H-NMR(400.2 MHz, CD3CN): δ= 8.8258 (2.3); 8.8242 (2.3); 8.8204 (2.4); 8.2857 (1.6); 8.2802 (1.6); 8.2641 (1.9); 8.2586 (1.8); 8.0425 (2.8); 8.0407 (2.6); 8.0209 (5.6); 8.0065 (0.4); 7.9832 (0.6); 7.9618 (3.3); 6.1847 (1.2); 6.1670 (1.7); 6.1492 (1.1); 3.0740 (0.5); 3.0567 (1.4); 3.0393 (1.9); 3.0220 (1.4); 3.0046 (0.6); 2.1646 (16.2); 1.9655 (1.0); 1.9591 (1.1); 1.9536 (9.4); 1.9474 (17.6); 1.9412 (24.6); frCRnnn / zznz / B / YiAi 121 1.9351 (16.9); 1.9289 (8.6); 1.6555 (8.4); 1.6382(8.4); 1.4362 (8.3); 1.3293 (16.0); 1.3119 (15.6); 1.2846 (0.5); 1.2688 (1.0); 1.2522 (0.6); -0.0002 (1.1) I-30 N cXX ÍN ° H N I-30:1H-NMR(400.2 MHz, CD3CN): 5= 9.1570 (2.4); 9.1529 (2.5); 9.0173 (2.2); 9.0146 (2.2); 8.8403 (2.5); 8.8389 (2.5); 8.8349 (2.6); 8.3761 (2.4); 8.2869 (1.8); 8.2814 (1.7); 8.2653 (2.1); 8.2598 (2.1); 8.0440 (2.9); 8.0424 (2.8); 8.0224 (2.5); 8.0208 (2.4); 7.9973 (0.6); 6.2325 (0.3); 6.2150 (1.4); 6.1972 (2.0); 6.1794 (1.4); 6.1619 (0.3); 3.0756 (0.6); 3.0582 (1.5); 3.0409 (2.1); 3.0236 (1.6); 3.0062 (0.6); 2.7288 (5.9); 2.2102 (28.8); 1.9671 (0.6); 1.9608 (0.7); 1.9551 (6.2); 1.9490 (11.6); 1.9428 (16.2); 1.9366 (11.2); 1.9304 (5.7); 1.6646 (9.2); 1.6473 (9.1); 1.4354 (0.4); 1.3285 (16.0); 1.3112 (15.7); 1.2840 (0.5); 1.2683 (0.8); 1.2537 (0.5); -0.0002 (0.7) 1-31 N 'y / / N 0 h n-4! 1-31: 1H-NMR(400.2 MHz, d6-DMSO): 5= 9.4063 (4.0); 9.3887 (4.1); 9.0115 (7.4); 9.0077 (6.9); 9.0060 (7.0); 8.5330 (5.2); 8.5274 (5.1); 8.5115 (5.6); 8.5059 (5.7); 8.3160 ​​(1.1); 8.2885 (7.5); 8.1724 (6.9); 8.1232 (7.2); 8.0108 (6.9); 8.0092 (7.5); 7.9893 (6.4); 7.9876 (7.0); 6.0799 (0.6); 6.0625 (2.9); 6.0450 (4.6); 6.0276 (3.0); 6.0103 (0.6); 3.9051 (0.7); 3.3250 (385.6); 2.6757 (2.5); 2.6712 (3.4); 2.6667 (2.6); 2.5246 (10.0); 2.5110 (203.7); 2.5067 (410.1); 2.5022 (544.2); 2.4977 (405.5); 2.4933 (203.1); 2.3335 (2.4); 2.3291 (3.3); 2.3246 (2.4); 2.0869 (0.8); 2.0748 (1.8); 2.0660 (1.9); 2.0540 (3.7); 2.0419 (2.2); 2.0333 (1.9); 2.0210 (1.0); 1.6079 (16.0); 1.5905 (16.0); 1.3978 (5.3); 1.2341 (0.3); 1.0302 (0.3); 1.0218 (0.3); 1.0012 (4.7); 0.9959 (6.6); 0.9804 (4.4); 0.9751 (6.8); 0.9562 (0.7); 0.9491 (0.6); 0.9138 (1.0); 0.9019 (1.1); 0.8894 (3.9); 0.8843 (2.1); 0.8772 (4.0); 0.8703 (2.7); 0.8639 frCRnnn / zznz / B / YiAi 122 (2.9); 0.8577 (2.2); 0.8523 (2.7); 0.8351 (1.2); 0.8267 (0.7); 0.1460 (0.9); 0.0080 (7.6); -0.0002 (232.8); 0.0084 (8.7);-0.1497 (1.0) I-32 ° H N-^ I-32:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.2626 (4.2); 9.2451 (4.4); 9.0095 (7.2); 9.0058 (7.4); 9.0040 (7.1); 8.5331 (4.8); 8.5276 (4.9); 8.5116 (5.2); 8.5061 (5.3); 8.3156 (0.4); 8.0069 (7.3); 7.9868 (6.2); 7.9853 (6.8); 7.9571 (4.9); 7.9533 (9.4); 7.9496 (7.2); 7.9235 (5.2); 7.9189 (9.5); 7.9145 (5.4); 7.8534 (5.9); 7.8493 (8.8); 7.8454 (6.0); 6.0489 (0.6); 6.0316 (2.9); 6.0142 (4.6); 5.9967 (2.9); 5.9793 (0.6); 3.3298 (409.8); 2.6762 (1.3); 2.6718 (1.7); 2.6675 (1.4); 2.5072 (201.7); 2.5028 (269.7); 2.4984 (211.4); 2.3340 (1.2); 2.3298 (1.6); 2.3252 (1.3); 2.0844 (0.8); 2.0725 (1.7); 2.0637 (2.0); 2.0519 (3.6); 2.0398 (2.2); 2.0311 (1.9); 2.0190 (0.9); 1.9893(0.4); 1.5871 (16.0); 1.5697 (16.0); 1.3975 (14.0); 1.2338 (0.9); 1.0294 (0.3); 1.0214 (0.4); 1.0016 (5.2); 0.9958 (7.2); 0.9808 (4.9); 0.9751 (7.3); 0.9563 (0.8); 0.9498 (0.7); 0.9399 (0.3); 0.9122 (1.0); 0.8999 (1.2); 0.8882 (3.7); 0.8761 (3.8); 0.8697 (3.2); 0.8632 (3.4); 0.8568 (2.5); 0.8510 (3.2); 0.8338 (1.3); 0.8249 (0.8); 0.1459 (0.5); 0.0078 (4.1); -0.0003 (109.3); -0.0082 (5.6); -0.1498 (0.5) I-33 V -n o vc5 IZ Q . / ¾ z= / I-33:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.3249 (4.4); 9.3074 (4.5); 9.0048 (7.2); 8.9995 (7.2); 8.5316 (4.9); 8.5261 (5.0); 8.5100 (5.2); 8.5045 (5.4); 8.3164 (0.5); 8.0082 (7.5); 7.9866 (7.0); 7.9438 (5.4); 7.9399 (9.0); 7.9363 (6.4); 7.7782 (6.2); 7.7169 (6.5); 6.0599 (0.7); 6.0424 (3.0); 6.0250 (4.6); 6.0075 (3.0); 5.9903 (0.6); 3.3250 (135.4); 2.6756 (1.5); 2.6714 (2.1); 2.6671 (1.7); 2.5068 (235.1); 2.5024 (314.6); 2.4980 (247.4); 2.3334 (1.4); 2.3293 (2.0); 2.3248 (1.5); 2.0862 (0.8); 2.0743 (1.8); 2.0654 (2.1); frCRnnn / zznz / B / YiAi 123 2.0535 (3.7); 2.0415 (2.3); 2.0330 (2.0); 2.0207 (1.0); 1.9088 (0.6); 1.5999 (16.0); 1.5825 (16.0); 1.3974 (1.7); 1.2341 (1.1); 1.0285 (0.4); 1.0232 (0.5); 1.0018 (5.0); 0.9961 (7.1); 0.9810 (4.7); 0.9753 (7.3); 0.9558 (0.8); 0.9496 (0.7); 0.9296 (0.3); 0.9129 (1.1); 0.9007 (1.4); 0.8886 (3.7); 0.8766 (3.8); 0.8685 (2.8); 0.8628 (3.3); 0.8556 (2.6); 0.8506 (3.2); 0.8334 (1.4); 0.8251 (0.8); 0.1456 (0.6); 0.0072 (5.1); -0.0002 (117.9); 0.0083 (10.3); -0.1498 (0.6) I-34 O o y^z z= / I-34:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.2457 (3.9); 9.2280 (3.8); 9.0111 (6.2); 9.0098 (6.5); 9.0058 (6.7); 9.0043 (6.2); 8.5335 (5.4); 8.5279 (5.1); 8.5120 (5.7); 8.5064 (5.7); 8.3161 (1.5); 8.0100 (6.9); 8.0085 (7.0); 7.9885 (6.5); 7.9869 (6.5); 7.7640 (5.5); 7.7601 (8.8); 7.7561 (5.8); 7.5460 (6.4); 7.5201 (7.0); 7.5137 (7.6); 7.5086 (3.6); 7.3375 (9.6); 7.1542 (4.7); 6.0565 (0.6); 6.0393 (3.0); 6.0219 (4.7); 6.0044 (3.0); 5.9871 (0.6); 3.3247 (501.0); 2.6800 (1.8); 2.6754 (3.8); 2.6709 (5.4); 2.6664 (3.9); 2.6620 (1.9); 2.6352 (0.4); 2.5244 (15.2); 2.5197 (22.1); 2.5110 (291.2); 2.5065 (599.7); 2.5019 (800.9); 2.4974 (585.2); 2.4928 (282.7); 2.3379 (1.6); 2.3334 (3.5); 2.3288 (5.0); 2.3242 (3.6); 2.3199 (1.6); 2.0835 (0.8); 2.0714 (1.8); 2.0625 (1.8); 2.0505 (3.8); 2.0384 (2.2); 2.0299 (2.0); 2.0176 (1.0); 1.5944 (16.0); 1.5770 (16.0); 1.3978 (9.3); 1.2350 (0.3); 1.0271 (0.3); 1.0198 (0.4); 1.0003 (4.7); 0.9945 (7.0); 0.9795 (4.3); 0.9737 (7.2); 0.9544 (0.7); 0.9484 (0.6); 0.9113 (1.0); 0.8983 (1.1); 0.8867 (3.5); 0.8816 (2.0); 0.8748 (3.4); 0.8692 (2.3); 0.8664 (2.2); 0.8609 (3.0); 0.8540 (2.0); 0.8487 (2.8); 0.8313 (1.2); 0.8225 (0.7); 0.1459 (1.8); 0.0180 (0.5); 0.0080 (13.3); -0.0002 (431.0); -0.0085 (14.2); 0.1495 (1.8) frCRnnn / zznz / B / YiAi 124 I-35 / = z ZI 3 m 1-35:1H-NMR(400.2 MHz, d6-DMSO): δ=9.3310 (3.2); 9.3135 (3.2); 9.0124 (5.3); 9.0081 (5.6); 8.5336 (4.0); 8.5280 (3.9); 8.5120 (4.3); 8.5065 (4.3); 8.3469 (3.8); 8.3430 (6.5); 8.3390 (4.5); 8.2873 (4.4); 8.2832 (7.4); 8.2790 (4.5); 8.2438 (5.0); 8.2404 (8.0); 8.2369 (4.3); 8.0105 (5.7); 7.9901 (5.2); 7.9889 (5.3); 6.0740 (0.5); 6.0568 (2.3); 6.0394 (3.7); 6.0220 (2.4); 6.0050 (0.5); 3.3254 (61.9); 2.6764 (0.6); 2.6720 (0.8); 2.6676 (0.6); 2.5253 (2.7); 2.5119 (48.9); 2.5075 (98.3); 2.5030 (130.4); 2.4985 (97.2); 2.4941 (49.0); 2.3344 (0.6); 2.3298 (0.8); 2.3253 (0.6); 2.0864 (0.6); 2.0742 (1.4); 2.0655 (1.6); 2.0535 (3.0); 2.0413 (1.8); 2.0328 (1.6); 2.0204 (0.8); 1.9894 (0.6); 1.5969 (12.8); 1.5795 (12.8); 1.3972 (16.0); 1.1755 (0.4); 1.0202 (0.5); 1.0027 (4.3); 0.9977 (5.6); 0.9820 (4.6); 0.9768 (5.4); 0.9611 (0.7); 0.9509 (0.5); 0.9141 (0.8); 0.9020 (0.8); 0.8908 (3.2); 0.8846 (2.0); 0.8782 (3.9); 0.8720 (3.1); 0.8680 (2.9); 0.8557 (2.5); 0.8416 (0.7); 0.8328 (0.5); 0.0077 (2.0); -0.0004 (59.9); -0.0086 (2.6) I-36 N Λ Β'Ό Φ ° Η N—? I-36:1H-NMR(400.2 MHz, CD3CN): δ= 8.8140 (4.3); 8.8102 (4.4); 8.2705 (3.0); 8.2650 (3.0); 8.2489 (3.6); 8.2433 (3.6); 8.0114 (4.5); 8.0098 (4.6); 7.9898 (3.8); 7.9882 (3.8); 7.8988 (2.4); 7.8944 (5.4); 7.8902 (5.0); 7.8759 (15.2); 7.8716 (10.7); 7.6505 (1.3); 7.6333 (1.3); 6.1380 (0.6); 6.1206 (2.2); 6.1025 (3.1); 6.0847 (2.3); 6.0671 (0.6); 2.1369 (34.7); 2.1199 (0.4); 2.1140 (0.4); 2.1076 (0.6); 2.1014 (0.4); 2.0568 (0.7); 2.0444 (1.4); 2.0362 (1.5); 2.0325 (1.1); 2.0238 (2.4); 2.0202 (1.6); 2.0114 (1.5); 2.0032 (1.6); 1.9908 (0.8); 1.9719 (0.5); 1.9646 (3.2); 1.9584 (3.9); 1.9527 (31.5); 1.9465 (59.6); 1.9404 (83.0); 1.9342 (58.1); 1.9280 (30.2); 1.7749 (0.4); 1.7689 (0.5); 1.7628 (0.4); 1.6024 (14.7); 1.5851 (14.9); 1.5676 frCRnnn / zznz / B / YiAi 125 (0.4); 1.4365 (16.0); 1.0293 (0.3); 1.0208 (0.8); 1.0111 (3.2); 1.0057 (5.5); 0.9979 (1.2); 0.9904 (3.6); 0.9850 (6.0); 0.9691 (1.9); 0.9612 (0.9); 0.9516 (3.4); 0.9454 (2.0); 0.9393 (3.3); 0.9318 (2.3); 0.9280 (2.0); 0.9243 (1.9); 0.9194 (1.5); 0.9152 (1.3); 0.9066 (1.0); 0.8980 (0.5); 0.8925 (0.4); -0.0002 (8.3) I-37 N XXnX>Í ÍN 0 H N I-37: 1H-NMR(400.2 MHz, CD3CN): δ= 8.8343 (0.6); 8.8325 (0.6); 8.8289 (0.6); 8.8270 (0.6); 8.2990 (1.4); 8.2814 (0.5); 8.2758 (0.5); 8.2598 (0.6); 8.2542 (0.6); 8.1522 (0.6); 8.0533 (0.7); 8.0514 (0.7); 8.0317 (0.6); 8.0299 (0.6); 6.1733 (0.4); 6.1554 (0.3); 2.1594 (20.4); 1.9653 (0.8); 1.9592 (0.7); 1.9533 (6.0); 1.9472 (11.3); 1.9410 (15.8); 1.9348 (10.9); 1.9286 (5.6); 1.6625 (2.2); 1.6452 (2.2); 1.3638 (16.0); -0.0002 (2.1) I-38 N CltfF T XX-nX^ »n 0 H N-^ I-38:1H-NMR(400.2 MHz, CD3CN): δ= 8.8310 (0.6); 8.8267 (0.7); 8.2797 (0.5); 8.2741 (0.5); 8.2581 (0.6); 8.2525 (0.6); 8.0477 (0.8); 8.0260 (0.6); 8.0166 (0.7); 7.9692 (0.8); 7.8762 (0.7); 6.1618 (0.4); 6.1440 (0.5); 6.1259 (0.4); 2.1514 (6.0); 1.9650 (0.6); 1.9588 (0.6); 1.9530 (5.6); 1.9469 (10.7); 1.9407 (15.0); 1.9345 (10.4); 1.9284 (5.4); 1.6436 (2.4); 1.6263 (2.4); 1.3642 (16.0); -0.0002 (2.5) I-39 N Cl I-39:1H-NMR(600.1 MHz, CD3CN): δ= 8.8634 (0.4); 8.8622 (0.4); 8.8597 (0.4); 8.8585 (0.3); 8.3306 (0.3); 8.3163 (0.4); 8.3126 (0.4); 8.3012 (0.8); 8.1577 (0.3); 8.0044 (0.4); 8.0032 (0.4); 7.9901 (0.4); 7.9889 (0.4); 6.1891 (0.3); 2.1392 (16.0); 1.9481 (2.8); 1.9439 (5.2); 1.9398 (7.6); 1.9357 (5.2); 1.9316 (2.6); 1.6976 (1.5); 1.6860 (1.5) frCRnnn / zznz / B / YiAi 126 I-40 N A f0 0 Cl 1-40:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.4781 (3.9); 9.4614 (4.0); 9.0732 (7.2); 9.0693 (7.0); 8.6065 (4.6); 8.6011 (4.5); 8.5851 (5.0); 8.5796 (4.9); 8.3165 (0.4); 8.2968 (7.6); 8.1871 (7.1); 8.1320 (7.3); 8.0523 (6.7); 8.0308 (6.3); 6.0747 (0.6); 6.0577 (2.8); 6.0405 (4.4); 6.0234 (2.8); 6.0060 (0.6); 5.7571 (12.1); 4.1068 (0.3); 4.0934 (0.3); 3.3323 (207.0); 3.1764 (1.8); 3.1632 (1.7); 2.6771 (1.1); 2.6729 (1.5); 2.6683 (1.1); 2.5083 (197.4); 2.5039 (248.5); 2.4995 (182.8); 2.3351 (1.1); 2.3307 (1.4); 2.3262 (1.1); 1.6533 (16.0); 1.6359 (15.9); -0.0001 (13.4); -0.0083 (0.7) 501.0 [M+H]+ 1-41 N »A χ-π, Q 1-41:1H-NMR(400.2 MHz, CD3CN): 5=8.8116 (5.9); 8.8090 (6.1); 8.2706 (3.2); 8.2678 (3.3); 8.2652 (3.1); 8.2490 (3.7); 8.2462 (3.7); 8.2436 (3.5); 8.0126 (5.7); 7.9909 (4.7); 7.9154 (7.1); 7.7708 (0.5); 7.7521 (0.6); 7.7150 (2.2); 7.6971 (2.3); 7.6585 (5.6); 7.6284 (5.7); 7.5876 (0.3); 6.1498 (0.8); 6.1323 (2.6); 6.1145 (3.7); 6.0965 (2.5); 6.0794 (0.6); 2.3078 (0.4); 2.1476 (42.9); 2.0576 (1.5); 2.0451 (2.3); 2.0364 (2.5); 2.0338 (2.5); 2.0240 (3.4); 2.0216 (3.5); 2.0120 (2.6); 2.0039 (2.6); 1.9915 (2.2); 1.9650 (4.8); 1.9531 (24.2); 1.9470 (41.8); 1.9437 (43.3); 1.9409 (56.0); 1.9381 (46.9); 1.9348 (39.4); 1.9321 (30.5); 1.9290 (20.5); 1.7697 (0.5); 1.6139 (16.0); 1.5967 (15.6); 1.4360 (0.5); 1.2686 (1.3); 1.2545 (0.9); 1.2385 (0.6); 1.2203 (0.4); 1.2037 (0.4); 1.0059 (6.7); 0.9852 (7.4); 0.9685 (2.8); 0.9611 (1.7); 0.9510 (4.0); 0.9389 (4.0); 0.9227 (2.7); 0.9033 (1.4); -0.0002 (4.1) frCRnnn / zznz / B / YiAi 127 I-42 N V.,· ¿ F v -^-N 0 η Ν-ίς 1-42:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.3371 (3.8); 9.3196 (3.9); 9.0124 (6.2); 9.0109 (6.8); 9.0070 (6.8); 9.0054 (6.5); 8.5329 (5.4); 8.5274 (5.2); 8.5114 (5.8); 8.5058 (5.8); 8.3161 (0.5); 8.0264 (6.1); 8.0122 (7.0); 8.0106 (7.2); 7.9907 (6.5); 7.9890 (6.7); 7.9679 (6.7); 7.8257 (5.9); 7.2295 (3.1); 7.0911 (7.1); 6.9527 (3.4); 6.0727 (0.6); 6.0556 (2.9); 6.0382 (4.7); 6.0207 (3.0); 6.0035 (0.6); 5.7564 (0.4); 3.3273 (145.6); 2.6811 (0.4); 2.6768 (0.9); 2.6722 (1.2); 2.6676 (0.9); 2.6631 (0.4); 2.5256 (3.8); 2.5209 (5.8); 2.5122 (68.6); 2.5077 (140.1); 2.5032 (185.9); 2.4986 (136.3); 2.4941 (66.8); 2.3389 (0.4); 2.3346 (0.8); 2.3300 (1.2); 2.3254 (0.8); 2.3210 (0.4); 2.0852 (0.8); 2.0730 (1.8); 2.0644 (1.9); 2.0612 (1.5); 2.0523 (3.8); 2.0401 (2.2); 2.0315 (2.0); 2.0192 (1.0); 1.6022 (16.0); 1.5848 (16.0); 1.0275 (0.3); 1.0025 (3.4); 0.9993 (4.5); 0.9938 (6.5); 0.9817 (3.1); 0.9785 (4.2); 0.9730 (7.0); 0.9527 (0.6); 0.9471 (0.6); 0.9418 (0.3); 0.9127 (1.0); 0.9003 (1.2); 0.8883 (3.3); 0.8836 (2.1); 0.8766 (3.2); 0.8713 (2.2); 0.8668 (2.1); 0.8616 (2.8); 0.8546 (2.1); 0.8495 (2.6); 0.8324 (1.2); 0.8237 (0.7); 0.0080 (1.7); -0.0002 (54.4);-0.0085(1.9) I-43 w i ΧΧνΧύ ) / N 0 H N-í' I-43:1H-NMR(400.2 MHz, CD3CN): 5=8.8114 (4.6); 8.8075 (4.8); 8.2705 (3.5); 8.2649 (3.4); 8.2489 (4.1); 8.2433 (4.1); 8.1284 (0.3); 8.0419 (5.1); 8.0154 (5.1); 8.0145 (5.1); 7.9939 (4.3); 7.9928 (4.3); 7.9185 (5.3); 7.8395 (4.8); 7.7987 (1.4); 7.7806 (1.4); 7.7529 (0.5); 6.1682 (0.6); 6.1508 (2.4); 6.1330 (3.5); 6.1151 (2.5); 6.0976 (0.7); 4.0680 (0.4); 4.0503 (0.4); 2.2490 (0.5); 2.2304 (0.6); 2.1518 (11.9); 2.1145 (2.0); 2.1081 (1.7); 2.1020 (1.3); 2.0960 (1.0); 2.0870 (0.8); 2.0563 (1.0); 2.0440 (1.8); 2.0356 (1.8); 2.0322 (1.3); 2.0233 (2.7); 2.0196 (1.8); 2.0110 (1.8); 2.0028 frCRnnn / zznz / B / YiAi 128 (1.8); 1.9904 (1.0); 1.9723 (2.1); 1.9650 (3.1); 1.9587 (3.6); 1.9531 (28.2); 1.9469 (52.5); 1.9407 (73.1); 1.9346 (50.7); 1.9284 (26.4); 1.7755 (0.4); 1.7693 (0.5); 1.7630 (0.4); 1.6286 (16.0); 1.6113 (16.0); 1.4363 (1.7); 1.2683 (3.4); 1.2218 (0.5); 1.2040 (1.0); 1.1862 (0.5); 1.0333 (0.4); 1.0192 (0.9); 1.0093 (3.2); 1.0039 (6.0); 0.9969 (1.4); 0.9930 (1.5); 0.9884 (2.9); 0.9831 (7.2); 0.9706 (1.5); 0.9656 (2.0); 0.9594 (1.2); 0.9536 (1.1); 0.9485 (3.3); 0.9432 (1.6); 0.9366 (3.3); 0.9293 (2.2); 0.9244 (2.0); 0.9210 (1.8); 0.9160 (2.0); 0.9127 (1.9); 0.9089 (1.3); 0.8984 (1.3); 0.8897 (0.6); 0.8853 (0.6); 0.8811 (0.6); -0.0003 (6.0) I-44 N I F A Au V \ \ ,N, 0 H N-^ I-44: 1H-NMR(400.2 MHz, CD3CN): δ= 8.8175 (4.6); 8.8135 (4.7); 8.3476 (5.5); 8.2828 (5.0); 8.2744 (3.9); 8.2687 (3.3); 8.2526 (3.8); 8.2471 (3.8); 8.2195 (4.8); 8.0213 (5.0); 8.0001 (4.2); 7.8324 (1.3); 7.8153 (1.3); 6.1946 (0.6); 6.1772 (2.4); 6.1595 (3.6); 6.1416 (2.4); 6.1243 (0.6); 2.1461 (68.9); 2.1206 (0.3); 2.1143 (0.4); 2.1081 (0.4); 2.1015 (0.4); 2.0579 (0.8); 2.0455 (1.5); 2.0372 (1.6); 2.0337 (1.1); 2.0248 (2.5); 2.0210 (1.8); 2.0126 (1.6); 2.0043 (1.6); 1.9918 (1.0); 1.9650 (2.9); 1.9530 (24.8); 1.9469 (46.6); 1.9407 (65.0); 1.9346 (45.2); 1.9284 (23.5); 1.7756 (0.3); 1.7693 (0.4); 1.6338 (16.0); 1.6166 (15.9); 1.4364 (4.1); 1.2689 (0.6); 1.0301 (0.4); 1.0224 (0.7); 1.0111 (3.5); 1.0064 (5.8); 1.0003 (1.3); 0.9907 (3.8); 0.9856 (6.5); 0.9703 (2.1); 0.9629 (1.1); 0.9532 (3.7); 0.9468 (2.2); 0.9405 (4.3); 0.9348 (2.7); 0.9275 (2.2); 0.9234 (1.9); 0.9168 (1.3); 0.9080 (1.0); 0.8952 (0.4); -0.0002 (5.4) frCRnnn / zznz / B / YiAi 129 I-45 N O1 χ-ο, ? 1-45:1H-NMR(400.2 MHz, CD3CN): δ=8.8149 (4.9); 8.8110 (4.7); 8.2721 (3.4); 8.2665 (3.3); 8.2505 (4.0); 8.2449 (3.9); 8.0155 (5.1); 7.9939 (4.2); 7.9779 (5.5); 7.9517 (4.0); 7.9473 (6.0); 7.9433 (3.6); 7.9291 (0.4); 7.8903 (4.8); 7.7529 (1.4); 7.7359 (1.4); 7.5864 (0.5); 6.1573 (0.6); 6.1397 (2.4); 6.1220 (3.4); 6.1039 (2.4); 6.0869 (0.6); 2.4694 (0.4); 2.4644 (0.6); 2.4599 (0.5); 2.1557 (189.8); 2.1198 (1.2); 2.1140 (1.4); 2.1078 (1.5); 2.1016 (1.1); 2.0955 (0.7); 2.0577 (0.9); 2.0456 (1.7); 2.0372 (1.8); 2.0337 (1.2); 2.0248 (2.8); 2.0212 (1.7); 2.0125 (1.7); 2.0042 (1.8); 1.9919 (1.1); 1.9647 (7.9); 1.9528 (71.5); 1.9466 (133.8); 1.9405(185.1); 1.9343(128.9); 1.9281 (66.5); 1.7809 (0.4); 1.7752 (0.8); 1.7689 (1.1); 1.7629 (0.8); 1.6205 (15.8); 1.6032 (16.0); 1.5830 (0.7); 1.2700 (0.4); 1.0346 (0.4); 1.0208 (0.9); 1.0111 (3.5); 1.0059 (6.3); 0.9983 (1.3); 0.9851 (7.2); 0.9712 (1.7); 0.9679 (2.1); 0.9603 (1.1); 0.9504 (3.5); 0.9446 (1.8); 0.9382 (3.4); 0.9323 (2.8); 0.9279 (2.1); 0.9243 (2.0); 0.9202 (2.0); 0.9158 (1.8); 0.9026 (1.1); 0.8982 (0.8); 0.8888 (0.5);-0.0002 (14.1) I-46 N χ-σ 9 8.8131 (4.6); 8.2715 (3.2); 8.2659 (3.2); 8.2499 (3.9); 8.2443 (3.8); 8.0163 (4.8); 8.0148 (4.8); 7.9947 (4.1); 7.9931 (4.1); 7.8643 (6.5); 7.8607 (4.5); 7.8495 (4.2); 7.8449 (6.1); 7.8409 (3.5); 7.7757 (3.6); 7.7715 (5.5); 7.7672 (3.2); 7.6963 (1.3); 7.6815 (1.3); 7.5833 (0.4); 7.2632 (3.0); 7.1232 (6.2); 6.9831 (3.1); 6.1521 (0.7); 6.1350 (2.4); 6.1170 (3.3); 6.0992 (2.4); 6.0818 (0.6); 2.1375 (94.3); 2.1136 (0.9); 2.1072 (1.1); 2.1012 (0.8); 2.0954 (0.4); 2.0572 (0.8); 2.0452 (1.7); 2.0368 (1.6); 2.0332 (1.2); 2.0244 (2.6); 2.0207 (1.7); 2.0122 (1.7); 2.0038 (1.8); 1.9916 (1.0); 1.9718 frCRnnn / zznz / B / YiAi 130 (1.3); 1.9643 (6.3); 1.9579 (8.1); 1.9524 (60.6); 1.9462 (113.6); 1.9401 (157.4); 1.9339 (109.0); 1.9277 (56.1); 1.7808 (0.4); 1.7748 (0.7); 1.7686 (0.9); 1.7624 (0.7); 1.7565 (0.4); 1.6148 (16.0); 1.5976 (15.9); 1.4368 (3.5); 1.2723 (0.4); 1.2213 (0.4); 1.2039 (0.6); 1.0350 (0.3); 1.0306 (0.4); 1.0210 (0.8); 1.0110 (3.4); 1.0059 (6.0); 0.9982 (1.2); 0.9901 (3.7); 0.9851 (6.8); 0.9687 (2.1); 0.9615 (1.0); 0.9511 (3.7); 0.9450 (2.0); 0.9387 (3.5); 0.9308 (2.2); 0.9269 (2.0); 0.9232 (1.9); 0.9186 (1.6); 0.9140 (1.3); 0.9055 (1.1); 0.8917 (0.5); 0.0079 (0.4); -0.0002 (13.5) I-47 N 0 Η N-y I-47: 1H-NMR(400.2 MHz, d6-DMSO): 6=9.2197 (3.3); 9.2022 (3.4); 9.0114 (5.5); 9.0097 (6.0); 9.0060 (6.0); 9.0041 (5.7); 8.5331 (4.6); 8.5275 (4.4); 8.5115 (4.9); 8.5060 (5.0); 8.3161 (0.7); 8.0113 (6.0); 8.0096 (6.1); 7.9899 (5.6); 7.9880 (5.7); 7.5116 (7.6); 7.4877 (13.5); 7.4822 (14.0); 7.3283 (16.0); 7.2248 (3.5); 7.2195 (6.3); 7.2141 (3.3); 7.1449 (7.9); 6.0646 (0.5); 6.0477 (2.4); 6.0302 (3.9); 6.0127 (2.5); 5.9952 (0.5); 3.3242 (164.4); 2.6800 (0.8); 2.6756 (1.6); 2.6710 (2.2); 2.6665 (1.6); 2.5245 (6.4); 2.5197 (9.8); 2.5110 (129.2); 2.5066 (262.8); 2.5021 (346.6); 2.4975 (253.5); 2.4930 (123.6); 2.3379 (0.7); 2.3335 (1.6); 2.3289 (2.2); 2.3244 (1.6); 2.0829 (0.7); 2.0707 (1.5); 2.0620 (1.6); 2.0590 (1.3); 2.0499 (3.2); 2.0377 (1.9); 2.0292 (1.6); 2.0168 (0.8); 1.6018 (13.4); 1.5844 (13.4); 0.9996 (4.0); 0.9940 (5.9); 0.9788 (3.8); 0.9732 (6.1); 0.9543 (0.6); 0.9478 (0.5); 0.9108 (0.8); 0.8982 (0.9); 0.8867 (3.0); 0.8813 (1.8); 0.8747 (3.1); 0.8682 (2.2); 0.8613 (2.6); 0.8547 (1.8); 0.8492 (2.4); 0.8323 (1.0); 0.8236 (0.6); 0.1458 (1.3); 0.0080 (10.6); 0.0002 (327.8); -0.0085 (12.2); -0.1496 (1.3) frCRnnn / zznz / B / YiAi 131 I-48 N Br 1-48:1H-NMR(600.4 MHz, CD3CN): 0= 8.8607 (3.7); 8.8595 (4.1); 8.8571 (4.4); 8.8558 (4.4); 8.3277 (3.6); 8.3240 (3.8); 8.3134 (4.0); 8.3097 (4.2); 8.2972 (8.9); 8.1538 (3.9); 8.0098 (4.3); 8.0085 (4.6); 8.0033 (1.0); 7.9955 (4.0); 7.9942 (4.2); 7.9890 (0.9); 7.8930 (1.2); 7.8828 (1.3); 6.2109 (0.6); 6.1992 (2.5); 6.1875 (3.8); 6.1808 (0.8); 6.1757 (2.6); 6.1641 (0.6); 2.1736 (0.4); 2.1659 (0.4); 2.1458 (495.8); 2.1401 (77.0); 2.1128 (7.9); 2.0579 (0.3); 2.0538 (0.6); 2.0497 (0.9); 2.0456 (0.6); 2.0414 (0.4); 1.9632 (12.4); 1.9551 (4.7); 1.9509 (5.1); 1.9471 (45.2); 1.9430 (87.0); 1.9388 (130.6); 1.9347 (97.9); 1.9306 (56.8); 1.8280 (0.5); 1.8239 (0.7); 1.8198 (0.6); 1.8157 (0.3); 1.6946 (15.6); 1.6865 (3.2); 1.6830 (16.0); -0.0001 (7.3); -0.0059 (0.9) I-49 N Br I-49:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.7072 (3.2); 9.6902 (3.4); 9.0709 (5.7); 9.0691 (6.4); 9.0655 (6.2); 9.0637 (5.7); 8.6027 (4.4); 8.5972 (4.2); 8.5812 (4.8); 8.5757 (4.7); 8.2221 (8.4); 8.2198 (8.8); 8.1777 (8.5); 8.0613 (5.8); 8.0596 (5.8); 8.0399 (5.5); 8.0381 (5.5); 6.1117 (0.5); 6.0944 (2.4); 6.0772 (3.8); 6.0600 (2.5); 6.0427 (0.5); 5.7561 (16.0); 3.3394 (452.8); 3.1763 (0.9); 3.1632 (0.9); 2.6775 (1.0); 2.6731 (1.3); 2.6685 (0.9); 2.5264 (4.6); 2.5128 (88.6); 2.5086 (168.4); 2.5042 (212.0); 2.4996 (151.6); 2.4953 (73.3); 2.3355 (0.9); 2.3310 (1.2); 2.3264 (0.9); 1.6553 (13.5); 1.6380 (13.2); 1.4433 (0.4); 1.2511 (1.0); 1.2339 (1.9); 1.2168 (1.0); -0.0002 (2.3) 501.9 [M+H]+ frCRnnn / zznz / B / YiAi 132 I-50 N j Λ Χο Q n^N Br I-50:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.5601 (3.7); 9.5431 (3.8); 9.2170 (6.5); 9.2128 (6.5); 9.1390 ​​(6.0); 9.1361 (5.9); 9.0789 (6.8); 9.0772 (7.2); 9.0736 (7.1); 9.0718 (6.4); 8.6030 (5.2); 8.5975 (4.9); 8.5888 (0.6); 8.5815 (5.5); 8.5760 (5.4); 8.5435 (6.1); 8.3160 ​​(0.4); 8.0666 (6.8); 8.0649 (6.6); 8.0451 (6.3); 8.0434 (6.2); 6.1182 (0.6); 6.1009 (2.9); 6.0837 (4.6); 6.0664 (2.9); 6.0490 (0.6); 5.7564 (10.4); 3.3336 (225.6); 3.1766 (0.8); 3.1634 (0.8); 2.6909 (0.4); 2.6776 (1.0); 2.6731 (1.4); 2.6685 (1.0); 2.5265 (4.7); 2.5215 (7.8); 2.5130 (90.0); 2.5087 (177.2); 2.5041 (226.9); 2.4996 (162.8); 2.4952 (78.9); 2.3399 (0.4); 2.3356 (0.9); 2.3310 (1.3); 2.3265 (0.9); 1.6628 (16.0); 1.6454(15.9); 1.2504 (0.4); 1.2319 (0.5); 0.0081 (0.5); -0.0001 (14.2); -0.0084(0.5) 466.0 [M+H]+ 1-51 N . I •rq ó ΥνΎ ,n ° H N0 Br 1-51: 1H-NMR(400.2 MHz, d6-DMSO): 5= 9.3926 (4.0); 9.3759 (4.1); 9.0621 (7.0); 9.0607 (7.6); 9.0570 (7.4); 9.0554 (6.6); 8.5973 (5.0); 8.5918 (4.7); 8.5759 (5.4); 8.5704 (5.2); 8.3157 (0.4); 8.0560 (6.9); 8.0545 (6.8); 8.0346 (6.4); 8.0330 (6.4); 7.9528 (5.9); 7.9490 (8.8); 7.9451 (6.0); 7.7923 (6.4); 7.7281 (6.5); 6.0594 (0.6); 6.0427 (2.9); 6.0255 (4.5); 6.0084 (2.9); 5.9910 (0.6); 5.7564 (10.1); 3.3377 (429.0); 3.1765 (1.1); 3.1634 (1.1); 2.6776 (1.2); 2.6731 (1.5); 2.6687 (1.1); 2.5263 (5.7); 2.5086 (207.9); 2.5042 (261.9); 2.4997 (191.4); 2.3354 (1.1); 2.3310 (1.5); 2.3265 (1.1); 1.6400 (16.0); 1.6226 (15.8); -0.0001 (4.8) 516.0 [M+H]+ frCRnnn / zznz / B / YiAi 133 I-52 N Ϊ Cl I-52:1H-NMR(400.2 MHz, d6-DMSO): δ=9.7112 (3.7); 9.6945 (3.8); 9.0745 (7.0); 9.0703 (7.0); 8.6106 (4.4); 8.6051 (4.3); 8.5891 (4.7); 8.5837 (4.7); 8.2212 (9.9); 8.1788 (9.9); 8.0558 (6.7); 8.0343 (6.2); 6.1071 (0.6); 6.0897 (2.8); 6.0726 (4.4); 6.0555 (2.8); 6.0385 (0.6); 5.7569 (16.0); 3.3314 (161.3); 3.1761 (1.1); 3.1630 (1.1); 2.6768 (1.0); 2.6726 (1.4); 2.6684 (1.0); 2.5081 (179.4); 2.5037 (224.6); 2.4994 (164.8); 2.3349 (1.0); 2.3304 (1.2); 2.3264 (0.9); 1.6607 (16.0); 1.6434 (15.8); 1.5972 (0.4); 1.2340 (0.4); -0.0002 (11.8) 458.0 [M+H]+ I-53 N I Br . ¢- Br I-53: 1H-NMR(400.2 MHz, d6-DMSO): 5=9.3311 (2.7); 9.3141 (2.7); 9.0666 (4.5); 9.0649 (5.1); 9.0612 (5.0); 9.0594 (4.7); 8.5993 (3.7); 8.5938 (3.5); 8.5779 (4.0); 8.5724 (3.9); 8.3153 (0.7); 8.0536 (4.8); 8.0520 (5.1); 8.0463 (3.9); 8.0419 (7.3); 8.0375 (4.8); 8.0323 (4.8); 8.0305 (4.8); 7.9857 (16.0); 7.9813 (14.2); 6.0421 (0.4); 6.0249 (2.0); 6.0077 (3.1); 5.9906 (2.0); 5.9730 (0.4); 5.7561 (14.0); 3.3345 (772.8); 3.1752 (1.3); 3.1620 (1.2); 2.6762 (1.9); 2.6718 (2.6); 2.6672 (2.0); 2.6627 (1.0); 2.5251 (9.5); 2.5117 (169.3); 2.5073 (338.0); 2.5028 (439.8); 2.4982 (319.7); 2.4937 (157.6); 2.3341 (1.9); 2.3296 (2.5); 2.3250 (1.9); 1.6233 (10.8); 1.6059 (10.8); 0.0080 (0.4); -0.0002 (11.4); -0.0084 (0.4) 556.8 [M+H]+ I-54 N - Λ n^N Cl I-54:1H-NMR(600.4 MHz, d6-DMSO): 5=9.3122 (3.2); 9.3010 (3.2); 9.0647 (4.9); 9.0637 (4.8); 9.0611 (5.1); 8.5975 (3.8); 8.5938 (3.7); 8.5832 (4.0); 8.5796 (3.9); 8.0404 (8.6); 8.0374 (7.6); 8.0345 (4.5); 8.0271 (5.2); 8.0261 (4.8); 7.9815 (16.0); 7.9786 (14.6); 6.0243 (0.6); 6.0127 (2.4); 6.0013 (3.6); 5.9898 frCRnnn / zznz / B / YiAi 134 (2.4); 5.9782 (0.5); 3.3060 (189.4); 2.6157 (1.4); 2.6127 (1.9); 2.6096 (1.4); 2.5216 (10.0); 2.5185 (12.0); 2.5154 (13.5); 2.5066 (116.0); 2.5037 (226.4); 2.5007 (302.7); 2.4977 (224.3); 2.4948 (110.7); 2.3876 (1.4); 2.3846 (1.9); 2.3816 (1.4); 1.6264 (13.3); 1.6148 (13.1); 1.3997 (0.3); 0.0053 (1.1); -0.0001 (22.7); -0.0056 (0.9) 512.8 [M+H]+ I-55 N Cl I-55:1H-NMR(400.2 MHz, d6-DMSO): δ= 10.9905 (0.4); 9.3961 (3.9); 9.3794 (4.0); 9.0670 (6.6); 9.0654 (7.3); 9.0617 (7.4); 9.0600 (6.9); 8.6049 (5.3); 8.5994 (5.1); 8.5835 (5.7); 8.5780 (5.7); 8.3161 (0.4); 8.1673 (0.4); 8.0838 (5.3); 8.0801 (8.9); 8.0764 (5.7); 8.0516 (7.0); 8.0499 (7.2); 8.0301 (6.5); 8.0284 (6.7); 8.0015 (0.3); 7.9504 (0.3); 7.8977 (5.8); 7.7575 (5.8); 7.7552 (5.2); 6.0531 (0.6); 6.0360 (2.8); 6.0189 (4.4); 6.0018 (2.9); 5.9847 (0.6); 5.7568 (11.5); 3.3348 (381.7); 3.1763 (1.3); 3.1632 (1.3); 2.6773 (1.1); 2.6728 (1.6); 2.6683 (1.2); 2.6639 (0.6); 2.5262 (5.6); 2.5213 (8.8); 2.5128 (102.9); 2.5084 (206.1); 2.5039 (267.4); 2.4993 (194.3); 2.4949 (96.0); 2.3352 (1.1); 2.3307 (1.5); 2.3261 (1.1); 1.6438 (16.0); 1.6264 (15.8); 0.0080 (0.3); -0.0001 (10.4); -0.0084 (0.4) 516.9 [M+H]+ I-56 N 1 ° H N-\ Br I-56:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.3923 (4.0); 9.3754 (4.1); 9.0610 (7.6); 9.0573 (7.3); 9.0556 (7.0); 8.5978 (5.2); 8.5923 (5.0); 8.5764 (5.5); 8.5709 (5.5); 8.3164 (0.5); 8.0825 (5.6); 8.0788 (9.1); 8.0751 (5.8); 8.0558 (6.9); 8.0543 (7.2); 8.0344 (6.4); 8.0328 (6.7); 7.9488 (0.3); 7.8968 (6.0); 7.7563 (6.1); 6.0576 (0.6); 6.0407 (2.9); 6.0235 (4.5); 6.0063 (2.9); 5.9890 (0.6); 5.7569 (14.2); 3.3324 (336.6); 3.1761 (1.5); 3.1630 (1.4); 2.6770 (1.3); 2.6726 (1.8); frCRnnn / zznz / B / YiAi 135 2.6680 (1.4); 2.5260 (6.3); 2.5124 (118.1); 2.5081 (234.8); 2.5036 (303.2); 2.4990 (220.0); 2.4947 (108.4); 2.3349 (1.2); 2.3304 (1.7); 2.3258 (1.2); 1.6380 (16.0); 1.6206 (15.8); 1.2340 (1.1); 1.2161 (1.6); 1.1985 (1.0); 0.0080 (0.6); -0.0002 (18.4); 0.0085 (0.7) 561.9 [M+H]+ I-57 N w ¿ VN Cl I-57: 1H-NMR(400.2 MHz, d6-DMSO): δ= 9.4819 (2.5); 9.4651 (2.6); 9.0733 (4.7); 9.0695 (4.7); 8.6065 (2.8); 8.6010 (2.8); 8.5850 (3.0); 8.5796 (3.0); 8.1639 (4.8); 8.1022 (4.9); 8.0848 (4.4); 8.0525 (4.2); 8.0323 (3.9); 8.0310 (3.9); 6.0773 (0.4); 6.0601 (1.8); 6.0430 (2.8); 6.0258 (1.8); 6.0085 (0.4); 5.7572 (16.0); 3.3319 (53.6); 3.1760 (0.5); 3.1634 (0.5); 2.6773 (0.8); 2.6728 (1.0); 2.6684 (0.8); 2.5261 (3.9); 2.5084 (133.8); 2.5039 (170.3); 2.4994 (124.7); 2.4953 (63.2); 2.3352 (0.7); 2.3307 (0.9); 2.3264 (0.7); 1.6552 (10.2); 1.6378 (10.2); 1.2333 (0.3); 0.0079 (0.4); -0.0002 (11.0); -0.0084 (0.4) 456.1 [M+H]+ I-58 o ΟλΛ IZ o Q Z' I-58:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.3376 (1.2); 9.3206 (1.2); 9.0721 (2.1); 9.0705 (2.2); 9.0668 (2.2); 9.0650 (2.0); 8.6069 (1.6); 8.6014 (1.5); 8.5855 (1.7); 8.5800 (1.7); 8.0504 (2.1); 8.0487 (2.1); 8.0290 (2.0); 8.0272 (2.0); 7.8248 (16.0); 6.0264 (0.9); 6.0092 (1.4); 5.9921 (0.9); 5.7569 (2.7); 3.3300 (51.4); 3.1760 (0.5); 3.1628 (0.4); 2.6723 (0.4); 2.6677 (0.3); 2.5257 (1.6); 2.5122 (29.7); 2.5079 (56.8); 2.5034 (71.8); 2.4988 (51.6); 2.4944 (25.1); 2.3301 (0.4); 1.6336 (5.0); 1.6162 (5.0); -0.0002 (4.8) 423.0 [M+H]+ frCRnnn / zznz / B / YiAi 136 I-59 N 1 Λ Cl 1-59:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.5638 (3.6); 9.5471 (3.6); 9.2180 (5.4); 9.1400 (5.1); 9.0825 (6.7); 9.0782 (6.6); 8.6105 (4.5); 8.6050 (4.4); 8.5890 (4.9); 8.5835 (4.8); 8.5447 (6.1); 8.0615 (6.5); 8.0400 (6.1); 6.1128 (0.6); 6.0955 (2.8); 6.0783 (4.4); 6.0612 (2.9); 6.0439 (0.6); 5.7571 (14.0); 3.3327 (181.1); 3.1763 (0.6); 3.1631 (0.5); 2.6774 (0.9); 2.6729 (1.3); 2.6684 (1.0); 2.5261 (4.3); 2.5127 (84.8); 2.5084 (167.6); 2.5039 (215.6); 2.4994 (155.9); 2.4951 (76.9); 2.3395 (0.4); 2.3353 (0.9); 2.3307 (1.2); 2.3262 (0.9); 1.6681 (16.0); 1.6507 (15.9); 1.6074 (0.6); 1.2478 (1.7); 1.2311 (3.3); 1.2144 (1.7); -0.0002 (7.4) 422.1 [M+H]+ I-60 N ;n 0 Η N—\ Cl I-60:1H-NMR(400.2 MHz, d6-DMSO): δ= 9.3963 (3.8); 9.3796 (3.9); 9.0671 (6.7); 9.0656 (7.4); 9.0619 (7.1); 9.0602 (6.9); 8.6049 (4.9); 8.5994 (4.8); 8.5834 (5.2); 8.5779 (5.2); 8.3162 (0.4); 8.1636 (0.6); 8.1020 (0.5); 8.0846 (0.5); 8.0519 (6.8); 8.0503 (7.0); 8.0305 (6.4); 8.0288 (6.6); 7.9547 (5.3); 7.9507 (8.4); 7.9470 (6.0); 7.8641 (0.3); 7.7926 (6.0); 7.7297 (6.1); 6.0557 (0.7); 6.0383 (2.9); 6.0212 (4.4); 6.0041 (2.8); 5.9872 (0.6); 5.7567 (12.7); 3.3347 (206.9); 3.1765 (0.6); 3.1636 (0.6); 2.6776 (1.1); 2.6730 (1.5); 2.6686 (1.1); 2.5263 (5.5); 2.5086 (202.0); 2.5041 (260.0); 2.4996 (192.2); 2.3354 (1.1); 2.3309 (1.5); 2.3265 (1.1); 1.6457 (16.0); 1.6283 (15.8); 1.2336 (0.3); 0.0080 (0.6); -0.0001 (15.2); -0.0084 (0.7) 471.0 [M+H]+ frCRnnn / zznz / B / YiAi 137 1-61 N A 9.2930 (1.3); 9.0170 (2.2); 9.0154 (2.3); 9.0116 (2.4); 9.0100 (2.2); 8.5448 (1.7); 8.5392 (1.6); 8.5232 (1.8); 8.5176 (1.8); 8.0431 (1.3); 8.0388 (2.9); 8.0346 (2.6); 8.0201 (8.0); 8.0158 (5.4); 7.9791 (2.3); 7.9775 (2.3); 7.9575 (2.2); 7.9558 (2.2); 6.0504 (1.0); 6.0331 (1.5); 6.0158 (1.0); 3.9629 (16.0); 3.3298 (22.6); 2.5266 (0.8); 2.5217 (1.2); 2.5131 (15.4); 2.5087 (31.0); 2.5042 (40.2); 2.4997 (28.9); 2.4953 (14.0); 2.0767 (0.8); 1.6016 (5.3); 1.5842 (5.3); 0.0002 (1.2) I-62 N „· A N 0 H N-< 0— I-62: 1H-NMR(400.2 MHz, d6-DMSO): 6= 9.3558 (1.2); 9.3387 (1.2); 9.0180 (2.2); 9.0163 (2.3); 9.0126 (2.3); 9.0108 (2.1); 8.5450 (1.7); 8.5394 (1.6); 8.5234 (1.8); 8.5178 (1.8); 8.3147 (0.3); 8.1750 (1.9); 8.1718 (3.2); 8.1685 (1.9); 8.0866 (0.8); 8.0834 (0.9); 8.0802 (0.9); 8.0772 (0.8); 8.0657 (0.8); 8.0624 (0.9); 8.0594 (0.9); 8.0564 (0.8); 7.9970 (0.9); 7.9934 (1.0); 7.9908 (1.0); 7.9835 (2.5); 7.9817 (2.3); 7.9735 (1.0); 7.9698 (1.1); 7.9670 (1.0); 7.9620 (2.6); 7.9601 (2.3); 6.0802 (0.9); 6.0629 (1.5); 6.0456 (0.9); 3.9641 (16.0); 3.3412 (110.0); 2.5269 (0.9); 2.5134 (18.8); 2.5090 (37.3); 2.5045 (47.9); 2.4999 (34.1); 2.4954 (16.3); 2.0757 (0.4); 1.6182 (5.2); 1.6008 (5.1); 0.0002 (1.3) I-63 N ηΛ-Ν'™ν „n θ Η N—\ 0— I-63:1H-NMR(400.2 MHz, d6-DMSO): 6= 9.4555 (1.3); 9.4385 (1.4); 9.0168 (2.4); 9.0114 (2.4); 8.5469 (1.7); 8.5414 (1.6); 8.5253 (1.8); 8.5198 (1.8); 8.1238 (2.4); 7.9855 (2.5); 7.9639 (4.0); 7.7883 (1.8); 7.2944 (1.0); 7.1562 (2.4); 7.0181 (1.1); 6.0888 (1.0); 6.0715 (1.5); 6.0542 (1.0); 3.9661 (16.0); 3.3341 (55.0); 2.5454 (0.7); 2.5149 (16.2); 2.5105 (31.6); frCRnnn / zznz / B / YiAi 138 2.5060 (40.9); 2.5015 (29.6); 2.4970 (14.6); 2.0787 (4.4); 1.6314 (5.5); 1.6140 (5.4) I-64 N ρ-ΑνΎ A F λ L A θ Η N—\ 0— I-64:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.2680 (1.3); 9.2509 (1.4); 9.0184 (2.3); 9.0144 (2.3); 9.0130 (2.2); 8.5480 (1.7); 8.5424 (1.6); 8.5264 (1.8); 8.5208 (1.8); 7.9848 (2.3); 7.9834 (2.3); 7.9633 (2.2); 7.9617 (2.2); 7.5306 (5.4); 7.5250 (5.9); 7.5224 (4.1); 7.3385 (5.8); 7.2404 (1.4); 7.2350 (2.5); 7.2297 (1.3); 7.1551 (2.9); 6.0706 (1.0); 6.0533 (1.5); 6.0360 (1.0); 3.9648 (16.0); 3.3362 (50.3); 2.5454 (0.7); 2.5284 (0.8); 2.5150 (14.6); 2.5106 (28.3); 2.5061 (36.2); 2.5015 (25.9); 2.4970 (12.5); 2.0787 (2.0); 1.6220 (5.3); 1.6045 (5.3) I-65 N .vA F 0 Η N-K O— I-65:1H-NMR(400.2 MHz, d6-DMSO): 5= 9.3729 (1.3); 9.3558 (1.4); 9.0204 (2.4); 9.0163 (2.4); 9.0150 (2.3); 8.5479 (1.7); 8.5424 (1.6); 8.5263 (1.8); 8.5208 (1.8); 7.9870 (2.3); 7.9857 (2.4); 7.9655 (2.2); 7.9640 (2.4); 7.9517 (2.4); 7.7892 (1.9); 7.5636 (2.0); 7.5474 (1.4); 7.3640 (2.9); 7.2564 (1.0); 7.1806 (1.4); 7.1179 (2.3); 6.9795 (1.1); 6.0848 (1.0); 6.0675 (1.6); 6.0502 (1.0); 3.9647 (16.0); 3.3380 (62.4); 2.5455 (0.9); 2.5284 (0.7); 2.5151 (14.7); 2.5108 (29.0); 2.5062 (37.5); 2.5017 (27.3); 2.4973 (13.6); 2.0787 (2.2); 1.6268 (5.5); 1.6094 (5.5) 1)‘lowT’ denotes that the measurement was carried out at a temperature of 260 Kelvin. 2) 'abs' denotes that the compound was obtained in an enriched or pure form of one enantiomer with the main stereoisomer having the absolute configuration shown in the drawing. 3)The indicated mass corresponds to the peak of the isotope pattern of the [M+H]+ion ion with the highest intensity. # denotes that the [M-H]i ion was recorded frCRnnn / zznz / B / YiAi 139 Table 2 (Intermediate) Example Structure2) NMR data1) ESI mass (m / z)3) INT-1 N ά 2 N—\ CIH \— 243.2 [M+H-HCI]+ INT-2 N HoN ais Ú 257.2 [M+H]+ INT-3 N Jn_ H2N ab / V N-\ CIH 255.1 [M+H-HCI]+ INT-4 N HjN'V / / N N-\. y- f F 265.2 [M+H]+ INT-5 N HoN abs^ / / J 0— 245.1 [M+H]+ frCRnnn / zznz / B / YiAi 140 INT-6 N A H2NzXX °x 259.3 [M+H]+ INT-7 N H 2 N 273.1 [M+H]+ INT-8 N A H2N 271.3 [M+H]+ INT-9 0. OH όχ X Ή NMR ( 400 MHz, CDCh) δ = : 6.90 (t, 1H, J = 74.4 Hz), 7.83 (t, 1H, J = 2 Hz), 8.14 (t, 1H, J = 2Hz), 8.20 (s, 1H), 10.50 (brs, 1H). (measured on a Varián Gemini 2000 machine). INT-10 O^OH XXv cr F Ή NMR (DMSO-d6, 400 MHz): δ = 13.65 (brs, 1H), 8.06 (s, 2H), 7.93 (S, 1H), 7.14 (t, J=55 Hz, 1H). INT-11 CN A Cl 249.2 [M+H]+ frCRnnn / zznz / B / YiAi 141 INT-12 CN , 8.14 (s, 1H), 7.88 (s, 1H), Measured using a Bruker 400MHz NMR machin...

Claims

1. Compound of formula (I) where R1 is hydrogen; R2 is phenyl or pyridine, the phenyl or pyridine being optionally substituted with one or two substituents, provided that the substituent(s) are not on any of the carbons adjacent to the carbon attached to the C=O group, each being selected independently from the set consisting of fluorine, chlorine, bromine, CN, -NO2, -SF5, methyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, methoxy, difluoromethoxy, trifluoromethoxy, difluoromethylthio, trifluoromethylthio, difluoroethylthio, and trifluoroethylthio; R3 is CrCsalkyl; R4 is pyridine, pyrimidine, or pyrazine, the pyridine, pyrimidine, or pyrazine being substituted with CN. R5 is ethyl, isopropyl, tert-butyl, difluoromethyl, cyclopropyl, methoxy, ethoxy, isopropoxy, or halogen.

2. Compound according to Claim 1, wherein R1 is hydrogen; R2, 3-chloro-5-(difluoromethoxy)phenyl, 3-bromo-5(trifluoromethoxy)phenyl, 3-bromo-5-chlorophenyl, 3,5-dichlorophenyl, 3,5-dibromophenyl, 3.5206 bis(trifluoromethyl)phenyl, 3-cyane-5-(trifluoromethyl)phenyl, 3,5-bis(difluoromethoxy¡)phenyl, 5bromopyridin-3-yl, 3-bromo-5-(trifluoromethyl)phenyl, 3-fluoro-5-cyanophenyl, 3-bromo-5cyanophenyl, 3-(difluoromethyl)-5-(trifluoromethoxy)phenyl, 3-(difluoromethoxy)-5(difluoromethyl)phenyl, 6-bromopyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6(trifluoromethyl)pyridin-2-yl, 2-chloro-6-(trifluoromethyl)pyridin-4-yl or 4-bromo-6(trifluoromethyl)pyridin-2-yl; R3 is methyl;R4 es 5-cianopiridin-2-ilo, R5 es etilo, iso-propilo, ter-butilo, difluorometilo, ciclopropilo, metoxi, etoxi, isopropoxi, cloro o bromo. frCRnnn / zznz / B / YiAi; 3. Compuesto de la fórmula (e) donde los elementos estructurales R3, R4 y R5 poseen los significados que se definen en la reivindicación 1 o en la reivindicación 2, including 6-[5-[(1 S)-1 -aminoet¡l]-3-ethyl-1,2,4-triazol1 -yl]pyridine-3-carbonitrilo, 6-[5-[( 1 S)-1 -aminoet¡l]-3-isoprop¡l-1,2,4-triazol-1 -yl]pyridine-3-carbonitrilo, 6-[5-[( 1 S)-1 -aminoet¡l]-3-cyclopropyl-1,2,4-triazol-1 -yl]pyridine-3-carbonitrilo, 6-[5(1 -aminoethyl)-3-(difluoromethyl)-1,2,4-triazol-1 -yl]pyridine-3-carbonitrilo, 6-[5-[(1 S)-1 aminoethyl]-3-methox¡-1,2,4-triazol-1 -yl]p¡ridine-3-carbon itrilo, 6-[5-[( 1 S)-1 -aminoethyl]-3-ethox¡1,2,4-triazol-1 -yl]pyridine-3-carbon¡trilo, 6-[5-[(1S)-1-aminoethyl]-3-¡sopropox¡-1,2,4-tr¡azol-1yl]pyridine-3-carbonitrilo, 6-[5-[(1 S)-1 -am inoeti l]-3-tert-butyl-1,2,4-triazol-1 -yl]pyridine-3carbonitrilo, 6-[5-( 1 -aminoethyl)-3-chloro-1,2,4-triazol-1 -yl]pyridine-3-carbonitrilo, and 6-[5-( 1 aminoethyl)-3-bromo-1,2,4-triazol-1-yl]pyridine-3-carbonitrile and the hydrochlorides thereof. 207, 5. Compounds 3-chloro-5-[(difluoromethyl)sulfanyl]benzoic acid, 3-chloro-5-(difluoromethyl)benzoic acid, 3-chloro-5-(pentafluoroethyl)benzoic acid, 3-(trifluoromethoxy)-5-(difluoromethyl)benzoic acid, and 3-(difluoromethoxy)-5-(difluoromethyl)benzoic acid and their salts.

6. Formulation, especially an agrochemical formulation, comprising at least one compound of formula (I) according to any of Claims 1 to 2.

7. Formulation according to Claim 6, which further comprises at least one diluent and / or at least one surfactant.

8. Formulation according to Claim 6 or 7, characterized in that the compound of formula (I) is in the form of a mixture with at least one additional active compound.

9. A method for controlling pests, especially animal pests, characterized in that a compound of formula (I) according to any of Claims 1 to 2 or a formulation according to any of Claims 6 to 8 is allowed to act on the pests and / or their habitat, excluding methods for treating the human or animal body by surgery or therapy and diagnostic methods performed on the human or animal body.

10. A method according to Claim 9, characterized in that the pest is an animal pest and comprises an insect, an arachnid or a nematode, or in that the pest is an insect, an arachnid or a nematode, excluding methods for treating the human or animal body by surgery or therapy and diagnostic methods performed on the human or animal body.

11. The use of a compound of formula (I) according to any of Claims 1 to 2 or of a formulation according to any of Claims 6 to 8 for controlling animal pests, excluding the use of methods for treating the human or animal body by surgery or therapy and diagnostic methods performed on the human or animal body. frCRnnn / zznz / B / YiAi 208 12. The use according to Claim 11, characterized in that the animal pest comprises an insect, an arachnid or a nematode, or in that the animal pest is an insect, an arachnid or a nematode, excluding the use of methods for treating the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body.

13. Use according to Claim 11 or 12 in crop protection, excluding use for methods for treating the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body.

14. Use according to Claim 11 or 12 in the field of animal health, excluding the use of methods for treating the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body.

15. A method for protecting seeds or germinating plants against pests, especially animal pests, comprising a method step in which the seed is brought into contact with a compound of formula (I) according to any of Claims 1 to 2 or with a formulation according to any of Claims 6 to 8, excluding methods for treating the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body.